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 -Albert Einstein- 
 
 
Science never solves a problem without creating ten more 
 
-George Bernard Shaw- 
 
 i 
Table of contents  
 
 
Chapter I: General introduction     1 
I.1. Soluble guanylyl cyclase     3 
 I.1.1. Historical perspective     3 
 I.1.2. sGC isoforms     3 
 I.1.3. Structure of the subunits     4 
 I.1.4. Genomic organisation of sGC     6 
 I.1.5. Expression of sGC     7 
 I.1.6. Transscriptional and post-transscriptional regulation of sGC     8 
 I.1.7. Post-translational regulation of sGC   11 
  I.1.7.1. sGC activation by ligands   11 
   * Nitric oxide (NO)   11 
   * Carbon monoxide (CO)   13 
   * YC-1   14 
   * BAY 41-2272   16 
   * BAY 41-8543, CFM-1571 and A-350619   17 
   * BAY 58-2667   17 
  I.1.7.2. sGC inhibition   19 
   * Methylene blue   19 
   * ODQ   19 
  I.1.7.3. sGC phosphorylation   21 
  I.1.7.4. Protein-protein interactions involving sGC   21 
  I.1.7.5. Other   23 
 I.1.8. References   26 
I.2. Soluble guanylyl cyclase-mediated smooth muscle relaxation   47 
 I.2.1. Soluble guanylyl cyclase effectors   47 
 I.2.2. Mechanisms of cGMP-dependent smooth muscle relaxation   48 
  I.2.2.1. Regulation of [Ca2+]i   49 
  I.2.2.2. Regulation of MLC dephosphorylation/Ca2+ sensitization   50 
  I.2.2.3. Thin filament regulation   51 
 I.2.3. References   53 
I.3. Role of the NO/cGMP pathway   59 
 I.3.1. Role of the NO/cGMP pathway in the vascular system   59 
  I.3.1.1. Source of NO   59 
  I.3.1.2. Direct vascular effects of NO   61 
  I.3.1.3. Other endothelium-derived relaxing substances   64 
   * Prostaglandins   64 
   *    Endothelium-derived hyperpolarising factor (EDHF)      66 
 I.3.2. Role of the NO/cGMP pathway in penile erection   68 
 ii 
  I.3.2.1. Anatomy of the penis   68 
  I.3.2.2. Physiology of the penile erection   71 
  I.3.2.3. Source of NO   72 
  I.3.2.4. Other peripheral neurotransmitters   74 
   * Vasoactive-intestinal polypeptide (VIP)   74 
  I.3.2.5. Other endothelium-derived modulators of penile erection   76 
   * Prostaglandins   76 
   * EDHF   77 
  I.3.2.6. RhoA/Rho kinase   79 
 I.3.3. References   80 
I.4. Summarising conclusions   99 
    
Chapter II: Aims of the work 101 
II.1. General aim 103 
II.2. Specific aims 103 
 II.2.1. Relaxation of vascular smooth muscle cells in sGCα1 knockout mice 
(sGCα1-/- mice) 
103 
 II.2.2. Relaxation of corpus cavernosum smooth muscle cells in sGCα1-/- mice 104 
 II.2.3. Relaxation of corporal and vascular smooth muscle cells in sGCβ1 
knockin mice (sGCβ1ki/ki mice) 
104 
II.3. References 105 
  
 
Chapter III: Materials and methods 107 
III.1. Introduction 109 
III.2. Mice models 109 
 III.2.1. sGCα1-/- mice 109 
 III.2.2. sGCβ1ki/ki mice 110 
III.3. Arteries 110 
 III.3.1. Dissection 110 
 III.3.2. Tension measurements 112 
  III.3.2.1. The apparatus 112 
  III.3.2.2. Mounting of a ring segment 112 
  III.3.2.3. Preparation of the femoral artery segments before the 
experiment 
114 
   * The normalisation procedure 114 
   * A detailed example of a normalisation procedure 116 
  III.3.2.4. Preparation of the aortic segments before the experiment 117 
 III.3.3. cGMP measurements 117 
III.4. Corpora cavernosa 119 
 III.4.1. Dissection 119 
 III.4.2. The apparatus 120 
 iii 
 III.4.3. Mounting of the penile tissue 120 
 III.4.4. Preparation of the tissue before the experiment 121 
III.5. References 122 
  
 
Chapter IV: Functional role of the soluble guanylyl cyclase α1 subunit in  
                      vascular smooth muscle relaxation. 
123 
IV.1. Abstract and keywords 125 
IV.2. Introduction 126 
IV.3. Materials and methods 127 
 IV.3.1. Animals and tissue collection 127 
 IV.3.2. Tension measurements 127 
 IV.3.3. Measurement of cGMP levels in thoracic aortic rings 128 
 IV.3.4. Measurement of sGC activity in femoral artery preparations 129 
 IV.3.5. Drugs 129 
 IV.3.6. Calculations and statistics 130 
IV.4. Results 130 
 IV.4.1. NO-dependent sGC-induced relaxations 130 
  IV.4.1.1. Effect of ACh 130 
  IV.4.1.2. Effect of SNP 131 
  IV.4.1.3. Effect of SNAP 133 
  IV.4.1.4. Effect of NO-gas 133 
  IV.4.1.5. Effect of basal NO 133 
 IV.4.2. NO-independent sGC-induced relaxations 134 
  IV.4.2.1. Effect of YC-1 134 
  IV.4.2.2. Effect of BAY 41-2272 135 
 IV.4.3. Relaxation induced by PDE-5 inhibition 136 
 IV.4.4. sGC-independent relaxations 136 
  IV.4.4.1. Effect of 8-pCPT-cGMP 136 
  IV.4.4.2. Effect of levcromakalim 138 
 IV.4.5. cGMP-measurements in thoracic aorta rings 138 
 IV.4.6. sGC enzyme activity levels in femoral artery rings 138 
IV.5. Discussion 140 
IV.6. Conclusions 143 
IV.7. Acknowledgments 143 
IV.8. References 144 
  
 
Chapter V: Role of the soluble guanylyl cyclase α1 subunit in mice corpus  
                    cavernosum smooth muscle relaxation. 
147 
V.1. Abstract and keywords 149 
V.2. Introduction 149 
 iv 
V.3. Materials and methods 150 
 V.3.1. Animals 150 
 V.3.2. Tissue collection 150 
 V.3.3. Tension measurements 151 
 V.3.4. Drugs 151 
 V.3.5. Calculations and statistics 152 
V.4. Results 152 
V.5. Discussion 157 
V.6. Conclusions 158 
V.7. Acknowledgements 159 
V.8. References 159 
  
 
Chapter VI: Vascular and coporal smooth muscle responsiveness in soluble  
                      guanylyl cyclase β1 His 105 Phe mutant mice. 
163 
VI.1. Abstract and keywords 165 
VI.2. Introduction 166 
VI.3. Materials and methods 167 
 VI.3.1. Animals 167 
 VI.3.2. Blood vessel study 167 
  VI.3.2.1. Tissue collection 167 
  VI.3.2.2. Tension measurements 167 
 VI.3.3. Corpora cavernosa study 169 
  VI.3.3.1. Tissue collection 169 
  VI.3.3.2. Tension measurements 169 
 VI.3.4. Drugs 169 
 VI.3.5. Calculations and statistics 170 
VI.4. Results 170 
 VI.4.1. Blood vessel study 170 
  VI.4.1.1. First set of experiments 170 
  VI.4.1.2. Second set of experiments 173 
  VI.4.1.3. Third set of experiments 174 
  VI.4.1.4. Fourth set of experiments 177 
  VI.4.1.5. Fifth set of experiments 179 
  VI.4.1.6. Last set of experiments 180 
 VI.4.2. Corpora cavernosa study 181 
VI.5. Discussion 183 
VI.6. Conclusions 189 
VI.7. Acknowledgments 189 
VI.8. References 190 
  
 
 v 
Chapter VII: Discussion and future perspectives 195 
VII.1. General discussion and future perspectives 197 
VII.2. Conclusions 205 
VII.3. References 205 
  
 
Chapter VIII: Addendum 211 
VIII.1 NO-dependent corpus cavernosum smooth muscle relaxation in Wnt-1 
conditional sGCα1-/- mice 
213 
 VIII.1.1. Introduction 213 
 VIII.1.2. Animals 213 
 VIII.1.3. Tissue collection 214 
 VIII.1.4. Tension measurements 214 
 VIII.1.5 Calculations and statistics 214 
 VIII.1.6. Results 214 
 VIII.1.7. Discussion 215 
 VIII.1.8. References 215 
VIII.2 Influence of the genetic background on the phenotype of the sGCα1-/- 
mice 
217 
 VIII.2.1. Introduction 217 
 VIII.2.2. Animals 217 
 VIII.2.3. Tissue collection 217 
 VIII.2.4. Tension measurements 217 
 VIII.2.5 Calculations and statistics 218 
 VIII.2.6. Results 218 
 VIII.2.7. Discussion 218 
 VIII.2.8. References 220 
    
Summary 221 
    
Samenvatting 225 
    
Dankwoord 229 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
     
 vii 
Abbreviations 
 
AC adenylyl cyclase 
ACh acetylcholine 
AGAP-1 the prototype of an ArfGAP protein with a GTPase-like domain, Ankyrin 
repeats, and a pleckstrin homology domain 
5’-AMP 5’-adenosine monophosphate 
ArfGAP ADP ribosylating factor GTPase-activating protein 
ATP adenosine triphosphate 
ATR atropine 
BK bradykinin 
BAY 41-2272 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b] pyridine-3-
yl]pyrimidin-4-ylamine 
BAY 41-8543 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-3-yl]-5(4-
morpholinyl)4,6-pyrimidinediamine 
BAY 58-2667 4-[((4-carboxybutyl) {2-[(4-phenethyl-benzyl)oxy] 
phenethyl}amino)methyl] benzoic acid 
Bay k 8644 1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-3- 
pyridinecarboxylic acid 
BPA bovine pulmonary arteries 
8-Br-cGMP 8-Bromo-guanosine 3’, 5’-cyclic monophosphate 
BSA bovine serum albumin 
[Ca2+]i intracellular Ca2+ concentration 
cAMP adenosine 3’, 5’-cyclic monophosphate 
CC corpora cavernosa 
CCT chaperonin containing t-complex polypeptide 
CDK cyclin-dependent kinase 
CFM-1571 1-benzyl-3-[3-(dimethylamino) propoxy]-N-(4-methoxyphenyl)-1 H-
pyrazole-5-carboxamide 
cGMP guanosine 3’, 5’-cyclic monophosphate 
CO carbon monoxide 
CO2 carbon dioxide 
COX cyclooxygenase 
CNG cyclic nucleotide-gated ion channel 
CPA cyclopiazonic acid 
CPI-17 PKC-potentiated myosin phosphatase inhibitor, 17 kDa  
C-terminal carboxy-terminal 
CYP cytochrome P450 
DOBE calcium dobesilate 
 viii
DMSO dimethylsulfoxide 
ED erectile dysfunction 
EDHF endothelium-derived hyperpolarising factor 
EDRF endothelium-derived relaxing factor 
EET epoxyeicosatrienoic acid 
EFS electrical field stimulation 
eNOS endothelial NOS  
ES  embryonic stem  
G418 geneticin 
GC guanylyl cyclase 
GFP green fluorescent protein 
5’-GMP 5’-guanosine monophosphate 
GSH gluthathion 
GST gluthathione S-transferase 
GTP guanosine triphosphate 
GUA guanethidine 
HA-1077 fasudil 
HEK human embryonic kidney 
His histidine 
H2O2 hydrogen peroxide 
HPRA human penile resistance artery 
Hsp heat shock protein 
HuR human R, embryonic lethal abnormal visual [ELAV]-like RNA  
binding protein 
ICP intracavernosal pressure 
IKca intermediate-conductance Ca2+-activated K+ channels 
iNOS inducible NOS 
IP3 inositol 1,4,5-triphosphate 
IRAG IP3 receptor-associated PKG I substrate 
JNK c-Jun NH2-terminal kinase 
KATP ATP sensitive K+ channel 
KCa channel Ca2+ sensitive K+ channel 
KRB Krebs-Ringer bicarbonate 
Lev levcromakalim 
LPS lipopolysaccharide 
L-NA NG-nitro-L-arginine 
L-NAME NG-nitro-L-arginine methyl ester 
L-NMMA NG-monomethyl-L-arginine 
LY-83583 6-anilino,5,8-quinolinedione 
 ix
MAPK mitogen-activated protein kinase 
MB methylene blue 
MLC myosin light chain 
MLC20 20 kDa light chain of myosin 
MLCK myosin light chain kinase 
MLCP myosin light chain phosphatase 
MYPT myosin phosphatase target subunit 
NADPH nicotinamide adenine dinucleotide phosphate 
NANC non-adrenergic non-cholinergic 
neo neomycine 
NGF nerve growth factor 
7-NI 7-nitroindazole 
NMDA N-methyl-D-aspartate 
nNOS neuronal NOS 
NO nitric oxide 
NOS NO synthase 
N-terminal amino-terminal 
O2 molecular oxygen 
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
ONOO- peroxynitrite 
PC12 pheochromocytoma cells 
8-pCPT-cGMP 8-(4-chlorophenylthio)-guanosine 3’,5’-cyclic monophosphate 
PDE phosphodiesterase 
PDZ post-synaptic density protein-95/Discs large/zona occludens-1 
PG prostaglandin 
PGF2α prostaglandin F2α 
PGI2 prostacyclin 
pGC particulate guanylyl cyclase 
Phe phenylalanine 
PI3Kγ phosphoinositide 3-kinase gamma 
PKA cAMP-dependent protein kinase 
PKC protein kinase C 
PKG cGMP-dependent protein kinase 
PLB phospholamban 
PLC phospholipase C 
PP1c protein phosphatase 1 catalytic subunit 
PPi pyrophosphate 
PSD-95 post synaptic density protein-95 
 x
Rho-GDI Rho-guanine nucleotide dissociation inhibitor 
ROS reactive oxygen species 
rPASMC rat pulmonary artery smooth muscle cells 
RYR ryanodine-sensitive Ca2+ release 
SERCA SR Ca2+-pumping ATPase 
sGC soluble guanylyl cyclase 
SHR spontaneously hypertensive rats 
SIN-1 3-morpholinosydnonimine 
SKca small-conductance Ca2+-activated K+ channel 
SNAP S-nitroso-N-acetylpenicillamine 
SNP sodium nitroprusside 
SOCC store-operated Ca2+ channel 
SR sarcoplasmic reticulum 
STOC spontaneous transient outward current 
T-1032 (methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-
(3,4,5-trimethoxy-phenyl)-3-isoquinoline carboxylate sulfate) 
TCA trichloroacetic acid 
TEA tetraethylammonium chloride 
TNF-α tumor necrosis factor-alpha 
TXA2 thromboxane A2 
UV ultraviolet 
VASP vasodilatory-stimulated phosphoprotein 
VIP vasoactive intestinal polypeptide 
WKY Wistar-Kyoto rats 
Y-27632 N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide 
YC-1 3-(5’-hydroxymethyl-3’-furyl)-1-benzylindazole 
 
  
 
 
 
 
 
 
                                 Chapter  I 
 
 
General introduction 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     General introduction 
 3 
I.1. Soluble guanylyl cyclase 
I.1.1. Historical perspective
 
A few years after the detection of guanosine 3’, 5’-cyclic monophosphate (cGMP) in the urine 
of rats 1, an enzyme capable of synthesizing cGMP, guanylyl cyclase (GC) was found in 
several mammalian tissues 2-6. It took until the mid-1970’s to find out that there are two 
different types of GC 7, which were subsequently found to differ not only in their cellular 
localization (cytosolic and membrane-bound) but also in their structure and regulation. In 
further research, nitric oxide (NO) released from vasodilators such as nitroglycerin and 
nitroprusside, was shown to activate the cytosolic GC enzyme or soluble guanylyl cyclase 
(sGC) 8. As at that point, NO was unknown in biological systems, the NO mediated activation 
of sGC was considered as a non-physiological phenomenon. However, when in the early 
1980’s Furchgott and Zawadski discovered an endothelium-derived relaxing factor (EDRF) 9, 
which was later identified as NO 10, 11, it was realized that sGC mediated many of the 
beneficial effects of endogenous NO in the cardiovascular system (vasodilatation, inhibition 
of platelet aggregation) 12. Later on, the importance of sGC in mammalian physiology further 
increased, as it became apparent that NO and so also its intracellular receptor sGC were not 
only involved in vasorelaxation but also in pheripheral and central neurotransmission 13, in 
phototransduction 14 and in immunomodulation 15. 
 
I.1.2. sGC isoforms 
In 1979 it was first described that the purified sGC enzymes from rat and bovine lung 
consisted of two subunits of around 72 kDA 16. Several years later, Kamisaki et al., showed 
that those two subunits, later designated α and β, were similar but not identical 17. Based on 
the protein sequence of the purified αβ
 
heterodimer, the first subunits, α1 and β1 were cloned 
18-21
. By homology screening, two other subunits were identified, known as α2 and β2 22, 23. 
Subsequently, αβ
 
pairs were cloned from Homo sapiens, which were originally termed α3 and 
β3 24. However, the so-called α3 and β3 subunits have, based on sequence homology, come to 
be generally accepted as the human orthologs of the rat α1 and β1 subunits rather than 
different isoforms 25. So, two isoforms of each subunit currently exist and are termed α1, α2, 
β1, β2, respectively. Despite multiple possible combinations, only the α1β1 and α2β1 
heterodimers have been demonstrated to occur at the protein level and to be catalytically 
active 26.  
Chapter I 
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Figure I.1: Schematic representation of the sGC heterodimer (adapted from Evgenov et al. 27 and 
Lucas et al. 28) 
 
I.1.3. Structure of the subunits 
Each sGC subunit contains three domains (figure I.1) that make up its structure and function: 
an N-terminal regulatory domain involved in heme-binding, a central domain commonly 
referred to as dimerization domain and a C-terminal catalytic domain.  
Compared to the central and catalytic domains, the N-terminal parts of the sGC subunits are 
relatively diverse. Only a stretch of about 100 amino acids shows a high degree of 
conservation among the isoforms of the α or β subunits, but not between the α and β subunits. 
Conceivably, the properties of an α or a β subunit are defined by these regions 29. 
Furthermore, the N-terminal parts bind and coordinate the heme moiety, which mediates the 
NO sensitivity of the enzyme. The binding of NO to the prosthetic heme group, induces a 
conformational change in the enzyme, resulting in a several-hundred-fold greater production 
of cGMP 30. Although there has been some debate in the past, the heme stoichiometry of sGC 
has now been agreed to be one mole per mole heterodimer 31. In contrast to other 
hemoproteins that use the heme group for the storage and transport of oxygen (O2), the heme 
group of sGC has remarkably overcome the inherent affinity for O2 32. The discrimination 
                                                                                                                     General introduction 
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against O2 binding, which is based on the lack of a residue capable of forming a strong H-
bound, is extremely important for the fidelity of NO-signaling 33.  
By sequential truncation experiments, Foerster et al., demonstrated the need of both (α and β ) 
subunits for heme to bind properly to the heterodimeric complex 34. On the other hand, Koglin 
and Behrends observed that deletion of the first 259 N-terminal amino acids of the α1-subunit, 
had no effect on heme-binding or NO-sensitivity of the enzyme 35. Furthermore, the 
importance of the β1 subunit as primary heme-binding subunit was suggested, as the 
expression of the N-terminal part of β1 resulted in a domain capable of binding heme 36. 
Moreover, a histidine residue (His-105) of the β1 subunit, was identified as the heme-
coordinating residue 37, 38. In addition, two highly conserved cysteines (78 and 214) adjacent 
to the His-105 on the β1 subunit appear to be important for the heme-binding affinity. 
Interestingly, mutation of the corresponding cysteines on the α1-subunit, did not alter the NO-
responsiveness, what provides additional proof for the predominant role of the β1 subunit in 
heme-binding 39. So, the function of the N-terminal part of the α-subunit is not clear, 
compared to that of the β1 subunit. As the central part of the sGC enzyme, known as the 
dimerization domain, shows considerable homology to the membrane-bound or particulate 
GC (pGC), it was suggested in analogy, that this region would be involved in the dimerization 
of the subunits 40. Additional evidence was derived from multiple N-and C-terminal deletion 
experiments, where in both subunits of the α1β1 isoform, the central region but also the 
regulatory domain was reported to contribute to heterodimer formation 41. Besides hetero-and 
homodimerization, Koglin and Behrends concluded that the central domain of the α-subunit 
would be involved in sensitivity to NO and the exogenous activator YC-1 35.  
The C-terminal domains of sGC (responsible for guanosine triphosphate (GTP) binding and 
conversion to cGMP) are the most conserved regions, not only among the four subunits but 
also between both pGC and the adenosine 3’, 5’ -cyclic monophosphate (cAMP)-generating 
adenylyl cyclases (AC). This evolutionarily conserved catalytic domain defines sGC, pGC 
and AC as a single family of nucleotide cyclases 42, 43. Homology modelling of sGC, based on 
the crystal structure of AC, revealed the existence of a low affinity nucleotide-like binding 
site, in addition to the putative catalytic site 44. Despite its low affinity for nucleotide, this 
pseudosymmetric counterpart of the catalytic site appears to be of significance for the 
regulation of sGC activity. It has been shown to be responsible for the allosteric pattern of 
non-competitive inhibition by purine nucleotides such as GTP and adenosine 3’, 5’-cyclic 
triphosphate (ATP) 45. This notion was further supported by the finding that the 
Chapter I 
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pseudosymmetric site acts as an ATP sensor site of sGC 46. Besides inhibition of the NO-
stimulated activity, the pseudosymmetric site was also found to be a target for sGC-
stimulators like YC-1 and BAY 41-2272, that lead to potentiation of the NO-stimulated 
activity 47.  
Many aspects of the sGC-catalysed conversion of GTP to cGMP are poorly understood. 
According to Senter et al., the catalysis proceeds by way of a single displacement reaction, 
with the pyrophosphate-leaving group in the nucleotide being displaced by the 3’-hydroxyl 
group on the ribose 48. On activation, under conditions of surplus substrate (GTP) and 
activator (NO), the enzyme exhibits straightforward Michaelis-Menten-type kinetics: cGMP 
accumulates at a constant rate with time 49. Nuclear magnetic resonance spectroscopy 
demonstrated that only pyrophosphate and cGMP in amounts corresponding to the amount of 
GTP utilized were produced 50. As for all nucleotide cyclases, divalent cations (Mn2+ and 
Mg2+) are needed as substrate cofactors and allosteric modulators to express maximum 
catalytic activity 51. As the residues required for substrate recognition and catalysis are 
distributed on the α and β subunit of the heterodimeric sGC enzyme, cyclase activity is 
dependent upon the presence of both subunits 52. Co-expression of the C-terminal regions of 
the α and β subunits, which form a heterodimer and that possess dimerization and catalytic 
regions, is sufficient for basal cGMP production 53.  
Clearly, the above observations demonstrate that the regulatory, catalytic as well as 
dimerization properties of sGC can be attributed to different domains of each subunit and that 
both subunits are required to render the sGC enzyme function.  
 
I.1.4. Genomic organisation of sGC 
In medaka fish 54, rat 55, human 56 as well as mouse 57, the genes encoding the sGCα1 and β1 
subunit are found on the same chromosome and are located very close to each other (mouse: 
3E3-F1, rat: 2q31, human: 4q32). Moreover, in the medaka fish genome, the sGCα1 and β1 
genes are tandemly organized like a single gene, which suggests that the transcriptional 
regulation of the two subunits is cis-coordinated 54. However, this has not been duplicated in 
any mammalian system. The sGCα2 58 and β2 59 subunits on the other hand appear to be 
localized on different chromosomes and seperate chromosomes than the α1 and β1 subunit 60. 
The chromosomal localisation of the sGC subunits, gave the opportunity to address and 
identify whether the α and β subunits of sGC are possible candidate genes for linkage in 
NO/cGMP-mediated disease states. Azam et al., investigated such a linkage for the sGCα and 
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β genes with respect to blood pressure in the Dahl salt-sensitive rat 55. They showed that the 
genes for the sGCα1 and β1 subunits are closely linked to the GC-A locus, which has been 
shown to cosegregate with blood pressure, and the Na+, K+-ATPase α1 isoform and 
calmodulin-dependent protein kinase II-δ genes, which have been shown to flank a 
quantitative trait locus for blood pressure in the Dahl rat 61-63. In addition, the β2 locus was 
also closely linked to the endothelin-2 locus, known to cosegregate strongly with systolic 
blood pressure. Moreover, the mRNA and protein level for the sGCβ2 subunit are increased in 
kidney of Dahl salt-sensitive vs. salt-resistant rats 64, 65. Together, these results suggest that the 
sGC subunit loci of α1, β1 and β2 are good candidates for genes controlling salt-sensitive 
hypertension in the Dahl rat 55.  
 
I.1.5. Expression of sGC 
The expression of the sGC subunits does not appear to be limited to any specific tissue. The 
α1β1 heterodimer, is the most abundant and ubiquitously distributed isoform in mammalian 
tissues with α1 and β1 mRNA being expressed at high levels in the lung, brain, heart, kidney, 
spleen and muscle 21. The α2 subunit has a more restricted expression pattern, with the highest 
level in the brain, where the α1 subunit was present in comparable amounts. The placenta, 
pancreas, spleen and uterus contain a lower level of the α2 subunit. In most tissues sGCα1β1 is 
the
 
prevailing isoform 22. The β2 subunit was detected in kidney and liver 66. However, 
methods and sensitivity of measuring the transcripts of sGC vary in each report. In the study 
of Mergia et al., the β2 subunit mRNA levels were almost undetectable in most tissues and 
relatively most abundantly in the testis and the placenta 67. No sGC heterodimer containing 
the β2 subunit has been isolated from tissues or cells and several investigators failed to 
express a catalytically active α1β2 or α2β2 complex. Therefore, the physiological relevance of 
the β2 subunit is questionable. However, using a chimeric form in which the rat β2 is fused 
downstream of the green fluorescent protein (GFP), Gupta et al., demonstrate that an α1β2 
heterodimer does exhibit enzyme activity, albeit considerably lower when compared to the 
α1β1 enzyme. More importantly, these authors reported that the β2 subunit could act as a 
negative regulator of NO-stimulated activation of the α1β1 sGC enzyme by complexing with 
the α1 subunit and reducing the NO-sensitivity of sGC 64. One explanation for this novel 
finding of catalytic activity is that GFP in the GFP-β2 fusion substitutes for the missing N-
terminal heme-binding region of β2. This may also account for the reported ability of the β2-
Chapter I 
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GFP fusion construct to form a catalytically active homodimer 68. On the other hand, a 
frameshift deletion has been shown in the human β2 gene population that is incompatible with 
the occurrence of the β2 subunit on protein level. The fact that the human β2 subunit is 
exclusively expressed in gastric tumors, raises the possibility that this subunit would have a 
role in tumorigenesis or cell growth 69. Anyhow, as the actions of NO are so widespread, sGC, 
no matter which isoform, is likely to be present in all tissues. 
For each α and β subunit, spliced variants have been reported. In several human tissues and 
cell lines, Behrends et al. discovered a variant of the α2 subunit (α2i) containing 31 additional 
amino acids in the catalytic domain. The α2i subunit retained its ability to heterodimerize, but 
the resulting α2iβ1 isoforms exhibited no sGC activity 70. For the α1 subunit, three mRNA 
species were identified, of which only one contained the full expression sequence, necessary 
for the formation of a functional α1 subunit. The other two, N-terminal truncated variants 
have a significantly reduced enzymatic activity, suggesting that they do not contribute to the 
cGMP formation 71. Using PCR, Chhajlani et al. detected a splice variant of the β1 subunit 
that lacks 33 amino acids when compared to the original β1 subunit 72. Finally, an 
alternatively spliced variant of the β2 subunit was reported in human corpus cavernosum. It is 
suggested that this subunit may be NO insensitive because of the absence of 2 exons that are 
homologous to the N-terminal heme-binding domain 73.  
 
I.1.6. Transcriptional and post-transcriptional regulation of sGC 
Several factors are known to regulate sGC expression. The chronic exposure of cultured rat 
pulmonary artery smooth muscle cells (rPASMC) to NO donor compounds has been shown to 
decrease sGC subunit mRNA in a cGMP-dependent way 74. Also other investigators 
suggested that cGMP regulates sGC subunit gene expression. Ujiie et al., observed that 
incubation of cultured rat medullary interstitial cells with cGMP-elevating agents, decreased 
sGCα1 and β1 subunit mRNA levels 75. Similarly, in aortic smooth muscle cells the sGC 
subunit gene expression was shown to decrease upon incubation with the phosphodiesterase 
(PDE) type 5 inhibitor Zaprinast 76. Increased cGMP levels may alter sGC subunit gene 
expression via downregulation of the RNA-binding protein HuR (human R, embryonic lethal 
abnormal visual [ELAV]-like RNA-binding protein), thereby destabilizing sGC mRNA 77. 
Similarly, also cAMP has been reported to decrease the expression and RNA binding of HuR 
78
. So, alternatively, cGMP may also inhibit the class III cAMP phosphodiesterase activity 79, 
leading to increased cAMP levels that in turn may decrease sGC subunit mRNA levels. This 
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cAMP-mediated reduction of the sGC mRNA and protein levels has not only been described 
in rat aortic smooth muscle cells 80 but also in other cells like rat fetal lung fibroblasts 81 and 
pheochromocytoma (PC12) cells 82. cGMP may also exert its effect through activation of the 
cGMP-dependent protein kinase, which is known to phosphorylate splicing factor 1 and 
thereby inhibiting the prespliceosome assembly 83. 
In certain disease states, such as hypertension, atherosclerosis, hypercholesterolemia and 
Alzheimer’s disease 84, 85, it is demonstrated that disturbances in sGC levels and/or activity 
may play an important role in the pathophysiology of these disorders. Ruetten et al. found a 
significant reduction in mRNA and protein expression of both the sGCα1 and β1 subunits in 
the aortic rings of young and aging spontaneously hypertensive rats (SHR) when compared 
with normotensive Wistar-Kyoto rats (WKY), which correlated with an attenuated response to 
YC-1 activation of sGC 86. Further evidence for a role of sGC in hypertension comes from a 
study of Kloss et al, that showed a downregulation of the sGCβ1 subunit expression in 
senescent SHR compared with age-matched WKY 87. In addition to hypertension, both 
research groups demonstrated that also aging lowers the mRNA and protein levels of sGC in 
aortic smooth muscle cells and so worsen the NO-dependent vasodilator mechanism of the rat 
aorta. Furthermore it is suggested that the sGCα
 
and β
 
subunits can be independently 
regulated, as the expression of the β
 
subunit and not of the corresponding α subunit has been 
shown to be switched off in aortic smooth muscle cells of old rats compared with newborn 
and adult rats 88. An age-induced reduction of the sGC activity has also been reported in 
nonvascular smooth muscle cells 89, suggesting that the downregulation of smooth muscle 
sGC may be a common response to aging. Furthermore, reduced β1 but increased β2 mRNA 
and protein levels have been reported in kidney of Dahl salt-sensitive rats 64. Therefore, the 
reduced renal sGC activity found in the Dahl salt-sensitive rats was suggested to be due to a 
higher formation of the physiologically non-active α1β2 heterodimer.  
Hypercholesterolemia is reported to induce an overexpression of the sGC enzyme, albeit in a 
dysfunctional form 90, which may contribute to the pathogenesis of atherosclerosis 91. 
Similarly, chronic myocardial infarction has been shown to increase the sGC expression 
despite the altered vasodilator responses 92. As many cardiovascular diseases are known to be 
associated with an increased vascular oxidative stress, it is not surprising that inhibition of 
sGC activity under pathological conditions such as hypercholesterolemia and atherosclerosis 
is redox-controlled 93. Further evidence is provided by the involvement of reactive oxygen 
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species (ROS) and cyclooxygenase (COX)-2 in the downexpression of the sGCβ1 subunit 
induced by lead in the rat vascular wall 94.  
The effect of hypoxia on sGC expression has been a source of controversy. Crawley and 
colleagues reported that sGC function was impaired in pulmonary arteries from rats exposed 
to 10 % oxygen, leading to decreased cGMP accumulation and vasorelaxation 95. On the other 
hand, Li and associates reported that exposure of rats to hypoxia significantly upregulates 
pulmonary sGC expression 96. The in vitro report of Hassoun et al., is however in line with the 
in vivo study of Crawley et al., as in rPASMC sGC subunit mRNA levels were significantly 
reduced in response to hypoxic concentrations of oxygen 97. Furthermore, also allergic asthma 
has been documented as a down-regulating condition for sGC 98.  
sGC subunit levels have also been shown to be developmentally regulated. During pregnancy, 
stimulation of the sGCβ1 mRNA and protein levels is evident in uterine arterial smooth 
muscle tissue 99. Concomitantly, sGCα1 and β1 subunit mRNA levels rise in unborn rat 
pulmonary artery, beginning at approximately 20 days of gestation, and mRNA and protein 
remain elevated for at least 8 days following birth 100. This concurs with the gentle decrease 
of α1 mRNA in mouse kidney after birth 101. Also in the rat brain, sGC activity was found to 
be high immediately after birth and to decrease during the early postnatal weeks 102. In the 
prenatal rat brain, it has also been shown that only α1 mRNA is expressed, while β1 is absent. 
In the early postnatal stage, however, the expression pattern was reported to be essentially the 
same as at adult age, with a more widespread distribution of the β1 subunit compared to its 
heterodimeric partner sGCα1 103. Also in rat heart, sGC expression underlies a dynamic 
change, as it was shown to shift from endothelial and smooth muscle cells in the neonatal 
stage to only endothelial cells in adult animals. In addition to this anatomical change, also a 
higher cardiac sGC activity was found in the perinatal period 104. The reported changes in 
expression levels, activity and cell types expressing sGC at different times of development 
and in different organs, clearly demonstrate a dynamic regulation of the sGC enzyme.  
Various additional factors like the nerve growth factor (NGF), estradiol, cytokines and 
lipopolysaccharide (LPS) also appear to reduce the sGC enzyme expression. The NGF-
dependent decrease of the sGC subunit mRNA levels was shown to occur via activation of the 
Ras-MAPK signaling cascade 82. Furthermore, it is suggested that the estrogen receptor-
dependent pathway for the regulation of the sGCα1 and β1 subunits by estradiol 105, 106, 
proceeds via NGF, as an elevated level of the NGF is reported in the rat uterus during 
pregnancy 107. Takata and coworkers have demonstrated that inflammatory cytokines, such as
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 interleukin-1β and tumor necrosis factor-α (TNF-α) negatively modulate sGC subunit gene 
expression via NO-dependent and NO-independent mechanisms 108. Also exposure to the 
bacterial inflammatory mediator LPS, causes a reduction in sGC mRNA abundance, enzyme 
mass and enzyme activity 109, 110. The possibility of NGF 111, estradiol 112 and cytokines 113 to 
stimulate the JNK signaling pathway and the blocking effect of an c-Jun NH2-terminal kinase 
(JNK)-II inhibitor on the inhibition of sGCα1 mRNA expression by NFG, TNF-α and 
interleukin-1β 114, implicate a role for the c-Jun kinase in the regulation of the sGC 
expression.  
 
I.1.7. Post-translational regulation of sGC 
I.1.7.1. sGC activation by ligands 
*Nitric oxide (NO) 
It is generally accepted that NO binds to the prosthetic heme group associated with the β 
subunit of sGC, which finally leads to activation of the enzyme and enhanced cGMP 
production. In the unligated state, the heme group displays an absorbance maximum at 431 
nm, the Soret band, indicative of five-coordinated ferrous heme with a histidine as axial 
ligand. The presence of the heme moiety in the reduced Fe2+ state is a major prerequisite for 
the NO-induced activation of sGC, as its removal or oxidation abolishes any NO-induced 
enzyme activation. 
Upon binding of NO, the absorbance maximum shifts to 399 nm 32. Together with the finding 
that heme-free sGC could be activated by the iron-free heme precursor, protoporphyrin IX, it 
was hypothesized that active sGC required a five-coordinate nitrosyl heme complex 115. 
However, much speculation has centered on the precise steps involved in the formation of this 
five-coordinate nitrosyl heme complex (figure I.2). First, sGC was thought to behave as a 
traditional signal transduction receptor and to follow a simple two-step activation process. In 
the first step, NO binds to the sixth coordination position of the heme, forming a 6-coordinate 
ferrous-nitrosyl species with an absorbance maximum at 399 nm. Subsequently, the bond 
joining the heme to His105 breaks, resulting in the five-coordinate species. This second step 
is considered to initiate conformational changes in sGC that greatly increase the catalytic 
activity of the enzyme 116. It is agreed that the initial rate of association is a fast second-order 
process, whereas for the second step, different kinetics have been reported. Zhao et al., found 
that the rate of transition from the six-coordinate to the five-coordinate sGC also depends on 
the NO-concentration 117. This suggested a novel mechanism for sGC regulation, whereby NO 
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not only determines the amount of occupied enzyme but also how quickly the enzyme is 
activated. It was concluded that various additional reactions of NO with sGC, including the 
presence of a second NO-binding site, accounted for this finding. The requirement for two 
NO molecules for full sGC activation, was supported by the work of Russwurm and Koesling 
118
. They presented the all-heme site model that proposes two five-coordinated NO-bound 
states of the enzyme: an active and nonactive state. In the presence of the reaction products or 
substrate and additional NO, the high catalytic activity or active species is formed, whereas in 
the absence of the enzyme’s products, the low catalytic activity or nonactive species is 
formed. Based on the cristal structure of cytochrome c’, it was suggested that the binding of 
the second NO molecule occurred to the heme 119. However, more recently, a second non-
heme site model has been proposed, in which the second NO-binding event involves the 
binding of NO at a non-heme site, or at least at a site that does not influence the heme 
spectrum 120. This model, derived from the observation that the rate at which NO dissociates 
from sGC is much slower than the rate of enzyme deactivation, has significant in vivo 
implications. Under normal resting conditions, during which basal levels of NO are 
synthesized, sGC is most likely to have NO stably bound at the heme and to be partially 
activated (long-lasting tonic activity). Other physiological processes require a rapid rise in 
cGMP levels, driven by an acute increase in NO. In this case the enzyme becomes fully 
activated by NO binding to the non-heme site (phasic activity) and deactivation occurs rapidly 
when levels of NO drop. Both two-site models (all-heme site and non-heme site) account for 
much of the behaviour of sGC in vitro, especially the presence of a low-activity form that is 
spectrally indistinguishable from the fully active sGC. According to Roy and Garthwaite, the 
non-heme site model for the regulation of sGC activity by NO is of doubtful relevance to cells 
121
. Their in vivo measurements of cGMP production by platelet and cerebellar cells are 
entirely consistent with the involvement of only a single ligand binding site and with the 
concept that activation and deactivation follow binding and unbinding of NO to this site. 
Earlier on, criticism on the existence of a second NO-binding site was raised by Bellamy et 
al., who swear by the simple two-state, single-site model 122. To conclude that there is some 
fundamental difference between the behaviour of purified sGC compared to the behaviour of 
sGC in the intracellular milieu, further research has to be done.  
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Figure I.2: Three possible mechanisms 
for the activation of sGC by NO. In all 
schemes, NO binds rapidly to the five-
coordinate ferrous heme (431 nm), 
forming a six-coordinate ferrous-
nitrosyl intermediate (420 nm). The 
scheme depicted by the interrupted line 
(● −●) represents the simple two-step 
binding model. The full lines (−−) show 
the possible steps of the all-heme site 
model, whereas the dotted lines (●●●) 
represent the steps of the non-heme site 
model. The latter two models account 
for the experimental observation that 
there is a low-activity form of sGC 
(depicted in red) that is spectrally 
indistinguishable from the fully active 
sGC (depicted in green)  
(adapted from Poulos 123, and Ballou et al.124).  
 
*Carbon monoxide (CO) 
CO, similarly to NO, binds to the distal side of the prosthetic heme, leading to a 4-6 fold 
increase in cGMP production 32. The binding of CO results in formation of a hexacoordinate, 
rather than pentacoordinate complex without axial ligand displacement. It has been suggested 
that the dissociation of CO from sGC, proceeds through a pentacoordinate intermediate, 
which, by its structural similarity to the heme-nitrosyl complex, presumably is responsible for 
the activation of sGC 125. By steric hindrance, the tyrosine phenyl ring in the sGC distal heme 
pocket, creates a heme environment in which CO binding is strongly impeded 126. Given its 
rather poor sGC-activating property in vitro (30-100 times lower than that of NO), it remains 
unclear how CO can exert physiological signaling effects. However, multiple studies have 
demonstrated modulation of cGMP levels by endogenous produced CO. Moreover, there is 
substantial evidence that CO can regulate sGC, in particular in olfactory neurons in which 
heme oxygenase produces CO 127. In the presence of YC-1, a synthesized benzyl indazole 
derivative, CO has been shown to activate sGC to the same level as that of NO 128. So, the 
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modulation of sGC activity by an endogenous substance mimicking YC-1, could provide the 
molecular basis for CO functioning as a signaling molecule.  
 
*YC-1 
YC-1 or 3-(5’-hydroxymethyl-3’-furyl)-1-benzylindazole, was first shown to inhibit platelet 
aggregation, to disaggregate platelets and to prolong bleedings in mice 129. Additional 
findings, all consistent with its ability to activate sGC, showed that YC-1 inhibits proliferation 
of vascular smooth muscle cells 130 and relaxes smooth muscle cells 131-133. YC-1 activates 
sGC directly, without the intermediate production of NO or some other factor capable of 
activating sGC 30, 128, 133 . However, similar to NO, the activating effect of YC-1 crucially 
depends on the presence of the reduced prosthetic heme moiety of sGC.  
In vitro studies with the purified sGC enzyme demonstrated that incubation with YC-1 leads 
to a 10-fold increase of purified sGC enzyme activity, an effect that was slightly further 
potentiated in the presence of NO 128, 132. In intact cells on the other hand, this synergistic 
effect of NO and YC-1 on activation of sGC was obvious as YC-1 combined with NO was 
reported to be up to 100 fold more effective than the individual compounds 132, 134-136. 
Moreover, YC-1 has been reported to potentiate the weak sGC activator CO to a level of 
effectiveness comparable to NO 30, 128, 137. Those overadditive effects are suggested to be due 
to the facilitated formation of an active five-coordinate NO- or CO-heme complex 138. In other 
studies, the sensitizing action of YC-1 is explained by a reduction of the ligand dissociation 
rate from the heme group yielding a prolonged half-life of the ligand-heme complex 133, 139. 
Besides the data on the mechanism of theYC-1-induced sGC activation, also the data on the 
location of the YC-1 binding site on sGC are controversial. YC-1 was shown not to alter the 
ultraviolet-visible absorptionspectrum of basal or stimulated sGC 128 and, in addition, to still 
bind to a heme-depleted enzyme 133, suggesting that YC-1 combines with a site different from 
the heme group. Furthermore, the inability of YC-1 to sensitize a sGC mutant with a changed 
substrate specificity utilizing ATP instead of GTP, proposed the involvement of a special 
structure within the catalytic domain 139. Guided by structure modelling of sGC with AC as 
template 44, 140 and by the results of mutational studies 45, 47, 141, it was suggested that YC-1 
binds to a pseudosymmetrical site in the catalytic domain, which is equivalent to the allosteric 
regulatory forskolin-binding pocket in AC. Although these findings do not support a direct 
interaction of YC-1 with the heme group, some reports indicate that YC-1 binding to CO-sGC 
results in a shift of the Soret absorption band by 4 nm to a shorter wavelength 142, 143. 
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Additionally, raman resonance studies of the YC-1 interaction with sGC, detected 
spectroscopic alterations of the CO-heme bound in full-length sGC and in a heme-containing 
fragment of the β-subunit in the absence of the catalytic domain 144. Moreover, YC-1 would 
lack the ability to increase the basal activity of a heme-deficient sGC mutant 128. Furthermore, 
a region in the regulatory domain of the α1 subunit has been reported to be important in the 
signal transduction of NO and to represent the target for YC-1 35. These apparently conflicting 
results postulate two or more binding mechanisms, but definitive conclusions await protein 
crystallography 27. Besides the stimulatory effect on sGC, YC-1 has been shown to increase 
the intracellular cGMP level in different cell types by inhibition of cGMP breakdown through 
PDE’s 129, 145. In addition to the cGMP-degrading PDE-1 and 5, the activity of cAMP specific 
PDE- isoenzymes (2-4) was also significantly suppressed by administration of YC-1 134. 
Furthermore, it has been suggested that YC-1 has an indirect effect to stimulate sGC. 
Wohlfart et al. argued that YC-1 stimulates the NO-production by endothelial cells through 
activation of endothelial NO synthase (eNOS) and that the released NO may stimulate sGC 
and increase the intracellular cGMP level 146. However, according to the study of Chun et al., 
the stimulatory effect of YC-1 on the synthesis of endothelial NO is not due to the activation 
of eNOS 147. On the other hand, the results of Schmidt et al., suggest that a heat-labile factor 
present in the endothelial cells potentiates the effect of YC-1 on NO-activated sGC 135. Even 
many other reports have established that YC-1 exhibits some additional effects that do not 
involve cGMP. For example, in rat neutrophils, YC-1 has been shown to block the Ca2+ entry 
through inhibition of the tyrosine kinase activity 148 and to inhibit the generation of 
superoxide anions 149. Additionally, it has an inhibitory effect upon the human white blood 
cell function through a cAMP-dependent pathway 150. Besides the antiproliferation effect 
through activation of sGC, YC-1 also demonstrates an inhibitory effect on cell proliferation 
via a cGMP-independent pathway. In rat mesangial cells, the YC-1-induced cell-cycle arrest, 
proceeded through suppression of cyclin D1 synthesis and related cyclin-dependent kinase 
(CDK)4 kinase activity 151, whereas in human umbilical vein endothelial cells, the increased 
level of the CDK-inhibitory protein p21 and associated lower CDK2 activity, was the 
underlying mechanism 152. A study in endothelial and chromaffin cells from bovine adrenal 
medulla showed that prolonged exposure to YC-1 at concentrations that activate sGC and 
cause vasorelaxation, results in apoptotic death in association with increased caspase-3-like 
activity 153. An additional mode of action of YC-1 is the enhancement of the gene expression 
and production of the TNF-α in LPS/interferon-γ-activated rat alveolar macrophages 154. 
According to Yeo et al., YC-1 has the potential to become an anticancer agent, as it appears to 
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inhibit hypoxia-inducible factor-1-α and consequently halts tumor growth by blocking tumor 
angiogenesis and tumor adaptation to hypoxia 147, 155.  
The effects of YC-1 seems to vary dependent on the cell type and perhaps also on the 
experimental conditions. In isolated rat aortic smooth muscle cells, YC-1 increases the 
intracellular cGMP concentration, whereas in the ventricular myocardium it does not 131. On 
the other hand, in rat cardiomyocytes in vivo, YC-1 was shown to induce apoptosis via cGMP 
signaling 156. YC-1 increases cGMP levels in platelets and smooth muscle cells by direct 
activation of sGC without any effect on the production of NO 157. Nevertheless, in bovine 
aortic endothelial cells and human umbilical vein endothelial cells, YC-1 stimulates the 
production of NO 146, as discussed above. 
 
*BAY 41-2272 
From a new series of potent pyrazolopyridine derivatives synthezised using the YC-1 
chemical lead structure, BAY 41-2272 was selected as a promising heme-dependent, but NO-
independent, sGC-stimulator. In vitro studies showed that BAY 41-2272 activates purified 
sGC up to 30-fold and that it potentiates sGC activation by NO at ~ 100-fold lower 
concentrations than its analog YC-1 158. However, the potency of BAY 41-2272 in vivo, with 
respect to platelet aggregation, is considerably reduced and certainly much lower than its 
hypotensive actions 159. The structural similarity between BAY 41-2272 and YC-1 suggests 
that both compounds have similar mechanisms of action. However, the effect of BAY 41-
2272 on PDE-5 activity is at present controversial. Stasch et al., 158 and Bischoff and Stasch 
160
 observed that BAY 41-2272 was devoid of any inhibitory effect on PDE-5 up to a 
concentration of 10 µmol/L. However, at higher doses, Mullershausen et al. demonstrated 
PDE-5 inhibitory effects of BAY 41-2272 in platelets. They observed that this inhibitory 
action critically depends on the substrate concentration, indicating a competitive component 
in the mechanism of inhibition 161. Still, as the concentration of BAY 41-2272 used by 
Mullershausen et al., is several orders of magnitude above those needed for sGC stimulation, 
the PDE-5 inhibition by BAY 41-2272 is rather considered as irrelevant 27. In addition, other 
non-cGMP specific effects have been reported for BAY 41-2272, although much less in 
comparison to YC-1. In ovine pulmonary artery, BAY 41-2272 seems to stimulate the 
sarcolemmal sodium pump independent from cGMP 162. Furthermore, it was demonstrated 
that besides stimulating sGC, inhibition of the Ca2+ entry also represents an important 
mechanism in BAY 41-2272-induced relaxation of rat basilar 163 and mesenteric artery 164. In 
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rabbit aorta 165 as well as in human and rabbit corpus cavernosum 166, the relaxant responses 
to BAY 41-2272 were only partially attenuated by ODQ, suggesting an additional cGMP-
independent mechanism.  
As a 3H-labelled derivative of BAY 41-2272 was bound to the cysteines 238 and 243 of the α1 
subunit of sGC after radiation, it was suggested that these residues or the surrounding region 
might represent the target site for non-NO sGC-stimulators 158, 167. However, the observation 
that this region is poorly conserved in the α2 subunit of sGC and that the α2β1 heterodimer is 
also activated by YC-1 and BAY 41-2272 168, argue against the binding of those sGC-
stimulators to this N-terminal region of the α subunit. As with YC-1, the postulated allosteric 
site involved in NO sensitization of sGC will have to be validated by co-crystallization 
studies.  
 
*BAY 41-8543, CFM-1571 and A-350619 
Like BAY 41-2272, BAY 41-8543 and CFM-1571 were synthesized based on YC-1 as lead 
structure, whereas the chemical structure of A-350619 shares no structural similarity with 
YC-1. As members of the class of heme-dependent sGC-stimulators, their activity depends on 
the presence of the reduced heme moiety of sGC and is characterised by strong synergistic 
enzyme activation when combined with NO. They also increase the maximal catalytic rate of 
the sGC enzyme, except for CFM-1571 27. BAY 41-8543 is regarded as the most promising 
compound with respect to potency, specificity as well as availability after oral administration. 
Like its close chemical analogue BAY 41-2272, it is about two orders of magnitude more 
potent than YC-1 in vitro 169. However, in several in-vivo models a 3-fold higher dose of 
BAY 41-2272 would be needed to show an effect comparable to BAY 41-8543 170.  
 
*BAY 58-2667 
Through a high-throughput screening using a read-out system consisting of a chinese hamster 
ovary cell line expressing sGC 171, a cyclic GMP-sensitive cation channel and aequorin 172, a 
class of aminodicarboxylic acids were identified as a new type of sGC activators. Following 
chemical optimization, BAY 58-2667 was identified as the most potent member. With an 
EC50 value in the subnanomolar range, it is about 160 fold more potent than BAY 41-2272. In 
contrast to heme-dependent sGC stimulators like BAY 41-2272, that show a strong synergism 
when combined with NO and a loss of effect after the removal or oxidation of the heme 
moiety, BAY 58-2667 produces an additive, not synergistic effect when combined with NO 
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and its activity is maintained, even enhanced, in oxidized or heme-free enzyme 173. This 
differential activity of BAY 58-2667 on sGC activity together with binding studies and 
photoaffinity labelling studies, suggested two high affinity binding sites for BAY 58-2667: 
one that is saturable at nanomolar concentrations and shows no direct interference with the 
heme moiety and a second one, which changes its affinity for BAY 58-2667 from low to high 
upon oxidation or removal of the heme moiety of sGC 174. Subsequently, it was shown that 
this heme-dependent high affinity site for BAY 58-2667 exhibits a direct competitive 
inhibition between the negatively charged carboxylic groups in BAY 58-2667 and the 
propionic acids of the heme for the tyrosine 135 and arginine 139 residues of the β subunit. 
As those two aminoacids, together with serine 137, form a unique heme-binding motif (Y-x-
S-x-R) 175, this competition results in the displacement of the heme moiety and as a 
consequence activation of sGC due to release of the axial heme ligand. Those actions are 
facilitated by oxidation of the heme moiety as this has been shown to strongly reduce the 
binding affinity for the heme-binding motif 176.  
 
To overcome a pathological state of NO-deficiency, different NO donor compounds have 
been clinically used for over 100 years, e.g. in angina pectoris and coronary heart disease. 
However, there are certain disadvantages with NO donor-based therapies, such as the 
development of tolerance, insufficient biometabolism, unpredictable pharmacokinetics of NO 
and non-specific interactions of NO with other biological molecules, including the formation 
of peroxynitrite (ONOO-) resulting in tyrosine nitration. Therefore compounds that directly 
activate sGC in an NO-independent manner might offer considerable efficacy and safety 
advantages over current therapies in a variety of applications, including cardiovascular and 
sexual dysfunctions 27, 177. Indeed, the vasorelaxant and/or anti-platelet actions of non-NO 
sGC-stimulators like YC-1, BAY 41-2272 and BAY 41-8543 and non-NO sGC-activators 
like BAY 58-2667 in vitro are mirrored in vivo 170, 174, 178, 179. Moreover, the selectivity of 
BAY 58-2667 to activate oxidation-impaired/heme free sGC has serious implications for its 
use as diagnostic tool or as highly innovative therapy for vascular disease. After all, the NO-
insensitive ferric/heme-free form of sGC is present physiologically and its level increases 
under pathological conditions associated with oxidative stress 180-182. Not only do these 
compounds offer novel therapeutic approaches, they also highlight previously unknown 
regulatory sites on the enzyme which may be important physiologically, representing target 
sites for endogenous molecules modulating sGC activity. 
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I.1.7.2. sGC inhibition 
*Methylene blue  
Methylene blue (MB) has been widely used to probe the involvement of the NO/cGMP 
signal-transducing pathway in various biological processes. It is known to be an inhibitor of 
sGC 183-185, although its action is not specifc for this enzyme. This is apparent from the 
numerous reports in the literature which showed that MB was more potent in inhibiting 
endothelium-dependent than nitrovasodilator-induced relaxation 186-188. Subsequent 
experiments revealed that MB directly inhibits eNOS at concentrations some 100-fold lower 
than those that inhibit sGC 189. In addition, it was demonstrated that MB lowers NO 
concentrations by the production of superoxide anions from its reduced form 187, 190. Both 
non-sGC specific effects were also reported for LY-83583, another compound recognized as 
sGC-inhibitor 191, 192. Additional studies that have questioned the mechanism of action of MB, 
have revealed that this compound is also active in inhibiting prostacyclin synthesis 193 and in 
altering the noradrenaline uptake, release and metabolism 194. Furthermore, MB appears to 
modulate the cholinergic system 195, 196 by inhibition of the cholinesterase activity and by 
muscarinic receptor antagonism 197, 198. Clearly, those drawbacks may lead to 
misinterpretations. Therefore, the identification and study of cGMP-dependent and -
independent effects, benefit substantially from a more potent and selective sGC-inhibitor, 
such as the oxadiazoloquinoxaline derivative, ODQ. 
 
*ODQ 
Garthwaite et al., demonstrated that ODQ inhibited the basal and NO-stimulated sGC-activity 
without interfering with the steps leading to NO synthesis 199. Its mechanism of action is 
believed to be specifically related to the oxidation of Fe2+ into Fe3+ 200, which decreases the 
sensitivity of the heme group for NO and the subsequent cGMP elevation 201. This is 
translated into a significant rightward shift of the NO concentration-response curve. In 
addition, ODQ also attenuates the maximal sGC activity, pointing to a mixed 
competitive/noncompetitive type of inhibition, instead of a simple competitive antagonism. 
However, in the study of Feelisch et al., no evidence for a mixed type of inhibition was 
obtained 202. In contrast to the irreversible inhibition of purified sGC 200, ODQ was shown to 
reversibly inhibit basal and NO-enhanced sGC activity in neuronal tissues in vivo 203. 
Removal of the oxidized heme and insertion of the ferrous heme into the apoenzyme was 
suggested as endogenous mechanism to reactivate sGC. This hypothesis is supported by the 
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finding that the heme may move in and out of its sGC-pocket in the presence of lipophilic 
compounds 34, and that NO promotes heme transfer from hemoproteins to apo-sGC 204.  
The previous reports on the ability of ODQ to inhibit the basal sGC activity are contradicted 
by the study of Zhao et al., showing that ODQ-treated sGC had the same basal activity as 
untreated sGC. They state that sGC inhibition is based on a selective interaction and oxidation 
of the heme group, without adversely affecting the catalytic domain. In addition, re-reduction 
of the heme by dithionite completely restored the NO sensitivity 205. On the contrary, 
Kosarikov et al. did not observe a reversal of sGC inhibition when in the presence of ODQ, 
the heme is re-reduced by dithionite. This suggests that in addition to its role as oxidant of the 
sGC heme, ODQ may have another mechanism, which involves the binding to a region that is 
not associated with NO, metal or nucleotide binding. Moreover, since the changes in the far-
UV circular dichroism spectrum of NO-activated sGC induced by ODQ were strikingly 
similar with those induced by YC-1, it was concluded that these compounds bind to sGC at 
the same site or overlapping sites 206. 
Although ODQ has been shown to be a potent and highly selective inhibitor of sGC, it is not 
infallible. Besides its action on sGC, it was found to inhibit basal and stimulated NO-
production. It should however be mentioned that this effect is related to relative high 
concentrations of ODQ. Still, preincubation with ODQ, markedly potentiated its NOS 
inhibitory effect, suggesting that ODQ may be metabolically converted to a more potent NOS 
inhibitor. Moreover, ODQ would also affect vasorelaxation induced by organic nitrates and 
NO-donors like sodium nitroprusside by inhibiting their bioactivation via the heme-containing 
cytochrome P-450 (CYP) system 202. In addition, also the heme enzymes myoglobin and 
hemoglobin have been shown to be targets of ODQ. The ODQ scavenger function of 
myoglobin was suggested to account for the failure of ODQ to inhibit the NO-induced 
increase in cGMP content of the myoglobin-rich ventricular cardiomyocytes 207. Indirectly, 
this also reflects the higher effectiveness of ODQ in aortic tissue, which contains no 
detectable amounts of myoglobin 208. It was shown that the inhibitory effect of ODQ is 
abolished by its reaction with oxyhemoglobin and the resulting formation of methemoglobin. 
Given the high level of oxyhemoglobin in blood, this reaction is likely to significantly alter 
the potency of ODQ in vivo and has therefore serious implications for the therapeutic use of 
ODQ 205, 209. Furthermore, the inhibitory effect of ODQ on N-acetylcysteine-induced 
relaxation in LPS-treated aortic rings 210 and on nonadrenergic-noncholinergic (NANC) 
relaxation in rectum longitudinal muscle strips 211, has also been related to mechanisms other 
than inhibition of sGC.  
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I.1.7.3. sGC phosphorylation 
Phosphorylation delineates one of the most important molecular mechanisms by which 
several signals produce their biological responses. Both α1 and β1 subunits of sGC contain 
putative phosphorylation sites for multiple kinases and may represent potential target sites 
contributing to the regulation of sGC activity. Early studies on sGC have demonstrated that 
sGC could be phosphorylated ‘in vitro’ by the Ca2+-dependent protein kinase C (PKC) and 
cAMP-dependent protein kinase (PKA), resulting in increased activity 212, 213. In yet another 
study, PKC was reported to increase phosphorylation and activity of sGC in PC12 cells 214. 
Kostic et al., showed that the stimulatory action of PKA on the production of cGMP proceeds 
through the phosphorylation of two N-terminal serine residues of the sGC α subunit and this 
mechanism accounts for the NO-independent AC-controlled production of cGMP 215.  
The cGMP-dependent protein kinase (PKG) on the other hand, attenuates the catalytic 
capacity of sGC, most likely through an inhibitory feedback mechanism. The studies of 
Murthy et al., demonstrate inhibition of sGC activity via PKG-dependent phosphorylation, 
which is analogous to PKA-mediated inhibition of AC 216, 217. Those data are not in line with 
those of Ferrero et al., who demonstrate that a PKG-dependent stimulation of protein 
phosphatase(s), that reduces the Ser/Thr phosphorylation level of the sGCβ1, is the underlying 
mechanism for the feedback sGC inhibition 218. In line with the notion that phosphorylation is 
important for sGC function, 17β-estradiol is reported to inhibit sGC by stimulation of protein 
tyrosine phosphatase activity and subsequent dephosphorylation 219. Moreover, it was recently 
reported that both inhibition of tyrosine phosphatases and the presence of ROS induce 
tyrosine phosphorylation of the sGCβ1 subunit accompanied by a reduced NO sensitivity and 
enhanced basal activity 220. This latter effect can be due to Src-like kinase-mediated 
phosphorylation of AGAP-1 (the prototype of an ArfGAP protein with a GTPase-like domain, 
Ankyrin repeats, and a pleckstrin homology domain), which binds to sGC in a 
phosphorylation-dependent way 221.  
 
I.1.7.4. Protein-protein interactions involving sGC 
Protein-protein interactions can alter both the activity and subcellular localization of the 
interacting partners. In the case of sGC, the chaperonin containing t-complex polypeptide 
(CCT) subunit η interacts with the β1 subunit of sGC and, in cooperation with some other 
factor, inhibits NO-stimulated sGC activity by modifying the binding of NO to the heme 
group or the subsequent conformational changes 222. On the other hand, the interaction of sGC 
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with the heat shock protein (Hsp) 70 has been reported to increase the cGMP-forming ability 
of sGC 223. Additionally, the binding of Hsp90 to the β1 subunit of sGC was shown to regulate 
the pool of active enzymes by affecting the protein levels of the two subunits. The abundantly 
expressed Hsp90, has also been found to bind to eNOS 224, 225, to facilitate the calmodulin-
dependent disruption of eNOS binding with the inhibitory protein caveolin-1 226 and to 
mediate the interaction with between eNOS and protein kinase B/Akt 227, 228. Therefore it was 
suggested that in cells that express eNOS or nNOS along with sGC, Hsp90, in addition to 
preserving sGC levels, would facilite the autocrine actions of NO by bringing together the NO 
source and its target 229. This prevents the inactivation of NO by superoxide anion and the 
formation of peroxynitrite, which is a toxic molecule that has been implicated in the 
pathology of several vascular diseases. Data by Venema et al. show that in endothelial cells, 
the majority of the sGC is membrane-associated, whereas in vascular smooth muscle cells 
most of sGC is found in the cytosol. Therefore it was speculated that eNOS, which is located 
in specific plasmalemmal microdomains called caveolae 230, recruits sGC to the plasma 
membrane through their mutual interaction with Hsp90, whereas in the eNOS-negative 
smooth muscle cells, sGC remains mostly in the cytosol 231. Analogously Hsp90 is suggested 
to play an essential role in the translocation of sGC to the plasma membrane in response to an 
agonist-induced elevated cytosolic Ca2+ concentration 232, 233. The membrane-associated sGC 
had a higher apparent sensitivity toward NO, demonstrating that the subcellular localization 
of sGC can modulate its activation properties and is functionally important. Also in the 
sarcolemmal region of skeletal muscles, sGC was found in colocalization with NOS and the 
CO-producing enzyme Heme Oxygenase-2 234. In contrast with Hsp90 and CCTη that only 
bind to the sGC β1 subunit, the multivalent scaffold protein AGAP1 has been reported to bind 
to the α1 and β1 subunit of sGC. Thereby, it serves as a bidentate partner accomodating both 
subunits of sGC, without affecting its enzymatic capacity or NO sensitivity. The finding that 
AGAP1 is subject to tyrosine phosphorylation, most likely by members of the Src family and 
the fact that this significantly enhances its interaction with sGC, points to a convergence of 
signal transduction pathways at the level of AGAP1 involving Arf-type GTPases, Src-like 
kinases, and the NO/cGMP signaling cascade 221. Moreover, cross-talk between the 
NO/cGMP and tyrosine kinase signaling pathways has also been reported at the level of sGC 
220
.  
Besides the association of the α1β1 heterodimer with the plasma membrane, the α2 subunit has 
been shown to target to synaptosomal membranes through its interaction with the third PDZ 
                                                                                                                     General introduction 
 23 
(post-synaptic density protein-95/Discs large/zona occludens-1)-domain of the post-synaptic 
density protein-95 (PSD-95) 235. As PSD-95 integrates the NMDA receptor with its first PDZ-
domain 236, 237 and nNOS with its second PDZ-domain 238, a signal transduction unit is formed 
downstream of the NMDA receptor which is important for synaptic plasticity and learning 239. 
So, PSD-95, just like Hsp90 for eNOS and sGCα1β1, serves as a linker between nNOS and 
sGCα2β1. In both cases NO would not need to travel through the cell to reach its cytosolic 
receptor sGC, but NO/cGMP signaling would be more confined to a protein complex, 
presumably at or near the cell membrane 233. Clearly, those findings challenge the designation 
of sGC as a purely cytosolic enzyme. The term ‘soluble’ or ‘cytosolic’ GC may therefore be 
misleading and instead some prefer to use the term ‘NO-sensitive GC’. 
 
I.1.7.5. Other 
Before the identification of NO as the physiological activator of sGC, a multitude of redox 
active substances have been proposed as activators. Several mechanisms of activation have 
been postulated and subsumed as “redox-regulation” of sGC 240-242. The importance of thiol 
groups of sGC has been shown by various reports. The use of several thiol blockers led to 
inhibition of basal as well as stimulated activity of sGC, a process prevented by an excess of 
the thiol-reductant dithiothreitol 243, 244. Furthermore, formation of mixed disulfides occurred 
as 32S-labeled cysteines were shown to be incorporated into sGC 245. Those findings clearly 
favour an oxidative-reductive mode of sGC modulation which involves sulfhydryl-disulfide 
interconversions on the sGC enzyme. In contrast to the various reports observing largely 
inhibitory effects of thiol-oxidizing compounds such as diamide, the study of Wu et al., 
proposed a concentration-dependency of the diamide-induced regulatory effect on sGC. They 
demonstrated in platelets that low concentrations of thiol-oxidizing compounds or partial 
oxidation is associated with increased sGC activity, whereas higher concentrations or massive 
oxidation results in loss of enzymatic activation 246. Also a more recent study demonstrated an 
inhibitory effect on NO-elicited relaxation of endothelium-denuded bovine pulmonary arteries 
(BPA) and stimulation of sGC activity in BPA homogenates by 1 mM of diamide, however 
not with lower doses of diamide. Furthermore, this study supports the possibility that besides 
the direct oxidation of sGC thiols, diamide also inhibits the NO-induced stimulation of sGC 
through oxidation of glutathione (GSH). The level of cytosolic NADPH controlled by the 
pentose phosphate pathway, appears to regulate this GSH balance and therefore this system is 
suggested to be an additional potentially important physiological mechanism of controlling 
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sGC activity 247. In addition to modulation of the redox status of sGC thiols, also more 
indirect effects such as an improved NO-generation from NO-donors 248 and the reconversion 
of reactive NO-derived metabolites such as ONOO- to NO 249, participate in the thiol-
mediated effect on sGC stimulation. Like ONOO-, also the reactive oxidant species hydrogen 
peroxide (H2O2), has been shown to stimulate sGC activity and to promote vascular relaxation 
250-252
. Besides a direct effect of H2O2 on sGC activity, also activation of NO-synthase was 
reported to be partially involved 253-256. This was not supported by Garcia-Gardena et al, who 
claim that H2O2 increases eNOS tyrosine phosphorylation, which reduces its activity 257. 
However, in several following reports, the relaxation and sGC activation elicited
 
by H2O2, 
could be confirmed and the
 
participation of NO in this response excluded 258-260. Recently, 
tyrosine phosphorylation as mentioned above, was reported as a potential mechanism for the 
H2O2-mediated regulation of sGC 220. 
In human platelets 261 and bovine lung 262, an endogenous inhibitor of sGC has been isolated. 
However, the molecular identity of this inhibitor is still unknown. The 149 kDa protein 
detected in lung tissue is suggested to be an allosteric regulator, whereas the inhibitory effect 
by the platelet-derived inhibitor, results from the presence of the heme.  
Isoliquiritigenin, a chalcone derivative of vegetable origin, was shown to exert a vasorelaxant 
effect on precontracted rat aortic rings by activating sGC and increasing cGMP 263. However, 
later on, this finding was refuted by the lack of the potent and selective sGC inhibitor ODQ to 
influence the action of isoliquiritigenin. Instead, it was suggested that the effects of 
isoliquiritigenin are due to direct inhibition of phosphodiesterase activity for which evidence 
has also been obtained in cell-free preparations 264 and in rat ventricular heart muscle 265. 
Copper sulphate has been reported to inhibit sGC by the reversible high affinity binding of 
Cu+-ions to a site of the protein that is critically involved in enzyme catalysis. This Cu+-
mediated inhibition of sGC may not play a major role under normal physiological conditions 
but become significant under pathophysiological conditions 266.  
Also rather likely in pathological states is the inhibition of basal and NO stimulated sGC 
activity by biliverdin IX, a heme-degradation product of heme oxygenase besides CO. The 
inhibitory mechanism of biliverdin IX is suggested to be different from ODQ as biliverdin IX 
was able to inhibit protoporphyrin IX activation whereas ODQ was not 267.  
For many enzymes, product inhibition is a relevant mechanism of regulating catalytic activity. 
In case of sGC, feedback inhibition by both cGMP and pyrophosphate (PPi) has been 
demonstrated in an adapted Sf9 cells/baculovirus system for overexpression of an 
enzymatically active human sGC protein. Both reaction products displayed independent 
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binding and cooperativity with respect to enzyme inhibition. The extent of inhibition by 
cGMP depended on the activation state of the enzyme, whereas inhibition by PPi was not 
affected by the enzyme state 268. The sodium nitroprusside (SNP)-stimulated enzyme was 
reported most susceptible to cGMP inhibition, although even in this case the IC50 was in the 
6-10 mM range, concentrations that are unlikely to occur in vivo. Moreover, kinetic studies of 
sGC catalysis reveal a linear relation between the cGMP concentration and the time, 
indicating that the enzyme is not subject to feedback, or ‘end-product’, inhibition 49.  
Ca2+ has been reported to be a negative allosteric modulator of sGC, which is in line with the 
antagonistic functions of Ca2+ and cGMP in several physiological systems 269-271. According 
to Parkinson et al., Ca2+ decreases both Vmax and Km of sGC , consitent with an uncompetitive 
mechanism of inhibition, in which Ca2+ directly interacts with the enzyme 269. The calcium 
concentrations used to inhibit sGC in the studies (5 to 250 µmol/L) are, however, much higher 
than those commonly observed in cells, even when responding to Ca2+-elevating stimuli. 
Therefore, a relevant role for Ca2+ in regulating sGC under physiological conditions can not 
be assumed. Moreover, the study of Parkinson et al. that shows a decrease in the cGMP 
accumulation in NO-stimulated HEK (human embryonic kidney)-293 cells in response to an 
influx of Ca2+, failed to address the possible involvement of a cGMP-hydrolysing Ca2+-
calmodulin sensitive PDE-1 which has a sensitivity to Ca2+ in the appropriate range for 
physiological Ca2+ signaling 269. However, as discussed above, Ca2+ appears to regulate the 
association of sGC with cellular membranes accompanied by increased sensitivity toward NO 
232
.  
On protein level, also alternative heterodimerization and changes in the extent of 
homodimerization may play a role in regulating sGC activity. As discussed above, the study 
of Gupta et al., indicates that the β2 subunit complexes with the α1 subunit of sGC to form a 
heterodimer with reduced sensitivity to NO and that the β2 subunit can inhibit the NO-
stimulated cGMP accumulation in cells containing the α1β1 form of sGC by exchanging with 
the β1 subunit. Therefore, enhanced expression of the β2 subunit has been implicated in the 
downregulation of renal sGC activity in Dahl salt-sensitive rats 64. Expression of alternative 
splice variants exposing modified N-or C-terminal portions but retaining the dimerization 
region may contribute to the fine tuning of sGC activity through proteasomal degradation of 
the resultant complexes 41. Likewise, the variant of the α2 subunit α2i can compete with the α1 
subunit and may act as a dominant negative inhibitor 70. Although naturally occurring 
homodimers have not been isolated, glutathione S-transferase (GST)-tagged recombinant 
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human α1- and β1-subunits have been shown to form homodimeric GST-α1α1 and GST- β1β1 
complexes that are devoid of enzymatic activity. Upon coexpression of the respective 
complementary subunits, heterodimers were preferentially formed, whereas homodimers were 
still detectable. Those observations suggest the possibility of an physiological equilibrium 
between homo-and heterodimers that regulates sGC activity in cells 272.  
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I.2. Soluble guanylyl cyclase-mediated smooth muscle 
relaxation 
 
I.2.1 Soluble guanylyl cyclase effectors 
Stimulation of sGC and the resultant accumulation of cGMP regulate complex signaling 
cascades through immediate downstream effectors, including PKG’s, cyclic nucleotide-gated 
(CNG) ion channels and cGMP-regulated PDE’s. The specificity of cellular responses to 
cGMP is dictated by cGMP-binding motifs in the target proteins. Two evolutionarily distinct 
allosteric sites for binding of cGMP are present in eukaryotic cells. One occurs with 
significant sequence homology in PKG’s and PKA’s and in the CNG channels, while the 
other occurs in PDE’s. In addition, the outcome of an increased intracellular cGMP level is 
determined by the type and combination of target proteins and substrates, the cGMP-
metabolizing enzymes expressed in cells, and their intracellular colocalization and 
organization into selective compartments and organelles 1.  
The principal intracellular mediator of the cGMP signal is the family of PKG’s, that become 
active as serine/threonine kinase upon binding of cGMP 2. In mammals, two types of PKG’s 
have been described: the cytosolic 76 kDa homodimer PKG I 3 and the membrane-associated 
86 kDa monomer PKG II 4. The type I form is more widely distributed and has a particularly 
high expression level in the cerebellum, platelets and all types of smooth muscle cells 5. 
Furthermore, it consists of an α and a β isoform, which arise from alternative splicing 3, 6. By 
immunological analysis, PKG Iβ was shown to be mainly expressed in cells that also have 
been reported to contain high concentrations of sGC, such as smooth muscle cells. It is 
suggested that the Iβ isoform is predominantly expressed in those tissues to dampen the 
physiological effects of short-term increases of cGMP 7, as the Iβ isoform requires a 10-fold-
higher concentrations of cGMP for activation than the Iα isoform 8. The type II form of PKG 
is mainly expressed in intestine, kidney, chondrocytes and specific brain regions, but notably 
absent from cells of the cardiovascular system 5. Because of the significant homology 
between the cyclic nucleotide binding domains, PKA’s can also be targets for cGMP, 
although with a 50-fold lower selectivity than for cAMP 5, 9. Insight into PKG functions were 
obtained from analyses of substrates phosphorylated by PKG and from PKG knockout mice. 
Homozygous deletion of the PKG I gene in mice abolishes relaxation of vascular 10, visceral 
10, 11
 and penile smooth muscle cells 12, resulting in a very low ability to reproduce and severe 
vascular and intestinal dysfunction with death at early age 10. In addition, the PKG I knockout 
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mice also showed an increased platelet adhesion and aggregation 13. The phenotype of the 
PKG II knockout mice on the other hand, included a normal lifespan 14, decreased 
longitudinal bone growth 14, decreased intestinal chloride secretion 14, 15 and altered renin 
secretion 16. Those data support that PKG I plays an important role in regulating smooth 
muscle tone, proliferation and differentiation of vascular smooth muscle cells, endothelial cell 
and platelet function, whereas PKG II has an influence on the hemodynamic parameters via 
regulation of renin release and ion transport in the kidney 17. 
Another target for cGMP includes the voltage-gated CNG channels. In the principal family of 
CNG channels, each member consists of 4 subunits that form a voltage-responsive core in the 
plasmamembrane that directly opens upon binding of cyclic nucleotides 18. They regulate the 
influx of Na+ and Ca2+ into cells and are critical for the regulation of phototransduction and 
neurotransmission in the retina 19.  
PDE’s are the last group of cGMP activated effectors. Those enzymes which catalyze the 
conversion of cAMP or cGMP to 5’-adenosine monophosphate (5’-AMP) or 5’-guanosine 
monophosphate (5’-GMP), respectively, are crucial for the modulation of the intracellular 
concentration of cyclic nucleotides 20. Based on their specificity for cGMP and/or cAMP 
hydrolysis and tissue specific expression, multiple families of PDE’s have been characterized 
21
. PDE-5, a homodimer of 93 kDa subunits specifically degrades cGMP and is predominantly 
expressed in smooth muscle cells 22. Direct binding of cGMP to allosteric sites has been 
shown to promote phosphorylation of PDE-5 by either PKG or PKA, thereby indirectly 
stimulating enzyme activity 1.  
 
I.2.2. Mechanisms of cGMP-dependent smooth muscle relaxation 
The mechanism underlying the contractile activity of the smooth muscle cell is based on 
synergistic and antagonistic forces regulating the intracellular Ca2+ concentration ([Ca2+]i). 
Increases in the levels of cytosolic [Ca2+]i initiate smooth muscle contraction by binding to the 
universal intracellular Ca2+ receptor calmodulin 23, which in turn binds to and activates 
smooth muscle light chain kinase (MLCK) 24. Activated MLCK catalyzes the phosphorylation 
of serine 19 on the 20 kDa light chain of myosin (MLC20) 25, thereby increasing its actin-
activated ATPase activity 26 and subsequent cross-bridge cycling. As a means to balance 
MLCK activity, myosine’s actin-activated ATPase activity is attenuated by dephosphorylation 
of MLC20 by myosin light chain phosphatase (MLCP), a smooth muscle specific 
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serine/threonine protein phosphatase 27, 28. Decreases in [Ca2+]i and MLC dephosphorylation 
are considered as 2 salient, independently controlled events in smooth muscle relaxation 29.  
 
I.2.2.1. Regulation of [Ca2+]i 
As increases in Ca2+ are required for MLC phosphorylation and contraction, reduction of the 
free intracellular cytosolic Ca2+ concentrations was the first mechanism proposed for cGMP-
dependent smooth muscle relaxation 30, 31. Several sites of action have been reported to 
account for the cGMP-dependent reduction of [Ca2+]i , with PKG I as principal mediator 
(figure I.3). PKG I inhibits the release of Ca2+ from the sarcoplasmic reticulum (SR), either by 
phosphorylation of the inositol 1,4,5-triphosphate (IP3) receptor 32, 33 and/or by inhibition of 
agonist-induced generation of IP3 34. An SR-targeting protein for PKG I termed IRAG (IP3 
receptor associated PKG I substrate) has been characterized and shown to be necessary for the 
phosphorylation of the IP3 receptor 35. Furthermore, PKG I has been shown to increase the 
Ca2+ sequestration through activation of the smooth endoplasmic reticulum Ca2+-pumping 
ATPase (SERCA) 36. The correlation between vascular smooth muscle relaxation and 
phosphorylation of the SR membrane protein, phospholamban (PLB), supports the hypothesis 
that PKG I regulates the Ca2+-ATPase activity via PLB phosphorylation. Moreover, in rat 
aortic smooth muscle cells, PLB has been shown to have an inhibitory effect on the Ca2+ -
ATPase, which is relieved when PLB is phosphorylated and subsequently dissociates from the 
ATPase 37, 38. However, a study on the aorta of mice lacking the PLB gene has demonstrated 
that PLB plays only a minor role, if any, in cGMP-mediated vasorelaxation 39. In aortic 40 and 
airway 41 smooth muscle cells, this SERCA-dependent refilling of the intracellular stores, has 
also been reported to prevent the Ca2+ influx through store-operated Ca2+ channels (SOCC) 42, 
43
, thereby maintaining the decrease in Ca2+. Another PKG I substrate group in the SR, are the 
tightly clustered ryanodine-sensitive Ca2+ release (RYR) channels. The combined effect on 
SR Ca2+ load and RYR channels, results in an increased subplasmalemmal Ca2+ transient or 
Ca2+ spark frequency, which in turn activates nearby sarcolemmal Ca2+-sensitive K+ (KCa) 
channels 44. In addition, PKG I has also been reported to directly increase the open probability 
of the KCa channels 45, 46. Together these actions increase the frequency and amplitude of the 
“spontaneous transient outward currents” (STOC’s) of K+ ions 47. This results in 
hyperpolarization, which in turn closes voltage-dependent L-type Ca2+ channels leading to 
reduced global [Ca2+]i 48-50. Besides this indirect hyperpolarization-mediated inhibition of the 
Ca2+ channels, the Ca2+ influx is also decreased through a direct impairment of the Ca2+ 
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channel activity by PKG I 51. Furthermore, activation of two different ionic channels, the 
plasma membrane Ca2+-pumping ATPase 52 and the Na+/ Ca2+ exchanger 53, may mediate an 
increased efflux of Ca2+ from the smooth muscle cell. The driving force for extrusion of Ca2+ 
from the cell through the Na+/ Ca2+ exchanger, in turn, is dependent on two other effects 
mediated by PKG I, depletion of intracellular Na+ via activation of Na+/K+ ATPase 53 and 
hyperpolarization of the cell membrane via an enhanced STOC activity.  
According to the study of Zolle et al. localized increases in cGMP have distinct regulatory 
effects on the concentration of [Ca2+]i within individual cells. They claim that pGC or the 
particulate pool of cGMP is involved in the inhibition of Ca2+ efflux via the plasma membrane 
Ca2+-pumping ATPase, whereas sGC or the soluble pool of cGMP modulates [Ca2+]i via an 
increased reuptake of Ca2+ into the intracellular stores without affecting cation influx or Ca2+ 
efflux 54.  
 
I.2.2.2. Regulation of MLC dephosphorylation/Ca2+ sensitization 
In addition to the multiple Ca2+ lowering mechanisms, PKG I also mediates cGMP-dependent 
relaxation of the smooth muscle cell by lowering the Ca2+ sensitivity of the contractile 
apparatus or “Ca2+ desensitization” 24 by stimulation of the MLCP activity (figure I.3). An 
appreciation for the role of MLCP in the regulation of MLC phosphorylation and smooth 
muscle contraction began with studies on “calcium sensitization” of contraction 55. These 
studies demonstrated that G-protein-coupled agonist-induced MLC phosphorylation and 
contraction of smooth muscle were apparent at relatively low concentrations of [Ca2+]i 
compared with phosphorylation and contraction initiated by membrane depolarization using 
elevated K+ solutions 56-58. Later on, several protein kinase pathways were reported to mediate 
calcium sensitization including PKC, which is activated on agonist-dependent stimulation of 
phospholipase C (PLC) , and the small molecular weight G-protein, Rho A, which activates 
Rho kinase 59. Rho kinase inhibits the MLCP, resulting in an increase in MLC20 
posphorylation and force in the smooth muscle cell 60. It has been shown that PKG I inhibits 
the RhoA-mediated Ca2+ sensitization pathway through phosphorylation of RhoA at Ser 188, 
which subsequently induces its translocation from the membrane to the cytosol 61. Thus PKG 
I inactivates RhoA and consequently activates MLCP to dephosphorylate MLC. The 
phosphatase inhibitor protein CPI-17 is another potential mediator of Ca2+ sensitization, which 
on phosphorylation by a variety of kinases including Rho kinase and PKC 62, inhibits the 
MLCP catalytic subunit (PP1c), resulting in Ca2+ sensitized force independent of the 
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inhibitory phosphorylation of the regulatory subunit (MYPT1) of MLCP 63. PKG I has been 
shown to prevent the inhibition of MLCP in vivo by accelerating dephosphorylation of CPI-
17 64. Additionally, MYPT1 is also reported to be a target of PKG I. The phosphorylation of 
Ser 695 of MYPT1, prevents phosphorylation of Thr 696 by MYPT1 kinase and RhoA-
activated kinases, thereby blocking inactivation of MLCP 65. Moreover, interaction between 
the leucine zipper region at the C terminus of some MYPT1 isoforms and the leucine zipper 
domain of PKG leads to direct stimulation of MLCP 66. A role for this interaction in Ca2+ 
desensitization is supported by in vivo experiments demonstrating that only smooth muscles 
expressing MYPT1 isoforms containing the leucine zipper motif were sensitive to relaxation 
by 8-Bromo-guanosine 3’, 5’ -cyclic monophosphate (8-Br-cGMP), a membrane permeable 
cGMP analogue. The expression of leucine zipper positive isoforms has been demonstrated to 
be tissue specific and developmentally regulated, suggesting a correlation with the diversity in 
NO-mediated smooth muscle relaxation 67. Although the MYPT1 leucine zipper may serve to 
target PKG, it is not known whether this is required for phosphorylation of Ser 695 or 
structurally whether this is feasible 68. Furthermore, Wu et al. demonstrated that PKG-
mediated Ca2+ desensitization of visceral smooth muscle involves phosphorylation of the 
myosin-binding protein telokin, which accelerates the dephosphorylation of MLC 69.  
 
I.2.2.3. Thin filament regulation 
Despite numerous studies performed aiming to unravel the role of the thin filament in actin-
myosin cross-bridge cycling or force regulation in smooth muscle cells, this issue remains 
controversial. Thin filament-associated proteins regulate and contribute to the contractile 
activity of the cell, but there have been very few reports regarding the role of second 
messenger regulation of thin filament protein function 70. The thin filament/actin-binding 
proteins vasodilatory-stimulated phosphoprotein (VASP) and the 20 kDa Hsp (Hsp20) raised 
interest in possible regulation of smooth muscle contraction, as they have been shown to be 
phosphorylated by PKG. This PKG-specific phosphorylation decreases the binding of VASP 
to actin filaments, possibly through its dissociation from the actin binding protein profilin 71. 
In case of Hsp20 this PKG-mediated phosphorylation is reported to be associated with smooth 
muscle relaxation 72. Tropomyosin, caldesmon, calponin and SM22 are also purported to bind 
actin and possibly regulate cross-bridge function 73, but this is not regulated by PKG.  
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Figure I.3: The [Ca2+]i lowering and Ca2+ desensitization mechanisms underlying smooth muscle 
relaxation mediated by cGMP. cGMP reduces [Ca2+]i by decreasing Ca2+ mobilization through (1a) 
inhibition of the IP3 receptor in the sarcoplasmic reticulum (SR) or (1b) inhibition of agonist-induced 
IP3 formation; (2a) increasing Ca2+ sequestration through activation of the SR Ca2+-pumping ATPase 
((2b) the SERCA-dependent reuptake into the SR will in turn inhibit the SOCC’s); (3) inhibiting Ca2+ 
influx through L-type Ca2+ channels; increasing Ca2+ efflux through activation of (4a) Na+/ Ca2+ 
exchanger and (4b) the Ca2+-pumping ATPase; also, cGMP may produce hyperpolarization through 
activation of (5a) the Na+/K+ ATPase and (5b) KCa channels (increased STOC of K+). Those KCa 
channels can also be activated by an increased Ca2+ spark frequency, which results from the cGMP-
mediated activation of (5c) RYR channels and SERCA. The resulting hyperpolarization will in turn 
increase Ca2+ extrusion by the Na+/ Ca2+ exchanger. cGMP desensitizes the contractile apparatus to 
Ca2+ by (6) inhibition of the RhoA-dependent suppression of the myosin light chain phosphatase 
activity, (7) accelerating the dephosphorylation of CPI-17, activating the myosin light chain 
phosphatase by (8a) leucine zipper interaction with MYPT1 and by (8b) exclusion of phosphorylation 
of MYPT1 and (9) phosphorylation of telokin. 
R, receptor; G, G protein; PLC, phospholipase C; MLC20, 20 kDa light chain of myosin; MLCK, 
myosin light chain kinase; MLCP, myosin light chain phosphatase; PKC, protein kinase C; PLC, 
phospholipase C; DAG, diacylglycerol; CPI-17, 17 kDa PKC-potentiated myosin phosphatase 
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inhibitor; STOC, spontaneous transient outward current; SOCC, store-operated Ca2+ channel; RYR, 
ryanodine receptor; IP3R, IP3 receptor; KCa, Ca2+ sensitive K+ channel; MYPT1, MLCP regulatory 
subunit; PP1c, MLCP catalytic subunit; 
 
: inhibitory/negative effect; 
 
: stimulatory/positive 
effect (adapted from Porter et al. 47, Jaggar et al. 50, Lucas et al.1 and Jin and Burnett 74).  
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I.3. Role of the NO/cGMP pathway  
I.3.1. Role of the NO/cGMP pathway in the vascular system 
As illustrated in the previous part, NO plays an important role in vascular tone regulation 
through the activation of sGC and subsequent production of cGMP. Beyond its vasodilator 
actions, NO was found to inhibit vascular smooth muscle proliferation and platelet 
aggregation and to regulate interactions between leucocytes and the blood vessel wall. All 
these findings established NO as a homeostatic regulator in the vasculature, the absence of 
which plays a role in a number of conditions and pathological states 1.  
 
I.3.1.1. Source of NO 
The endothelium, a cell monolayer which constitutes the internal lining of the entire 
circulatory system, has long been considered as a passive physical barrier whose only 
function was to provide vessels a smooth surface that prevented clotting and turbulence of the 
blood flow 2. This vision changed upon the findings of Furchgott and Zawadzki, who first 
demonstrated that the relaxation of vascular smooth muscle cells in response to acetylcholine 
is dependent on the anatomical integrity of the endothelium 3. They named the factor 
responsible for this intercellular relationship the EDRF. Some years later, EDRF was 
recognized as the free radical gas NO 4, 5. Following the identification of NO, many 
laboratories jumped into this field of cardiovascular research to study the physiological 
importance and pathophysiological roles of endothelium-dependent vasodilatation and 
endogenous NO and cyclic cGMP in the regulation of systemic blood pressure, organ blood 
flow, hemostasis and cell proliferation. 
In mammalian tissues, NO is derived from the amino acid L-arginine, that is accumulated 
from the extracellular space and is synthesized intracellularly. Under physiological 
conditions, not the availability of L-arginine 6, but the activity and expression of the NO-
producing enzymes termed NOSs are the rate-limiting factors for the production of NO. This 
family of enzymes uses NADPH as electron donor and employs five enzyme cofactors (e.g. 
tetrahydrobiopterin) 7 to catalyse a five electron oxidation of L-arginine to NO with 
stoichiometric formation of citrulline 8. The now widely accepted nomenclature identifies the 
three mammalian enzyme isoforms as neuronal NOS, inducible NOS, and endothelial NOS, 
reflecting the tissues of origin for the original protein and cDNA isolates. However, their 
expression patterns are now known to overlap in a complex manner. For example, muscle 
cells appear to express all three NOS isoforms. Both nNOS and eNOS are expressed in 
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cardiac myocytes and hippocampus neurons 9. Vascular endothelial cells express eNOS but 
can be induced to express iNOS. The nNOS and eNOS isoforms are similar, in that they are 
generally constitutively expressed and their activity is regulated by [Ca2+]i. In contrast, iNOS 
is only present after induction by immuno-inflammatory stimuli such as tumor necrosis factor 
or interferon 9, 10 and is not regulated by Ca2+. However, it is now known that the level of gene 
expression as well as the activity of both eNOS and nNOS can be induced or upregulated 
under different physiological conditions 11. Mechanical stimulation, especially fluid shear 
stress exerted on the endothelium by the streaming blood, represents a major stimulus for the 
production of NO in vivo 12. The ability of shear stress to enhance the activity of eNOS has 
been reported to involve the opening of stretch-activated Ca2+ channels, thereby leading to an 
increase in [Ca2+]i 13-15. Under basal conditions, eNOS interacts directly with caveolin-1, 
leading to an inhibitory effect on eNOS activity. This inhibitory effect can be completely 
reversed by Ca2+/calmodulin, a complex elicited upon the influx of Ca2+. The activated eNOS 
synthesizes NO until the [Ca2+]i decreases to the point where the calmodulin dissociates and 
the inhibitory eNOS-caveolin-1 complex reforms 16, 17. This mechanism accounts for the 
initial peak of shear stress-induced NO production but not for the following sustained plateau 
phase which is maintained as long as shear stress is applied. In case of sustained shear stress, 
NOS has been reported to be activated at basal levels of [Ca2+]i via a mechanotransduction 
cascade that involves tyrosine phosphorylation and that can be modulated by changes in the 
intracellular pH 18. 
Besides physico-chemical stimuli such as shear stress, pressure and hypoxia, also receptor-
mediated mechanisms have been shown to initiate the Ca2+-dependent activation of eNOS. A 
number of agonists varying as neurotransmitters (acetylcholine (ACh)), hormones (insulin), 
autacoids (bradykinin, histamine) and some released by aggregating platelets (serotonin, 
adenosine) have been reported to act on receptor-operated Ca2+ channels, thereby leading to 
an increase in [Ca2+]i 12. The initial increase in the endothelial cell Ca2+ is however mediated 
by the phosphatidylinositol pathway, which mobilizes intracellular Ca2+ from the 
endoplasmatic reticulum 2. As the extent of Ca2+ increase is modified by the membrane 
potential of the endothelial cells, the opening of potassium channels with hyperpolarisation of 
the endothelium will facilitate Ca2+ entry and thus synthesis of NO 19. Recently, several 
reports have shown that activation of eNOS can even occur in the presence of low Ca2+ 
concentrations by the action of the serine/threonine kinase Akt. Akt phosphorylates the serine 
1177-residue and renders NOS activated by increasing the affinity of eNOS for calmodulin 20. 
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I.3.1.2. Direct vascular effects of NO 
It is now appreciated that NO is continuously generated from vascular endothelial cells in the 
absence of added endothelium-dependent vasodilators. Despite the fact that the intrinsic 
stimulus for basal production of NO was not appreciated in the early 1980’s, later studies 
revealed that the shear stress generated by flowing blood against the endothelial cell surface 
triggered the generation of NO in the endothelial cells 21-23. The mechanism by which the 
endothelium is able to sense changes in shear stress on its luminal surface remains obscure, 
although there have been reports that disruption of the endothelial cytoskeleton may be 
responsible for initiating some of the changes associated with the exposure to shear stress 24, 
25
. The level of shear stress and the release of NO elicited by altering either diameter or flow 
are positively correlated, suggesting that local changes in tone are as important as changes in 
flow for the regulation of endothelial NO release in vivo 26, 27. The main physiological 
consequence of this relationship is that any decrease in vessel diameter (myogenically- or 
neurogenically-induced contraction), at constant flow, increases the shear stress to which the 
endothelial layer is exposed and elicits the release of NO, which in turn feeds back to inhibit 
the original vasoconstriction 28. This tone-dependent NO release constitutes a local vascular 
reflex mechanism to sustain regional blood flow into arterial beds in the presence of 
vasoconstriction. The basis of the autoregulatory properties of any given vascular bed is the 
myogenic contraction, which occurs in response to instantaneous increases in transmural 
pressure. The modulation of myogenic constriction by NO is more pronounced in larger than 
in smaller (terminal) arterioles. As the metabolic activity of a tissue increases, the local 
metabolic changes (e.g. decrease in the partial pressure of O2, increase in the partial pressure 
of CO2, and decrease in pH) promote the relaxation of precapillary sphincters, causing an 
increase in capillary blood flow. Despite the fact that the products of energy metabolism are 
effective dilators, the accumulation of metabolites alone has relatively little effect on vascular 
resistance. The reason for this is that in order to achieve optimal vascular conductance both 
small arterioles and the larger arterioles feeding them must dilate in concert. This 
phenomenon of “conducted dilation” is thought to be determined by local changes in 
membrane potential as well as by flow-dependent dilation of larger arterioles 29. The flow-
induced dilatation of proximal arterioles, combined with metabolite-induced dilation of distal 
arterioles, allows a perfect adaptation between tissue O2 consumption and tissue O2 supply. 
The significance of the shear stress-dependent endothelium-derived NO in global 
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cardiovascular homeostasis is demonstrated by the increase in mean arterial blood pressure 
and the reduction in blood flow upon the selective inhibition of the NO.  
The most often used approach to modulate the actions of NO involves the inhibition of NOS 
activity. Compounds with chemical modifications of the guanidine group of L-arginine (e.g. 
NG-monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine (L-NA), and NG-nitro-L-
arginine methyl ester (L-NAME)) 30 compete with the interaction of L-arginine on the NOS 
active site or with the uptake of L-arginine, thus reducing the availability of substrate for NOS 
catalysis 31. In 1989 Rees et al., observed that L-NMMA by itself produced a dose-dependent 
and endothelium-dependent contraction of rabbit aorta, suggesting the loss of a continuous 
NO-dependent relaxing tone 32. Subsequent studies in the whole animal demonstrated that the 
intravenous administration of L-NMMA caused an immediate and marked increase in blood 
pressure that could be reversed by infusion of L-arginine 33. This finding was very important 
for the understanding of the mammalian cardiovascular system, as it was concluded that 
peripheral resistance was the main determinant of blood pressure regulation. Blood pressure 
increase after inhibition of NO synthesis has been confirmed in a variety of studies in animals 
and humans. In Wistar rats, chronic blockade of NOS with L-NAME induced a dose-
dependent increase in blood pressure and a reciprocal decrease in aortic cGMP, which is 
mainly dependent on sGC activity 34. In healthy humans, L-NMMA increased mean arterial 
blood pressure by 10% and total peripheral resistance by 46% 35. Those data have led to the 
conviction that basal NO exerts a continuous dilatory influence on vascular tone, 
counterbalancing the contractile influences. Later on, those observations were extended to 
models of genetic manipulation. In these, knocking out the gene encoding eNOS in mice 
resulted in significant hypertension, although the magnitude of hypertension reported by 
different laboratories varies. Differences in systolic arterial pressure in conscious eNOS 
knockout mice compared with wild type mice range from 20 36 to 50 37, 38 mmHg, while 
differences in mean blood pressure in anesthetized mice range from 14 39 to 37 40 mmHg. The 
varying magnitude of the hypertension observed in eNOS knockout mice may be due to the 
use of different methods for measuring blood pressure or the genetic backgrounds of the 
strains used. However, even with these differences, eNOS knockout mice were found to be 
hypertensive in all cases. In vitro, endothelium intact aortic rings removed from these animals 
display no relaxation to acetylcholine and are unaffected by treatment with NOS inhibitors 41. 
In concert with those findings, mice with transgenic overexpression of eNOS are reported to 
be hypotensive 42. The importance of eNOS in the regulation of blood pressure and vascular 
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homeostasis is further demonstrated by the observation that a missense variant of the eNOS 
gene is positively associated with essential hypertension and myocardial infarction 43.  
It is frequently assumed that all hypertension in eNOS knockout mice is caused by the lack of 
endothelium-derived NO and the resulting increase in arterial tone and peripheral resistance. 
However, also other NO-related mechanism such as increased cardiac contractility and 
increased fluid absorption by the kidney may be involved in hypertension 44. Those 
mechanisms are known to control the cardiac output, which determines arterial blood pressure 
together with total peripheral resistance. Finally, genetic deletion of eNOS may disrupt the 
function of other important regulators of blood pressure by affecting central nervous system 
activity. Stauss et al. found that in resting eNOS deficient mice, arterial blood pressure 
fluctuations were more pronounced than in the control mice, indicating that baroreflex 
responses are blunted in the former 38. So, hypertension may also be caused by the 
involvement of eNOS in determining the baroreceptor blood pressure setpoint.  
Besides eNOS, also nNOS which is present both in vasomotor centres of the central nervous 
system and in peripheral nerves as well as certain vascular smooth muscle cells, is likely to 
play a role in the global regulation of blood pressure. This was concluded from the surprising 
observation that in eNOS deficient mice, the acute administration of the selective nNOS 
inhibitor 7-nitroindazole (7-NI) resulted in a decrease in mean arterial blood pressure which 
was prevented by L-arginine 36. Although this finding suggests that nNOS may be 
prohypertensive, in other cases it appears to be antihypertensive. For example, the chronic 
administration of 7-NI in drinking water significantly increased blood pressure in rats 45. 
However, blood pressure in nNOS knockout mice has generally been shown to be similar to 
that of wild type controls 46-48. This finding is in line with the observation that the systolic 
blood pressure in mice deficient in both eNOS and nNOS, is higher than in wild type mice 
and similar to eNOS knockout mice 49. So, those data suggest that genetic deletion of nNOS is 
compensated for, in terms of blood pressure regulation or that the hypotensive actions of 
nNOS may be counterbalanced by its hypertensive effects. Moreover they suggest that nNOS 
does not play an important role in the regulation of vascular tone 44. However, there is 
evidence that when eNOS-dependent vasodilatation is impaired, nNOS-derived NO mediates 
flow and agonist-induced dilatations. For example, inhibition of nNOS or sGC attenuated the 
acetylcholine-induced pial vessel dilatation in eNOS knockout mice, whereas in wild type 
mice inhibition of nNOS activity was ineffective 50. Those data suggest that nNOS-cGMP-
dependent mechanisms compensate or upregulate after deletion of the eNOS gene. This is 
supported by the Huang’s study, showing that nNOS-derived NO, together with 
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prostaglandins, maintains flow-induced dilatation in coronary arteries of eNOS knockout 
mice 51. In addition, these investigators found an upregulation of nNOS expression in the 
endothelium and smooth muscle of coronary arteries. Those data suggest that despite the 
small amount of nNOS in blood vessels, low levels of nNOS-derived NO could compensate 
for the lack of eNOS. In contrast to eNOS and nNOS, iNOS expression has not been found in 
the vasculature under physiological conditions and is thus not likely to play a role in the basal 
regulation of vascular tone 52. This is in line with the observation that in iNOS knockout mice, 
basal systolic blood pressure was not elevated 53, 54. Only in pathological states such as septic 
shock, iNOS-derived NO has been shown to affect vascular tone and to be responsible for 
severe systemic hypotension 55.  
 
I.3.1.3. Other endothelium-derived relaxing substances  
*Prostaglandins  
Although the era of endothelium-derived relaxing factors began with the seminal discovery of 
the EDRF, later identified as NO, prostaglandins were the first endothelium-derived relaxing 
factor to be discovered. In 1976, Moncada et al. described an anticlotting agent that was also 
capable of relaxing vascular smooth muscle cells 56. They called the entity PGX which, soon 
after, was identified as prostacyclin (PGI2) 57. In common with NO, PGI2 is lipid soluble and 
highly unstable in the body and thus it leaves the endothelial cell following its production and 
acts as a local anticoagulant and vasodilator 58. It is formed via the cyclooxygenase (COX) 
pathway, most commonly from arachidonic acid. After chemical (e.g. histamine, bradykinin) 
or mechanical (shear stress) stimuli, the enzyme phospholipase A2 in the endothelial cells, 
mobilizes arachidonic acid from membrane phospholipids. Subsequently, COX converts 
arachidonic acid to the prostaglandin endoperoxide H2, the precursor of all vasoactive 
prostanoids 59. Of the COX enzyme, two isozymes have been identified so far: COX-1 and 
COX-2, which are produced from two different genes. COX-1 is a constitutive enzyme and 
responsible for many physiological functions; it has been detected in most mammalian tissues 
under basal conditions, primarily in stomach, platelets and vascular endothelium 60. COX-2 
on the other hand, is an inducible isozyme 61-63 that is thought to be expressed in the 
cardiovascular system (and immune cells) only during pathogenic episodes. Nevertheless, 
COX-2 may have some homeostatic functions in some organs because it is constitutively 
present in the brain 64, kidney 65, gastrointestinal system 66 and vascular endothelium 67. In the 
last step of the prostaglandin biosynthesis, several PGH2 isomerases catalyse the 
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isomerisation of PGH2 to a variety of biologically active end-products (PGD2, PGE2, PGI2, 
PGF2α or thromboxane (TXA2)), depending on the enzymatic machinery present in a 
particular cell type 59. PGI2 is the major prostanoid produced by the endothelial cells, while 
platelets synthesize mainly TXA2 58. PGI2 elicits smooth muscle relaxation by activating 
specific cell surface receptors (IP) that are G-protein-coupled to AC and thereby elevate 
cAMP levels 68, 69. The formed cAMP activates PKA which phosphorylates selected target 
proteins, thereby reducing the [Ca2+]i and subsequently cause relaxation 70. The effect of PGI2 
is tightly connected with NO effects. Koller et al., demonstrated that increases in perfusate 
flow elicit endothelium-dependent dilatation of gracilis muscle arterioles, a response that is 
mediated by the combined release of NO and prostaglandins 71. Other studies demonstrated 
that NO stimulates prostaglandin synthesis in endothelial cells and macrophages via a 
mechanism involving a reaction with the heme-component that binds to the active site of 
COX enzymes 72, 73. Furthermore, NO has been shown to potentiate the effect of PGI2 in the 
smooth muscle cells through inhibition of cAMP-degrading PDE’s 74. In turn, PGI2 has been 
reported to increase eNOS gene expression and the release of NO from endothelial cells via 
cAMP signaling 75. On the other hand, there are also studies that indicate an enhanced 
production of prostaglandins as a consequence of inhibition of NO synthesis and thus support 
a negative relation between NO and prostaglandin synthesis. Also in eNOS knockout mice, 
COX-2 derived prostaglandins were reported to be enhanced and responsible for the 
maintenance of flow-induced dilatation 76, 77.  
In most vascular beds, PGI2, PGD2 and PGE2 have been shown to induce vasorelaxation, 
whereas PGF2α and TXA2 have been reported to initiate vascular smooth muscle contraction. 
The ratio of PGI2/ TXA2 appears to provide an important input into determining vascular tone 
78
. The ratio of these two vasoactive agents is reduced in a number of vascular diseases, 
namely pulmonary hypertension 79, selenium deficiency 80 and pre-eclampsia 81. In mice 
lacking the PGI2 synthase gene, the absence of PGI2 metabolism is associated with a five fold 
increase in the production of TXA2 82. This increase in TXA2 may enhance vasoconstriction 
and attribute to the elevated blood pressure in PGI2 synthase-deficient mice. The finding that 
the blood pressure of those mice increases with age, lends support to the contention that 
polymorphism of the human PGI2 synthase gene, which decreases the promoter activity, 
seems to be a risk factor for higher pulse pressure and systolic hypertension in the Japanese 
population 83. The PGI2 receptor-deficient mice, on the other hand, have been reported to be 
normotensive, suggesting that PGI2 is not involved in the regulation of blood pressure 84. 
Furthermore, those mice did not show renal abnormalities as reported in the PGI2 synthase-
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deficient mice. In the latter study, the high blood pressure could be secondary to the 
associated gross abnormalities in the kidney, as also suggested for the COX-2-deficient mice 
85, 86
. The genetic deficiency of COX-2 appears to disrupt the signaling pathway in the salt 
sensing region of the kidney, which is important for activation of the renin-angiotensin sytem 
87
. Under conditions where renin expression and activity are induced in wild type mice, renin 
production was not stimulated in the kidneys of COX-2-deficient mice 88, 89. Therefore, it is 
suggested that prostaglandins produced by COX-2 are responsible for maintaining renal 
homeostatic functions involved in the regulation of salt resorption, fluid volume and blood 
pressure 90. This was also confirmed by the study of Muscara et al., in which the chronic 
suppression of the COX-2 activity by the daily administration of selective COX-2 inhibitor 
celecoxib, significantly influenced the renal function, leading to severe fluid retention and 
elevated blood pressure. Therefore, they suggest that the hypertensive effects of celecoxib 
may have been due to effects of this drug on the kidney and not by virtue of suppression of 
vascular PGI2 synthesis 91. However, in contrast to the COX-2 deficient mice, mice deficient 
in COX-1 fail to produce an identifiable renal pathology 92. Still, they have been show to have 
an increased mean arterial blood pressure 93. Besides positive studies regarding the 
importance of COX in the regulation of blood pressure, there are also negative reports. The 
blood pressure of both COX-1 94 and COX-2 95 knockout animals has been reported to be not 
different from the corresponding control animals, suggesting that prostanoid products of 
COX-activity do not regulate baseline blood pressure or that compensatory mechanisms 
completely abolish the appearance of any effects. Likewise, baseline sodium and water 
balance has been shown to be unaffected by COX-2 deficiency 95. As COX produces 
vasoconstrictor and vasodilator metabolites, its role in the regulation of blood pressure and 
hemodynamics is difficult to predict and may explain the positive and negative results 
regarding the effect of COX inhibition.  
 
*Endothelium-derived hyperpolarising factor (EDHF) 
Not all endothelium-dependent relaxations can be fully explained by the release of either NO 
and/or prostacyclin. In 1984, Bolton and collaborators reported that an additional relaxant 
pathway associated with smooth muscle hyperpolarisation also exists 96. This 
hyperpolarisation was originally attributed to the release of an endothelium-derived 
hyperpolarizing factor (EDHF) that diffuses to and activates smooth muscle K+ channels. 
More recent evidence suggests that endothelial cell receptor activation by these 
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neurohumoural substances opens endothelial cell K+ channels 97. Several mechanisms have 
been proposed to link this pivotal step to the subsequent smooth muscle hyperpolarization, 
e.g. K+ 98, CYP metabolites 99, 100, lipoxygenase products 101, NO itself 102, ROS (H2O2) 103, 
cAMP 104, C-type natriuretic peptide 105, and electrical coupling through myoendothelial gap 
junctions 106. Up until today, a single molecule or pathway could not be identified which 
explained all features of EDHF signaling in different vascular beds and species. This led to 
the assumption that there are several distinct EDHF’s acting alone, in parallel, or even 
together 107. Although NO is the predominant endothelium-derived vasodilator in conduit 
arteries, as once descends the vascular tree the role of NO diminishes, whereas the influence 
of EDHF increases 108. In this way, the absolute vasodilator capacity of the arterial system is 
maintained. In mice, EDHF-mediated responses in resistance vessels appear to be at least as 
important as endothelium derived NO in mediating agonist-induced, endothelium-dependent 
vasodilatation because neither deletion of the gene encoding eNOS nor inhibition of NOS 
attenuates agonist-induced vasodilator responses in vivo and in vitro 109, 110. The large 
contribution of EDHF to endothelial vasodilatory mechanism in resistance-sized arteries and 
arterioles, which play a critical role in the control of organ blood flow and peripheral 
resistance, makes it probable that the EDHF system is an important determinant in regulating 
blood pressure and vascular homeostasis. There is some evidence that EDHF contributes to 
regulation of blood flow in vivo 111-113, however, extensive in vivo characterization of the 
physiological role of EDHF has been delayed because of the complicating effects of the 
agents used to explore EDHF responses. As also NO 114 and PGI2 115 can elicit dilatation via 
hyperpolarization of vascular smooth muscle cells, the isolation of EDHF responses 
necessitates NOS and COX inhibition, which can have profound inherent hemodynamic 
effects. Recently, Scotland et al. described the vascular phenotype of mice with targeted 
disruption of both the predominant endothelial isoform of NOS (eNOS) and COX (COX-1) 
and demonstrated that this “EDHF mouse” is the ideal model to investigate the physiological 
role of EDHF 116. Those mice showed that the EDHF system is capable of overcoming the 
loss of NO and PGI2. Interestingly, this occurs more effectively in female “EDHF mice”, 
which are normotensive, whereas male “EDHF mice” are hypertensive.
 
This gender-specific 
prevalence of EDHF may point to the cardiovascular protective role of the EDHF system in 
females. Sex-related differences in EDHF activity were also reported in estrogen receptor α 
and β knockout mice 117 and soluble epoxide hydrolase deficient mice 118. Studies using 
transgenic mice in which the expression of the small-conductance Ca2+-activated K+ channels 
(SKca) is constitutively suppressed by dietary doxycycline 119 and mice deficient in 
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intermediate-conductance Ca2+-activated K+ channels (IKca) 120, further highlighted the 
functional role of EDHF in the control of vascular tone. Nowadays, there is growing evidence 
for the importance of the SKca and IKca channels in endothelial hyperpolarisation, which is 
first required to initiate EDHF-mediated vasodilatation. Both suppression of the SKca 
channels and deletion of the
 
IKca channels increased the mean arterial blood pressure with 
respectively 20 mm Hg and 14 mmHg 121. The finding that genetic manipulation of the EDHF 
signaling has an impact on systemic blood pressure supports the notion that the EDHF system 
is important in the overall circulatory regulation.  
 
I.3.2. Role of the NO/cGMP pathway in penile erection 
Penile erection is a complicated neurovascular event modulated by psychological factors and 
hormonal status. Not all details of the mechanism are fully understood but ultimately an 
erection results from an increased blood flow into the penis and a concomitant decreased 
outflow through the compressed venous outflow. The engorgement is possible by relaxation 
of the blood vessels and the specialized smooth muscle cells of the penis, which is mainly 
mediated by the NO/cGMP signaling pathway.  
 
I.3.2.1. Anatomy of the penis 
The penis in man and in most other mammalian species consists of three corpora: dorsally 
paired corpora cavernosa (CC) which comprise the erectile tissue and the ventral corpus 
spongiosum that surrounds the urethra and forms the glans penis distally (Figure I.4). 
Surrounding each cavernosal body is a thick connective tissue sheath, the tunica albuginea, 
which fuses in the midline to form a perforated septum. The proximal portion of each CC, the 
crus, is attached to the inferior pubic ramus. Each crus is surrounded by the ischiocavernosus 
muscle. The proximal part of the corpus spongiosum, the bulb, lies in the midline in the 
perineum enclosed by the bulbospongiosus muscle. Both the ischiocavernosus and the 
bulbospongiosus muscles are important in producing a rigid erection and in ejaculation 122.  
The CC resembles a sponge, composed of a meshwork of interconnected hollow cavernous 
spaces or sinusoids, lined by vascular endothelial cells and separated by trabeculae, 
containing bundles of smooth muscle cells in a framework of elastic fibers and connective 
tissue 123. The main arterial supply to the penis is from the pudendal artery on each side that 
divides into the cavernosal and dorsal arteries. From the two cavernosal arteries, the 
resistance-like helicine arteries branch off and flow into the sinusoids, which fill with blood 
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and expand during an erection. The venous drainage of the penis consists of emissary veins 
that drain the sinusoidal spaces and pierce the tunica to drain into the circumflex veins, and 
then join the deep dorsal vein of the penis. Two dorsal arteries in the dorsal neurovascular 
bundle (which consists of two dorsal arteries, the deep dorsal vein, and the dorsal nerves) 
supply the glans penis. The flow of blood into and out of the penis is regulated by the 
autonomic erection centre. This provides sympathetic and parasympathetic input to the pelvic 
nerve plexus including innervation of the cavernosal arteries and trabecular smooth muscle 
124
.  
In a diverse range of mammals including carnivores, bats, rodents, insectivores, flying lemurs, 
and some primates, an os penis or baculum has been described. The os penis, designed for 
ready intromission, often shows great morphological diversity among even closely related 
species, especially among rodents and carnivores 125. It is a heterotopic bone that in rats and 
mice extends from the distal end of the body of the penis to the tip of the glans penis and is 
responsible for the right angle bend between the body and the glans penis in a non-erect penis 
(figure I.5) 126. It consists of a proximal segment and a distal segment. The proximal segment 
is formed by fusion of a hyaline growth cartilage in its proximal half and a membrane bone in 
its distal half. The distal segment is formed initially as fibrocartilage, and, in case of rats, 
becomes gradually ossified 127, 128 . Although there is no os in human glans, a strong 
equivalent-ligamentous structure, termed the distal ligament is arranged centrally and acts as a 
supporting trunk for the glans penis. Without this important structure, the glans would be too 
weak to bear the bulking pressure generated during coitus and too limber to serve as a patent 
passage for ejaculation, and it could be too difficult to transmit the intracavernosal pressure 
(ICP) surge along the entire penis during ejaculation. A fixed os penis in the human male 
would cause much awkward inconvenience in carrying out daily activities; therefore this 
strong distal ligament is optimal for concealment without sacrifice of tissue strength 129.  
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Figure I.4: Cross section through the human penis. 1: corpora cavernosa; 2: circumflex vein; 3: 
emissary vein; 4: subtunical venule; 5: nerve (n. dorsalis penis); 6: superficial vein (v. dorsalis); 7: 
deep dorsal vein (v. dorsalis profunda); 8: dorsal artery (a. dorsalis penis); 9: cavernosal artery (a. 
profunda penis); 10: helicine artery; 11: sinusoidal space; 12: tunica albuginea; 13: urethra; 14: corpus 
spongiosum; 15: urethral artery. 
Penile structure in mammals is thought to be generally similar to that in humans (adapted from Morton 
et al. 130) 
 
 
 
 
Figure I.5: Radiograph of the mice penis (adapted from Goyal et al. 126) 
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I.3.2.2. Physiology of the penile erection 
Erection is basically a spinal reflex that can be initiated by recruitment of penile afferents but 
also by visual, olfactory and imaginary stimuli. The generated nervous signals will influence 
the balance between the contracting and relaxing factors, which control the degree of 
contraction of the corporal smooth muscle cells and thus the functional state of the penis 131.  
Under basal conditions, cavernosal vasoconstriction narrows the arteriolar lumen and 
sinusoids, restricting blood flow to maintain low ICP and a flaccid penis (figure I.6). Various 
studies have suggested the endogenous constriction to be mediated primarily by the 
sympathetic nerve release of norepinephrine 132-134 and secondarily through the local 
production of endothelin-1 135-137. On sexual stimulation, nerve impulses cause the release of 
neurotransmitters from the parasympathetic nerve terminals and of relaxing factors from the 
endothelial cells, resulting in the relaxation of smooth muscle in the arteries and arterioles 
supplying the erectile tissue (figure I.6). This leads to a several fold increase in the penile 
blood flow and ICP. When the pressure begins to exceed diastolic pressure, there is a pulsing 
of blood flow into the penis during systole. At the same time, relaxation of the trabecular 
smooth muscle increases the compliance of the sinusoids, facilitating rapid filling and 
expansion of the sinusoidal system 138. There is an established base of evidence to support the 
idea that NO released during NANC neurotransmission and from the endothelium is the 
principal neurotransmitter mediating penile erection 139. The neuropeptide vasoactive-
intestinal polypeptide (VIP) 140 and prostanoids 122 have also been identified and shown to 
exert potent relaxing actions on penile tissue but the physiological role and involvement in the 
erectile process remains unclear. The corpora cavernosa will expand until they are restricted 
by the tunica albuginea. Herewith, the emissary veins and subtunical venules are compressed 
between the trabeculae and the tunica albuginea, resulting in an almost total occlusion of 
venous outflow. This process, known as veno-occlusion 141, temporarily retains the blood 
within the corpora cavernosa and further increases ICP to approximately 100 mmHg. During 
sexual intercourse, the ischiocavernous muscles forcefully compress the base of the blood-
filled corpora cavernosa and the tumescence of the penis even increases, with an ICP equal to 
the mean arterial blood pressure 123. During this phase, the inflow and outflow of blood are 
approximately equal, and ICP remains constant 142. A veno-occlusive mechanism has not been 
demonstrated in the corpus spongiosum. Thus the corpora cavernosa may be a “closed 
system”, whereas the corpus spongiosum is a “one-way flow system”, draining freely through 
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the penile veins 123. Therefore, the corpus spongiosum does not contribute to the rigidity and 
may, in fact, serve only to make the urethra an efficient conduit for the ejaculate 138.  
 
 
 
Figure I.6: Schematic illustration (only one sinusoidal space is depicted) of the mechanisms of 
erection and flaccidity. During erection, relaxation of the trabecular smooth muscle and vasodilatation 
of the cavernosal and helicine arteries, results in a several fold increase in blood flow, which expands 
the sinusoidal spaces to lengthen and enlarge the penis. The expansion of the sinusoids compresses the 
subtunical venules against the tunica albuginea, resulting in a physically obstructive reduction in 
outflow of blood. This simultaneous increase in outflow resistance, along with an increased inflow and 
relaxed sinusoidal smooth muscles produces an erection. In the flaccid state, inflow through the 
constricted and tortuous helicine arteries is minimal, and there is free outflow via the subtunical 
venular plexus. 
 
I.3.2.3. Source of NO 
Among several organs of the body in which it was early found to operate, also the penis as 
well as female genital tissue was shown to be a site of action of NO 143. Several functional 
studies involving isolated corporal tissues obtained from different specimens showed that NO 
causes relaxation of the corporal smooth muscle cells and thereby induces penile erection. 
The fact that those relaxant responses were susceptible for tetrodotoxin or inhibition of axonal 
conduction and resistant to cholinergic and adrenergic receptor blockade, affirmed the NANC 
neurogenic basis of the responses 144-146. The biological role for NO as mediator of cavernosal 
smooth muscle cell relaxation was strengthened by several in vivo studies in which the 
electrical stimulation of cavernous nerves and subsequent increase in the intracavernous 
pressure could be inhibited by NO synthase inhibitors 145, 147, 148. Moreover, 
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immunohistochemical tracing methods localized NO’s synthetic enzyme, nNOS in the 
autonomic innervation of the penis and the pelvic ganglion 149, 150. 
The ultimate proof for the neurotransmitter role of NO in the NANC mediation of penile 
erection would be lent by mice lacking the nNOS gene (nNOS-/- mice). Surprisingly, although 
the absence of nNOS in those mutant mice, NO-dependent erectile function was preserved 151. 
Further exploration of this discrepancy, revealed the alternative expression of splice variants 
of the nNOS gene. Residual NO produced by the shorter nNOS variant, nNOSβ is shown to 
be sufficient for normal physiological functioning and explains why the nNOS-/- mice 
maintain erection 152. Another important variant of the nNOS cDNA, penile nNOS also 
survives in the nNOS-/- mice and thus has a functional significance for penile erection in those 
mice 153. The other NO-producing enzymes eNOS and iNOS were also proposed as 
candidates for the NO-dependent penile erection in the nNOS-/- mice. As it was not possible to 
demonstrate the presence of iNOS in the penile tissue of nNOS-/- mice, it does not appear to 
be the source of NO in those mice 151. There is however evidence for a modulating role of 
iNOS in the erectile response, since mice deficient in iNOS (iNOS-/-), showed an altered 
function in the corporal tissue. However, further study is needed to affirm a potential role of 
iNOS in erectile function in vivo 154.  
By contrast, the eNOS gene expression is significantly upregulated in nNOS-/- corporal tissue, 
indicating a role for endothelial derived NO in mediating corporal smooth muscle relaxation. 
In many instances, compensatory mechanisms preserve the function in transgenic mice 
engineered with disruption of specific genes. Therefore the augmented eNOS activity in 
nNOS-/- mice presumably compensatory overcame the nNOS deficiency, which might suggest 
that nNOS derived NO is the primary source involved in penile erection 151, 155. However, the 
contribution of eNOS to the regulation of penile erection should not be underestimated, since 
the administration of the eNOS agonist, carbachol elicited penile erection in wild type mice 
but not in eNOS-/- mice. This suggests that eNOS physiologically would mediate erection via 
cholinergic stimulation 156. Moreover, it has been shown that upon nerve stimulation, 
acetylcholine can be released in the presence of endothelial cells, since neurons staining for 
choline acetyltransferase extend branches throughout the corpora cavernosa including the area 
of the endothelium 157. Despite several arguments in favour of the involvement of an 
endothelium dependent mechanism in penile erection, there are also arguments that do not 
support this hypothesis e.g. in isolated monkey and dog penile tissues, atropine and 
endothelium damage could not reduce the relaxant response to electrical field stimulation 
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(EFS) 158, 159 and a lack of eNOS immunoreactivity has been shown in the endothelium of 
cavernous sinusoids in rats 160.  
New concepts however, support the idea that besides the liberation of an ancillary source of 
NO from the penile endothelium by cholinergic stimulation, eNOS performs an even bigger 
assignment in penile erection. eNOS would facilitate maximal erection, whereas nNOS would 
initiate the penile process 161. The augmented blood flow, induced by the rapid, brief 
activation of nNOS at the onset of penile erection, generates a shear force on the endothelium, 
which activates the phosphatidyl-inositol 3-kinase / Akt pathway. The phosphorylated 
serine/threonine kinase Akt causes in turn direct phosphorylation of eNOS 20. Classified as a 
Ca2+/calmodulin-dependent enzyme, eNOS is normally activated by agonists after an increase 
in the intracellular Ca2+ concentration 162. Phosphorylation however, reduces its Ca2+ 
requirement and makes a maintained (over hours) production of NO and thus more sustained 
relaxation possible 163.  
Without any doubts, we can conclude that NO, produced by nNOS, acts as a neurotransmitter 
of NANC nerves innervating the penile tissue and plays a major role in penile erection. The 
role of eNOS derived NO is not established. However, irrespective of the fact that its relative 
importance is species-dependent 164, it can be accepted that in response to chemical and 
possibly mechanical stimuli, NO liberated from the endothelium also participates in penile 
erection.  
 
I.3.2.4. Other peripheral neurotransmitters 
*Vasoactive-intestinal polypeptide (VIP) 
The possible role of VIP as a transmitter mediating the relaxation necessary for penile 
erection has been discussed since the first reports were published on the occurrence of this 
peptide in the penis and on its effects on isolated penile tissue 165. Moreover, VIP 
immunoreactive vesicles were localized in the nerve fibers of the CC of several species 166 and 
an increased concentration of VIP was detected in blood drawn from the CC during penile 
erection 166, 167. However, the latter finding could not be confirmed in the studies of Dixson et 
al. 168 and Kiely et al. 169. The expression of VIP in rat CC appears to be androgen-
independent and to be unaffected by age of the animals 170, 171. However, an impairment of 
VIP-ergic innervation in penile tissue of diabetic rats 172 as well as a decreased level of VIP 
has been observed in the penis of impotent men 173, 174. Despite all efforts, no definitive 
consensus has been reached as to the exact role of VIP in the physiology of penile erection. 
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Many in vitro studies of strips of human CC tissue and cavernous vessels have shown that 
VIP has an inhibitory and relaxation-producing effect 175, 176, but it has been difficult to show 
convincingly that VIP released from nerves is responsible for relaxation of penile smooth 
muscle. Whilst the relaxant activity of exogenously administered VIP was blocked by VIP 
antiserum or α-chymotrypsin, it had no effect on the relaxation induced by EFS of the nerves, 
suggesting that VIP is unlikely to be the NANC transmitter under these conditions 177. Further 
evidence that VIP is not the key NANC transmitter mediating erection is that intracavernosal 
administration of the peptide did not produce full erections in normal 178 or impotent men 169, 
179
. However, the use of higher doses of VIP in combination with phentolamine has been 
reported to induce erections sufficient for intercourse 180. Moreover, Kim et al. reported that 
in rabbit CC a VIP antagonist inhibited electrically induced relaxations, suggesting that the 
peptide was released from nerves during stimulation 181. They concluded that VIP appeared to 
contribute to NANC mediated cavernosal relaxation, and that its mechanisms of relaxation are 
dependent on prostanoids and the generation of NO. This suggestion is supported by reports 
on the colocalization of VIP and NOS in the parasympathetic nerves innervating the CC and 
penile vasculature 182-184. It seems that most of these NO- and VIP-containing neurons are 
cholinergic, since they all contain the vesicular acetylcholine transporter 185, which has been 
suggested to be a unique marker for investigation of the distribution of cholinergic nerves in 
the peripheral and central nervous systems 186. Also in the submandibular gland 187, 188, VIP 
has been shown to contribute to the parasympathetic control of blood flow via NO. However, 
Hempelmann et al., who studied the effects of NO and the NO donor SIN-1 on human 
isolated cavernous artery and CC, found nonsynergistic, independent relaxant effects in both 
types of preparation 189. This finding does not favour the view of cooperative actions in 
neurotransmission or the simultaneous use of these agents in the treatment of erectile 
dysfunction. Not only NOS but also other peptides seem to be colocalized with VIP. Peptide 
histidine methionine 190, 191, pituitary adenylate cyclase-activating peptide 192 and helospectin 
193
 have been shown to be localized to nerves in close proximity of bundles of smooth muscle, 
around arteries in the human CC and in circumflex veins 194. Like VIP, those peptides seem to 
act through one of the VIP receptors 195, leading to activation of AC and increase in cAMP. 
They were found to be as effective as VIP for producing relaxation of human corporal tissue 
and for inhibiting contractions evoked by electrical stimulation of nerves 193. However, a role 
for those peptides as neurotransmitters and/or neuromodulators in the nervous control of 
penile erection has not been established.  
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I.3.2.5. Other endothelium derived modulators of penile erection 
 In the periphery, NO appears to play a key, if not pivotal role in the erectile process. Still, as 
with other vascular beds, the endothelium in the penis (both arterial and trabecular) produces 
a number of other endothelium-derived vasoactive factors, which may also be important in the 
control of corporal smooth muscle tone.  
 
*Prostaglandins 
The widespread use of intracavernosally injected PGE1 for the treatment of erectile 
dysfunction 196, 197 focused interest on the physiological functions of prostanoids in the 
mechanisms of penile erection. The ability of penile tissue to generate and metabolise 
prostaglandins (PGE2, PGI2, PGE1 and PGF2α) has amply been demonstrated in vitro 198-201. In 
strips of rabbit CC, there is a basal or tonic release of prostanoids including PGF2α, TXA2, 
PGI2, PGE2 and PGD2. Incubation of cavernosal strips with acetylcholine increases the level 
of all these prostaglandins, as determined by radioimmunoassay, implying that endothelium-
dependent stimulation by acetylcholine results not only in the production of NO, but also in 
stable COX products 202.  
PGI2 is known to be a potent vasodilator in a number of vascular beds 58, 203. By contrast, in 
human CC tissue, PGI2 released by muscarinic receptor stimulation was reported to cause 
contraction 198. Also when added to isolated corporal preparations pre-contracted with 
noradrenaline or PGF2α, PGI2 had no relaxant effect. Isolated pre-contracted preparations of 
the cavernosal artery, on the other hand, were effectively relaxed 204, which suggests that PGI2 
may serve as a vasodilator in the initial phase of penile erection 205.
 
Direct intracavernous 
injection of PGI2 into the penis of pigtailed monkeys resulted in a large reduction of the 
cavernosal compliance, owing to smooth muscle contraction, but there was no increase in 
cavernosal arterial blood flow 206. This argues against the fact that PGI2 directly contributes to 
regulation of corporal smooth muscle tone. It is more likely that during penile enlargement 
and blood stasis this prostanoid, synthesised from the vascular endothelium and corporal 
trabecular tissue, counteracts local thrombosis formation 123.  
By contrast, PGE1, seems to be a better candidate for the modulation of the corporal smooth 
muscle tone. PGE1 effectively relaxed human trabecular tissue, and pre-contracted segments 
of the cavernous artery 204. Furthermore, radioligand binding studies have demonstrated the 
presence of PGE1 receptors in penile tissues from humans and monkeys 207, 208. 
Correspondingly, intracorporal injection of PGE1 in those species resulted in erection. Besides 
                                                                                                                     General introduction 
 77 
through the activation of AC and the subsequent increase in the production of cAMP 209, 
PGE1 has been shown to decrease the [Ca2+]i through inhibition of the voltage-dependent L-
type Ca2+ channels 210. Moreover, PGE1 appears to inhibit the electrical release of 
noradrenaline from human penile adrenergic nerves, which may contribute to its relaxant 
action. In contrast, PGD2 increases its release, suggesting the possibility that prostanoid 
receptors may exist presynaptically, thereby modulating tonic sympathetic tone 211. Moreover, 
constrictor prostanoids have been shown to negatively modulate the antagonizing effect of 
NO on the adrenergic tone. In rabbit CC, the contractile response to noradrenaline, following 
treatment with the sGC inhibitor LY-83583 (thereby blocking the effect of NO) was 
significantly increased but reversed by COX blockade 212. This indicates that under 
physiological conditions, cGMP may not only be a second messenger involved in smooth 
muscle relaxation, but it may also directly inhibit the contractile effects of noradrenaline. This 
alteration in vascular reactivity secondary to altered NO production has also been shown in a 
number of other vascular beds 213. For example, in rat caudal artery 214, endothelium derived 
NO/cGMP was shown to directly attenuate contractile responses to exogenous noradrenaline 
and sympathetic EFS induced contractions. This process appears to be modulated by 
prostaglandins, which sensitize the smooth muscle cell to α-agonist stimulation. Besides 
corporal smooth muscle, the sensitizing effect has also been reported in other vascular 
models, i.e. human chorionic artery 215 and pig testicular artery 216. In those ring segments 
treated with L-NA, there was an increase in the resting tension and enhanced contractile 
responses to potassium and serotonin respectively. Both these effects were reduced in the 
presence of indomethacin. These findings indicate that there is an important physiological 
interaction between contractile prostanoids and endothelium-derived NO. Under pathological 
conditions of impaired NO production, the unopposed actions of the contractile prostanoids 
may result in an increase in corporal smooth muscle tone, thus contributing to the 
development of erectile dysfunction 217.  
 
*EDHF  
In addition to NO, recent reports indicate that EDHF may be critical to successful erection. 
Angulo et al. demonstrated that in human penile resistance arteries (HPRA) a consistent 
relaxation to acetylcholine remains after NOS and COX inhibition that is abolished by a high 
extracellular K+ concentration that prevents hyperpolarisation of smooth muscle and 
endothelium 218. This observation is consistent with the existence of a hyperpolarizing factor 
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contributing to endothelium-dependent dilatation in horse penile resistance arteries 219 and 
with the relevant role of relaxations mediated by EDHF in other human resistance vessels 112, 
220
. Additionally, calcium dobesilate, an angioprotective agent that is proposed to potentiate 
the vasodilator effect of EDHF in human arteries, significantly improved endothelium-
dependent EDHF-like relaxation of HPRA and potentiated erectile responses in vivo 218. 
Further evidence for the involvement of EDHF in the endothelium-dependent relaxation is 
provided by the other study of Angulo et al., showing that sildenafil, which potentiates the 
NO/cGMP pathway through inhibition of PDE-5, was able to completely reverse endothelial 
dysfunction in human CC from diabetic patients but not in penile resistance arteries from 
those patients. Moreover, calcium dobesilate completely recovered endothelial function in 
penile arteries from diabetic patients 221. However, administration of DOBE also failed to 
significantly improve erectile function in diabetic rats while it had significant potentiating 
effects in nondiabetic rats 222. Those findings demonstrate that potentiation of EDHF alone is 
insufficient to reverse endothelial dysfunction or that normal function of both CC and penile 
arteries is essential for the hemodynamic events that initiate and maintain penile erection. The 
observations with calcium dobesilate are in line with a study showing that chronic treatment 
with evening primrose oil did not improve endothelium-dependent relaxation of CC from 
diabetic rats while this treatment recovered endothelial function in mesenteric resistance 
vessels from these animals by enhancing EDHF-mediated responses, thus in a similar way as 
DOBE differentially affects endothelial function in CC and penile arteries 223. Several 
candidates for EDHF have been proposed, and CYP epoxygenase metabolites, 
epoxyeicosatrienoic acids (EET’s) are one of the several putative mediators of endothelium-
dependent relaxation. Recently, Jin et al. proposed that EET’s function as endothelium-
derived relaxing factors in penile tissue and are essential to achieve full erection 224. In human 
penile arteries, the nonselective inhibition of CYP activities by miconazole, significantly 
attenuated the effect of DOBE on EDHF-mediated relaxations, suggesting that this agent is 
related to the enhancement of the production or the action of CYP derivatives 218. 
Additionally, the pharmacological inhibition of CYP by sulfaphenazole, attenuates cavernosal 
nerve mediated erectile responses in the rat, suggesting that a CYP metabolite may mediate an 
EDHF-dependent smooth muscle effect in the penis that may contribute to the erectile 
response 225. As this area of penile vascular biology is not fully elucidated, further research 
must be undertaken to evaluate the potential importance of this endothelium-derived relaxing 
factor in the regulatory control of penile erection.  
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I.3.2.6. RhoA/Rho kinase  
The RhoA/Rho kinase signaling pathway (see also caption I.2.2.2. Regulation of MLC 
dephosphorylation/Ca2+ sensitization) is suggested to be the major Ca2+ sensitization 
mechanisms in the smooth muscle. Ca2+ sensitization is brought about by agonist activation of 
heterotrimeric G-protein-coupled receptors, the exchange of GTP for GDP on the small 
GTPase RhoA, its activation and dissociation from its partner Rho-GDI (guanine nucleotide 
dissociation inhibitor). GTP-RhoA activates Rho-kinase, which inhibits MLCP by 
phosphorylating its regulatory subunit; this leads to an increase in MLC20 phosphorylation 
and tension at constant [Ca2+]i 226. This mechanism has been shown to make a significant 
contribution to agonist-induced contraction under physiological conditions in peripheral 
vasculature 227, 228. Using an in vivo rat model, the functional role of RhoA/Rho kinase was 
also demonstrated in penile corpus cavernosum. Injection of the specific Rho kinase 
antagonist Y-27632 into the CC sinuses, without nerve stimulation, resulted in a dose-
dependent increase in ICP 229. This suggests that the RhoA/Rho kinase is constantly active 
and plays an important role in maintaining the penis in the flaccid state. Inhibition of Rho 
kinase also potentiates EFS-induced erections 229. Electrical stimulation of the major pelvic 
ganglion has been demonstrated to result in a voltage-dependent increase in ICP, a process 
that is inhibited by NOS blockade (and is thus attributed to NO release from NANC nerves) 
230
. Additional experiments have demonstrated a similar potentiation of the effect of Rho 
kinase inhibition on ICP upon prior injection with a NO donor drug 231. These data suggest 
that NO potentiates the effect of Y-27632 and provide support for the hypothesis that NO-
induced penile erection is through the inhibition of endogenous Rho kinase constrictor 
activity. However, pre-injection of L-NA and MB or ODQ did not significantly alter the 
effect of Rho kinase antagonism, indicating that the Y-27632-induced rise in ICP is 
independent of a NO-mediated pathway 229, 232. Thus, antagonism of Rho kinase may offer a 
potential alternate avenue for the treatment of erectile dysfunction. Supporting such a 
suggestion, Wilkes et al. investigated the effects of Y-27632 on erectile responses in male 
SHR, and found a significant increase in neurogenic response after intracavernosal injection 
of Y-27632. They suggested that an increased hypertension-induced vasoconstrictor tone and 
impaired erectile response may be due to up-regulation of Rho kinase activity 233. 
Additionally, diabetic rabbit CC have been shown to have an increased sensitivity to 
stimulation by the endothelin-1 agonist 234, an increased expression of Rho kinase and 
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decreased relaxation of Y-27632 235. Also in aging male Brown-Norway rats, Rho kinase 
inhibition with Y-27632 was reported to improve erectile function 236.  
In vitro, Rho kinase inhibition has been shown to inhibit CC smooth muscle tone including 
human and rabbit 237. Furthermore, Y-27632 was found to relax isolated rat CC tissue that had 
been precontracted with KCl or phenylephrine to a similar extent 229. As in conduit vessels 
pre-constricted with KCl the effect of Y-27632 on vasorelaxation was attenuated as opposed 
to phenylephrine 238, 239, Rho kinase activity is suggested to be elevated in penile vasculature, 
as compared to conduit arteries. In addition, RhoA protein concentration was reported to be 
17 times greater in rabbit CC than in ileum, bladder, femoral artery and portal vein 240 
suggesting that RhoA/Rho kinase Ca2+ sensitization may play a substantial role in CC smooth 
muscle contraction. Furthermore, the detection of the MLCP inhibitory protein CPI-17 in 
human and rabbit CC, supports the possibility of CPI-17-mediated Ca2+ sensitization in the 
penis 240. Finally, the adeno-associated viral gene transfer of a dominant-negative RhoA 
mutant into the rat CC, confirmed the significance of the RhoA/Rho kinase signaling pathway 
in penile erection, as the mutant markedly increases basal ICP as well as cavernous nerve 
stimulation-induced ICP in vivo 241.  
 
I.3.3. References 
 1.  Arnal JF, nh-Xuan AT, Pueyo M, Darblade B, Rami J. Endothelium-derived nitric 
oxide and vascular physiology and pathology. Cell Mol Life Sci 1999;55:1078-1087. 
 2.  Van de Voorde J, Vanheel B. Basic Physiologic Principles in Angiology-Endothelial 
Modulation of Vascular Tone. In: Chang JB, Olsen ER, Prasad K, and Sumpio BE, 
eds. Textbook of Angiology. 1 ed. New york: Springer-Verlag, 2000:11-38. 
 3.  Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation 
of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376. 
 4.  Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological 
activity of endothelium-derived relaxing factor. Nature 1987;327:524-526. 
 5.  Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived 
relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl 
Acad Sci U S A 1987;84:9265-9269. 
 6.  Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological 
precursor for the formation of nitric oxide in endothelium-dependent relaxation. 
Biochem Biophys Res Commun 1988;153:1251-1256. 
 7.  Stuehr DJ, Kwon NS, Nathan CF, Griffith OW, Feldman PL, Wiseman J. N omega-
hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-
arginine. J Biol Chem 1991;266:6259-6263. 
                                                                                                                     General introduction 
 81 
 8.  Leone AM, Palmer RM, Knowles RG, Francis PL, Ashton DS, Moncada S. 
Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into 
both nitric oxide and citrulline. J Biol Chem 1991;266:23790-23795. 
 9.  Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 
1997;100:2146-2152. 
 10.  Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 
1997;100:2417-2423. 
 11.  Forstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' 
isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998;12:773-790. 
 12.  Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. 
FASEB J 1989;3:2007-2018. 
 13.  Falcone JC, Kuo L, Meininger GA. Endothelial cell calcium increases during flow-
induced dilation in isolated arterioles. Am J Physiol 1993;264:H653-H659. 
 14.  Shen J, Luscinskas FW, Connolly A, Dewey CF, Jr., Gimbrone MA, Jr. Fluid shear 
stress modulates cytosolic free calcium in vascular endothelial cells. Am J Physiol 
1992;262:C384-C390. 
 15.  Schwarz G, Droogmans G, Nilius B. Shear stress induced membrane currents and 
calcium transients in human vascular endothelial cells. Pflugers Arch 1992;421:394-
396. 
 16.  Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial nitric-
oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997;272:15583-
15586. 
 17.  Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-
caveolin regulatory cycle. J Biol Chem 1998;273:3125-3128. 
 18.  Ayajiki K, Kindermann M, Hecker M, Fleming I, Busse R. Intracellular pH and 
tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide 
production in native endothelial cells. Circ Res 1996;78:750-758. 
 19.  Pearson PJ, Vanhoutte PM. Vasodilator and vasoconstrictor substances produced by 
the endothelium. Rev Physiol Biochem Pharmacol 1993;122:1-67. 
 20.  Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, 
Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide 
production by the protein kinase Akt. Nature 1999;399:597-601. 
 21.  Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-
derived relaxing factor. Am J Physiol 1986;250:H1145-H1149. 
 22.  Bevan JA, Joyce EH. Flow-dependent dilation in myograph-mounted resistance artery 
segments. Blood Vessels 1988;25:101-104. 
Chapter I 
 82 
 23.  Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric 
oxide from endothelial cells grown on beads. Hypertension 1991;17:187-193. 
 24.  Wechezak AR, Viggers RF, Sauvage LR. Fibronectin and F-actin redistribution in 
cultured endothelial cells exposed to shear stress. Lab Invest 1985;53:639-647. 
 25.  Barbee KA, Davies PF, Lal R. Shear stress-induced reorganization of the surface 
topography of living endothelial cells imaged by atomic force microscopy. Circ Res 
1994;74:163-171. 
 26.  Griffith TM, Edwards DH. Myogenic autoregulation of flow may be inversely related 
to endothelium-derived relaxing factor activity. Am J Physiol 1990;258:H1171-
H1180. 
 27.  Pohl U, Herlan K, Huang A, Bassenge E. EDRF-mediated shear-induced dilation 
opposes myogenic vasoconstriction in small rabbit arteries. Am J Physiol 
1991;261:H2016-H2023. 
 28.  Hecker M, Mulsch A, Bassenge E, Busse R. Vasoconstriction and increased flow: two 
principal mechanisms of shear stress-dependent endothelial autacoid release. Am J 
Physiol 1993;265:H828-H833. 
 29.  De Wit C, Jahrbeck B, Schafer C, Bolz SS, Pohl U. Nitric oxide opposes myogenic 
pressure responses predominantly in large arterioles in vivo. Hypertension 
1998;31:787-794. 
 30.  Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three 
inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 
1990;101:746-752. 
 31.  Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-
arginine uptake: a mechanism for differential inhibition of NO synthases? Am J 
Physiol 1995;269:C750-C756. 
 32.  Rees DD, Palmer RM, Hodson HF, Moncada S. A specific inhibitor of nitric oxide 
formation from L-arginine attenuates endothelium-dependent relaxation. Br J 
Pharmacol 1989;96:418-424. 
 33.  Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the 
regulation of blood pressure. Proc Natl Acad Sci U S A 1989;86:3375-3378. 
 34.  Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine 
monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. 
J Clin Invest 1992;90:647-652. 
 35.  Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis 
increases blood pressure in healthy humans. J Hypertens 1993;11:1375-1380. 
 36.  Kurihara N, Alfie ME, Sigmon DH, Rhaleb NE, Shesely EG, Carretero OA. Role of 
nNOS in blood pressure regulation in eNOS null mutant mice. Hypertension 
1998;32:856-861. 
                                                                                                                     General introduction 
 83 
 37.  Stauss HM, Godecke A, Mrowka R, Schrader J, Persson PB. Enhanced blood pressure 
variability in eNOS knockout mice. Hypertension 1999;33:1359-1363. 
 38.  Stauss HM, Nafz B, Mrowka R, Persson PB. Blood pressure control in eNOS knock-
out mice: comparison with other species under NO blockade. Acta Physiol Scand 
2000;168:155-160. 
 39.  Beierwaltes WH, Potter DL, Shesely EG. Renal baroreceptor-stimulated renin in the 
eNOS knockout mouse. Am J Physiol Renal Physiol 2002;282:F59-F64. 
 40.  Wagner C, Godecke A, Ford M, Schnermann J, Schrader J, Kurtz A. Regulation of 
renin gene expression in kidneys of eNOS- and nNOS-deficient mice. Pflugers Arch 
2000;439:567-572. 
 41.  Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman 
MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. 
Nature 1995;377:239-242. 
 42.  Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, Sakoda T, 
Kurihara H, Yazaki Y, Yokoyama M. Hypotension and reduced nitric oxide-elicited 
vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J 
Clin Invest 1998;102:2061-2071. 
 43.  Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, 
Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi 
N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh 
H, Masuda I, Yasue H, Nakao K. Endothelial nitric oxide synthase gene is positively 
associated with essential hypertension. Hypertension 1998;32:3-8. 
 44.  Ortiz PA, Garvin JL. Cardiovascular and renal control in NOS-deficient mouse 
models. Am J Physiol Regul Integr Comp Physiol 2003;284:R628-R638. 
 45.  Ollerstam A, Pittner J, Persson AE, Thorup C. Increased blood pressure in rats after 
long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest 
1997;99:2212-2218. 
 46.  Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder 
SH. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. 
Nature 1995;378:383-386. 
 47.  Jumrussirikul P, Dinerman J, Dawson TM, Dawson VL, Ekelund U, Georgakopoulos 
D, Schramm LP, Calkins H, Snyder SH, Hare JM, Berger RD. Interaction between 
neuronal nitric oxide synthase and inhibitory G protein activity in heart rate regulation 
in conscious mice. J Clin Invest 1998;102:1279-1285. 
 48.  Vallon V, Traynor T, Barajas L, Huang YG, Briggs JP, Schnermann J. Feedback 
control of glomerular vascular tone in neuronal nitric oxide synthase knockout mice. J 
Am Soc Nephrol 2001;12:1599-1606. 
 49.  Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai 
IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, 
Chapter I 
 84 
Berkowitz DE, Hare JM. Nitric oxide regulates the heart by spatial confinement of 
nitric oxide synthase isoforms. Nature 2002;416:337-339. 
 50.  Meng W, Ayata C, Waeber C, Huang PL, Moskowitz MA. Neuronal NOS-cGMP-
dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout 
mice. Am J Physiol 1998;274:H411-H415. 
 51.  Huang A, Sun D, Shesely EG, Levee EM, Koller A, Kaley G. Neuronal NOS-
dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol 
Heart Circ Physiol 2002;282:H429-H436. 
 52.  Stoclet JC, Muller B, Gyorgy K, Andriantsiothaina R, Kleschyov AL. The inducible 
nitric oxide synthase in vascular and cardiac tissue. Eur J Pharmacol 1999;375:139-
155. 
 53.  Ullrich R, Bloch KD, Ichinose F, Steudel W, Zapol WM. Hypoxic pulmonary blood 
flow redistribution and arterial oxygenation in endotoxin-challenged NOS2-deficient 
mice. J Clin Invest 1999;104:1421-1429. 
 54.  Ihrig M, Dangler CA, Fox JG. Mice lacking inducible nitric oxide synthase develop 
spontaneous hypercholesterolaemia and aortic atheromas. Atherosclerosis 
2001;156:103-107. 
 55.  Gross SS, Kilbourn RG, Griffith OW. NO in septic shock: good, bad or ugly? 
Learning from iNOS knockouts. Trends Microbiol 1996;4:47-49. 
 56.  Moncada S, Gryglewski R, Bunting S, Vane JR. Enzyme Isolated from Arteries 
Transforms Prostaglandin Endoperoxides to An Unstable Substance That Inhibits 
Platelet-Aggregation. Nature 1976;263:663-665. 
 57.  Moncada S, Herman AG, Higgs EA, Vane JR. Differential Formation of Prostacyclin 
(Pgx Or Pgi2) by Layers of Arterial-Wall - Explanation for Anti-Thrombotic 
Properties of Vascular Endothelium. Thrombosis Research 1977;11:323-344. 
 58.  Parkington HC, Coleman HA, Tare M. Prostacyclin and endothelium-dependent 
hyperpolarization. Pharmacological Research 2004;49:509-514. 
 59.  Smith WL. Prostaglandin Biosynthesis and Its Compartmentation in Vascular Smooth-
Muscle and Endothelial-Cells. Annual Review of Physiology 1986;48:251-262. 
 60.  Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J 
Rheumatol Suppl 1997;49:15-19. 
 61.  Sheng H, Shao J, Morrow JD, Beauchamp RD, Dubois RN. Modulation of apoptosis 
and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 
1998;58:362-366. 
 62.  Ishaque A, Dunn MJ, Sorokin A. Cyclooxygenase-2 inhibits tumor necrosis factor 
alpha-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem 
2003;278:10629-10640. 
                                                                                                                     General introduction 
 85 
 63.  Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, 
Morrow JD, Coffey RJ. Stromal production of prostacyclin confers an antiapoptotic 
effect to colonic epithelial cells. Cancer Res 2003;63:1748-1751. 
 64.  Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De SA, Satta MA, Peskar 
BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy 
subjects. Thromb Res 1980;17:317-327. 
 65.  Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. 
Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases 
with salt restriction. J Clin Invest 1994;94:2504-2510. 
 66.  Porcher C, Horowitz B, Ward SM, Sanders KM. Constitutive and functional 
expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol 
Motil 2004;16:785-799. 
 67.  Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular 
consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin 
Invest 2006;116:4-15. 
 68.  Kukovetz WR, Holzmann S, Wurm A, Poch G. Prostacyclin increases cAMP in 
coronary arteries. J Cyclic Nucleotide Res 1979;5:469-476. 
 69.  Ignarro LJ, Harbison RG, Wood KS, Wolin MS, McNamara DB, Hyman AL, 
Kadowitz PJ. Differences in responsiveness of intrapulmonary artery and vein to 
arachidonic acid: mechanism of arterial relaxation involves cyclic guanosine 3':5'-
monophosphate and cyclic adenosine 3':5'-monophosphate. J Pharmacol Exp Ther 
1985;233:560-569. 
 70.  Tang DG, Grossi IM, Tang KQ, Diglio CA, Honn KV. Inhibition of TPA and 12(S)-
HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale 
for their antimetastatic effects. Int J Cancer 1995;60:418-425. 
 71.  Koller A, Sun D, Huang A, Kaley G. Corelease of nitric oxide and prostaglandins 
mediates flow-dependent dilation of rat gracilis muscle arterioles. Am J Physiol 
1994;267:H326-H332. 
 72.  Levin RI, Jaffe EA, Weksler BB, Tack-Goldman K. Nitroglycerin stimulates synthesis 
of prostacyclin by cultured human endothelial cells. J Clin Invest 1981;67:762-769. 
 73.  Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric 
oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993;90:7240-
7244. 
 74.  Delpy E, Coste H, Gouville AC. Effects of cyclic GMP elevation on isoprenaline-
induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of 
phosphodiesterase 3. Br J Pharmacol 1996;119:471-478. 
 75.  Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. 
Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue 
beraprost is mediated through cAMP-responsive element in vascular endothelial cells: 
close link between PGI2 signal and NO pathways. Circ Res 2003;93:523-530. 
Chapter I 
 86 
 76.  Sun D, Huang A, Smith CJ, Stackpole CJ, Connetta JA, Shesely EG, Koller A, Kaley 
G. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation 
in eNOS knockout mice. Circ Res 1999;85:288-293. 
 77.  Sun D, Liu H, Yan C, Jacobson A, Ojaimi C, Huang A, Kaley G. COX-2 contributes 
to the maintenance of flow-induced dilation in arterioles of eNOS-knockout mice. Am 
J Physiol Heart Circ Physiol 2006;291:H1429-H1435. 
 78.  Bunting S, Moncada S, Vane JR. The prostacyclin--thromboxane A2 balance: 
pathophysiological and therapeutic implications. Br Med Bull 1983;39:271-276. 
 79.  Adatia I. Recent advances in pulmonary vascular disease. Curr Opin Pediatr 
2002;14:292-297. 
 80.  Huang K, Liu H, Chen Z, Xu H. Role of selenium in cytoprotection against cholesterol 
oxide-induced vascular damage in rats. Atherosclerosis 2002;162:137-144. 
 81.  Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane 
production. Am J Obstet Gynecol 1985;152:335-340. 
 82.  Yokoyama C, Yabuki T, Shimonishi M, Wada M, Hatae T, Ohkawara S, Takeda J, 
Kinoshita T, Okabe M, Tanabe T. Prostacyclin-deficient mice develop ischemic renal 
disorders, including nephrosclerosis and renal infarction. Circulation 2002;106:2397-
2403. 
 83.  Iwai N, Katsuya T, Ishikawa K, Mannami T, Ogata J, Higaki J, Ogihara T, Tanabe T, 
Baba S. Human prostacyclin synthase gene and hypertension : the Suita Study. 
Circulation 1999;100:2231-2236. 
 84.  Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, 
Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S, Narumiya S. Altered pain 
perception and inflammatory response in mice lacking prostacyclin receptor. Nature 
1997;388:678-682. 
 85.  Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, 
Eng VM, Collins RJ, Czerniak PM, . Renal abnormalities and an altered inflammatory 
response in mice lacking cyclooxygenase II. Nature 1995;378:406-409. 
 86.  Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, 
Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 
gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482. 
 87.  Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular 
biology of renin secretion. Physiol Rev 1990;70:1067-1116. 
 88.  Yang T, Endo Y, Huang YG, Smart A, Briggs JP, Schnermann J. Renin expression in 
COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 
2000;279:F819-F825. 
 89.  Cheng HF, Wang JL, Zhang MZ, Wang SW, McKanna JA, Harris RC. Genetic 
deletion of COX-2 prevents increased renin expression in response to ACE inhibition. 
Am J Physiol Renal Physiol 2001;280:F449-F456. 
                                                                                                                     General introduction 
 87 
 90.  Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. 
Paracrine regulation of the renal microcirculation. Physiol Rev 1996;76:425-536. 
 91.  Muscara MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL. 
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and 
promotes leukocyte adherence. Br J Pharmacol 2000;129:1423-1430. 
 92.  Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, 
Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin 
synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation 
and indomethacin-induced gastric ulceration. Cell 1995;83:483-492. 
 93.  Kawada N, Solis G, Ivey N, Connors S, Dennehy K, Modlinger P, Hamel R, Kawada 
JT, Imai E, Langenbach R, Welch WJ, Wilcox CS. Cyclooxygenase-1-deficient mice 
have high sleep-to-wake blood pressure ratios and renal vasoconstriction. 
Hypertension 2005;45:1131-1138. 
 94.  Cheung RT, Pei Z, Feng ZH, Zou LY. Cyclooxygenase-1 gene knockout does not alter 
middle cerebral artery occlusion in a mouse stroke model. Neurosci Lett 2002;330:57-
60. 
 95.  Norwood VF, Morham SG, Smithies O. Postnatal development and progression of 
renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 2000;58:2291-2300. 
 96.  Bolton TB, Lang RJ, Takewaki T. Mechanisms of action of noradrenaline and 
carbachol on smooth muscle of guinea-pig anterior mesenteric artery. J Physiol 
1984;351:549-572. 
 97.  Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: 
bringing the concepts together. Trends Pharmacol Sci 2002;23:374-380. 
 98.  Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-
derived hyperpolarizing factor in rat arteries. Nature 1998;396:269-272. 
 99.  Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. 
Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-
497. 
 100.  Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived 
hyperpolarizing factors. Hypertension 2007;49:590-596. 
 101.  Faraci FM, Sobey CG, Chrissobolis S, Lund DD, Heistad DD, Weintraub NL. 
Arachidonate dilates basilar artery by lipoxygenase-dependent mechanism and 
activation of K(+) channels. Am J Physiol Regul Integr Comp Physiol 
2001;281:R246-R253. 
 102.  Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly 
activates calcium-dependent potassium channels in vascular smooth muscle. Nature 
1994;368:850-853. 
Chapter I 
 88 
 103.  Ellis A, Triggle CR. Endothelium-derived reactive oxygen species: their relationship 
to endothelium-dependent hyperpolarization and vascular tone. Can J Physiol 
Pharmacol 2003;81:1013-1028. 
 104.  Popp R, Brandes RP, Ott G, Busse R, Fleming I. Dynamic modulation of 
interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. 
Circ Res 2002;90:800-806. 
 105.  Wei CM, Hu S, Miller VM, Burnett JC, Jr. Vascular actions of C-type natriuretic 
peptide in isolated porcine coronary arteries and coronary vascular smooth muscle 
cells. Biochem Biophys Res Commun 1994;205:765-771. 
 106.  Griffith TM. Endothelium-dependent smooth muscle hyperpolarization: do gap 
junctions provide a unifying hypothesis? Br J Pharmacol 2004;141:881-903. 
 107.  Kohler R, Hoyer J. The endothelium-derived hyperpolarizing factor: insights from 
genetic animal models. Kidney Int 2007;72:145-150. 
 108.  Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, 
Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A. The importance of 
the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-
dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 
1996;28:703-711. 
 109.  Waldron GJ, Ding H, Lovren F, Kubes P, Triggle CR. Acetylcholine-induced 
relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide 
synthase. Br J Pharmacol 1999;128:653-658. 
 110.  Brandes RP, Schmitz-Winnenthal FH, Feletou M, Godecke A, Huang PL, Vanhoutte 
PM, Fleming I, Busse R. An endothelium-derived hyperpolarizing factor distinct from 
NO and prostacyclin is a major endothelium-dependent vasodilator in resistance 
vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci 
U S A 2000;97:9747-9752. 
 111.  Nishikawa Y, Stepp DW, Chilian WM. In vivo location and mechanism of EDHF-
mediated vasodilation in canine coronary microcirculation. Am J Physiol 
1999;277:H1252-H1259. 
 112.  Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. 
Characterization of endothelium-derived hyperpolarizing factor in the human forearm 
microcirculation. Am J Physiol Heart Circ Physiol 2001;280:H2470-H2477. 
 113.  De Vriese AS, Van de Voorde J, Lameire NH. Effects of connexin-mimetic peptides 
on nitric oxide synthase- and cyclooxygenase-independent renal vasodilation. Kidney 
Int 2002;61:177-185. 
 114.  Cohen RA, Plane F, Najibi S, Huk I, Malinski T, Garland CJ. Nitric oxide is the 
mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit 
carotid artery. Proc Natl Acad Sci U S A 1997;94:4193-4198. 
                                                                                                                     General introduction 
 89 
 115.  Corriu C, Feletou M, Edwards G, Weston AH, Vanhoutte PM. Differential effects of 
prostacyclin and iloprost in the isolated carotid artery of the guinea-pig. Eur J 
Pharmacol 2001;426:89-94. 
 116.  Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, Hobbs AJ, 
Ahluwalia A. Investigation of vascular responses in endothelial nitric oxide 
synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived 
hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 
2005;111:796-803. 
 117.  Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K. The oestrogen 
receptor beta contributes to sex related differences in endothelial function of murine 
small arteries via EDHF. J Physiol 2006;577:945-955. 
 118.  Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption 
of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 
2000;275:40504-40510. 
 119.  Taylor MS, Bonev AD, Gross TP, Eckman DM, Brayden JE, Bond CT, Adelman JP, 
Nelson MT. Altered expression of small-conductance Ca2+-activated K+ (SK3) 
channels modulates arterial tone and blood pressure. Circ Res 2003;93:124-131. 
 120.  Si H, Heyken WT, Wolfle SE, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing 
G, Maier T, Gross V, Bader M, de WC, Hoyer J, Kohler R. Impaired endothelium-
derived hyperpolarizing factor-mediated dilations and increased blood pressure in 
mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 
2006;99:537-544. 
 121.  Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we 
now? Arterioscler Thromb Vasc Biol 2006;26:1215-1225. 
 122.  Minhas S, Cartledge J, Eardley I. The role of prostaglandins in penile erection. 
Prostaglandins Leukot Essent Fatty Acids 2000;62:137-146. 
 123.  Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-
236. 
 124.  Ralph DJ. Normal erectile function. Clin Cornerstone 2005;7:13-18. 
 125.  Baryshnikov GF, Bininda-Emonds ORP, Abramov AV. Morphological variability and 
evolution the Baculum (Os Penis) in Mustelidae (Carnivora). Journal of Mammalogy 
2003;84:673-690. 
 126.  Goyal HO, Braden TD, Cooke PS, Szewczykowski MA, Williams CS, Dalvi P, 
Williams JW. Estrogen receptor alpha mediates estrogen-inducible abnormalities in 
the developing penis. Reproduction 2007;133:1057-1067. 
 127.  Murakami R. Development of the Os-Penis in Genital Tubercles Cultured Beneath the 
Renal Capsule of Adult-Rats. Journal of Anatomy 1986;149:11-20. 
 128.  Murakami R. A Histological Study of the Development of the Penis of Wild-Type and 
Androgen-Insensitive Mice. Journal of Anatomy 1987;153:223-231. 
Chapter I 
 90 
 129.  Hsu GL, Lin CW, Hsieh CH, Hsieh JT, Chen SC, Kuo TF, Ling PY, Huang HM, 
Wang CJ, Tseng GF. Distal ligament in human glans: A comparative study of penile 
architecture. Journal of Andrology 2005;26:624-628. 
 130.  Morton JS, Jackson VM, Daly CJ, McGrath JC. Endothelium dependent relaxation in 
rabbit genital resistance arteries is predominantly mediated by endothelial-derived 
hyperpolarizing factor in females and nitric oxide in males. J Urol 2007;177:786-791. 
 131.  Weiss HD. The physiology of human penile erection. Ann Intern Med 1972;76:793-
799. 
 132.  Traish A, Kim NN, Moreland RB, Goldstein I, I. Role of alpha adrenergic receptors in 
erectile function. Int J Impot Res 2000;12:S48-S63. 
 133.  Veronneau-Longueville F, Rampin O, Jardin A, Benoit G, Giuliano F. Expression of 
alpha 1 adrenoceptor subtypes in rat corpus cavernosum. Int J Impot Res 1998;10:187-
194. 
 134.  Sironi G, Colombo D, Poggesi E, Leonardi A, Testa R, Rampin O, Bernabe J, 
Giuliano F. Effects of intracavernous administration of selective antagonists of 
alpha(1)-adrenoceptor subtypes on erection in anesthetized rats and dogs. J Pharmacol 
Exp Ther 2000;292:974-981. 
 135.  Ari G, Vardi Y, Hoffman A, Finberg JP. Possible role for endothelins in penile 
erection. Eur J Pharmacol 1996;307:69-74. 
 136.  Dai Y, Pollock DM, Lewis RL, Wingard CJ, Stopper VS, Mills TM. Receptor-specific 
influence of endothelin-1 in the erectile response of the rat. Am J Physiol Regul Integr 
Comp Physiol 2000;279:R25-R30. 
 137.  Saenz de Tejada, I, Carson MP, de las Morenas A, Goldstein I, Traish AM. 
Endothelin: localization, synthesis, activity, and receptor types in human penile corpus 
cavernosum. Am J Physiol 1991;261:H1078-H1085. 
 138.  Jordan GH. Erectile function and dysfunction. Postgrad Med 1999;105:131-8, 143. 
 139.  Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol 
Ther 2005;106:233-266. 
 140.  Fahrenkrug J. Gut/brain peptides in the genital tract: VIP and PACAP. Scand J Clin 
Lab Invest Suppl 2001;234:35-39. 
 141.  Krane RJ, Goldstein I, Saenz dT, I. Impotence. N Engl J Med 1989;321:1648-1659. 
 142.  Aboseif SR, Lue TF. Hemodynamics of penile erection. Urol Clin North Am 
1988;15:1-7. 
 143.  Burnett AL, Musicki B. The nitric oxide signaling pathway in the penis. Current 
Pharmaceutical Design 2005;11:3987-3994. 
                                                                                                                     General introduction 
 91 
 144.  Kim N, Azadzoi KM, Goldstein I, Saenz dT, I. A nitric oxide-like factor mediates 
nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum 
smooth muscle. J Clin Invest 1991;88:112-118. 
 145.  Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a 
physiologic mediator of penile erection. Science 1992;257:401-403. 
 146.  Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 
1995;52:485-489. 
 147.  Finberg JP, Levy S, Vardi Y. Inhibition of nerve stimulation-induced vasodilatation in 
corpora cavernosa of the pithed rat by blockade of nitric oxide synthase. Br J 
Pharmacol 1993;108:1038-1042. 
 148.  Holmquist F, Stief CG, Jonas U, Andersson KE. Effects of the nitric oxide synthase 
inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation 
in the rabbit. Acta Physiol Scand 1991;143:299-304. 
 149.  Bredt DS, Hwang PM, Snyder SH. Localization of Nitric-Oxide Synthase Indicating A 
Neural Role for Nitric-Oxide. Nature 1990;347:768-770. 
 150.  Burnett AL, Tillman SL, Chang TSK, Epstein JI, Lowenstein CJ, Bredt DS, Snyder 
SH, Walsh PC. Immunohistochemical Localization of Nitric-Oxide Synthase in the 
Autonomic Innervation of the Human Penis. Journal of Urology 1993;150:73-76. 
 151.  Burnett AL, Nelson RJ, Calvin DC, Liu JX, Demas GE, Klein SL, Kriegsfeld LJ, 
Dawson VL, Dawson TM, Snyder SH. Nitric oxide-dependent penile erection in mice 
lacking neuronal nitric oxide synthase. Mol Med 1996;2:288-296. 
 152.  Hurt KJ, Sezen SF, Champion HC, Crone JK, Palese MA, Huang PL, Sawa A, Luo X, 
Musicki B, Snyder SH, Burnett AL. Alternatively spliced neuronal nitric oxide 
synthase mediates penile erection. Proc Natl Acad Sci U S A 2006;103:3440-3443. 
 153.  Gonzalez-Cadavid NF, Burnett AL, Magee TR, Zeller CB, Vernet D, Smith N, Gitter 
J, Rajfer J. Expression of penile neuronal nitric oxide synthase variants in the rat and 
mouse penile nerves. Biol Reprod 2000;63:704-714. 
 154.  Nangle MR, Cotter MA, Cameron NE. An in vitro study of corpus cavernosum and 
aorta from mice lacking the inducible nitric oxide synthase gene. Nitric Oxide 
2003;9:194-200. 
 155.  Nangle MR, Cotter MA, Cameron NE. An in vitro investigation of aorta and corpus 
cavernosum from eNOS and nNOS gene-deficient mice. Pflugers Arch 2004;448:139-
145. 
 156.  Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SF. Noncholinergic penile 
erection in mice lacking the gene for endothelial nitric oxide synthase. Journal of 
Andrology 2002;23:92-97. 
 157.  Gu J, Polak JM, Probert L, Islam KN, Marangos PJ, Mina S, Adrian TE, McGregor 
GP, O'Shaughnessy DJ, Bloom SR. Peptidergic innervation of the human male genital 
tract. J Urol 1983;130:386-391. 
Chapter I 
 92 
 158.  Okamura T, Ayajiki K, Toda N. Monkey corpus cavernosum relaxation mediated by 
NO and other relaxing factor derived from nerves. Am J Physiol 1998;274:H1075-
H1081. 
 159.  Okamura T, Ayajiki K, Fujioka H, Toda M, Fujimiya M, Toda N. Effects of 
endothelial impairment by saponin on the responses to vasodilators and nitrergic nerve 
stimulation in isolated canine corpus cavernosum. Br J Pharmacol 1999;127:802-808. 
 160.  Dail WG, Barba V, Leyba L, Galindo R. Neural and Endothelial Nitric-Oxide 
Synthase Activity in Rat Penile Erectile Tissue. Cell and Tissue Research 
1995;282:109-116. 
 161.  Hurt KJ, Musicki B, Palese MA, Crone JK, Becker RE, Moriarity JL, Snyder SH, 
Burnett AL. Akt-dependent phosphorylation of endothelial nitric-oxide synthase 
mediates penile erection. Proc Natl Acad Sci U S A 2002;99:4061-4066. 
 162.  Bredt DS, Snyder SH. Isolation of Nitric-Oxide Synthetase, A Calmodulin-Requiring 
Enzyme. Proceedings of the National Academy of Sciences of the United States of 
America 1990;87:682-685. 
 163.  Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of 
nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 
1999;399:601-605. 
 164.  Cartledge J, Minhas S, Eardley I. The role of nitric oxide in penile erection. Expert 
Opin Pharmacother 2001;2:95-107. 
 165.  Andersson KE, Stief CG. Neurotransmission and the contraction and relaxation of 
penile erectile tissues. World Journal of Urology 1997;15:14-20. 
 166.  Polak JM, Gu J, Mina S, Bloom SR. Vipergic nerves in the penis. Lancet 1981;2:217-
219. 
 167.  Ottesen B, Fahrenkrug J. Vasoactive intestinal polypeptide and other preprovasoactive 
intestinal polypeptide-derived peptides in the female and male genital tract: 
localization, biosynthesis, and functional and clinical significance. Am J Obstet 
Gynecol 1995;172:1615-1631. 
 168.  Dixson AF, Kendrick KM, Blank MA, Bloom SR. Effects of Tactile and Electrical 
Stimuli Upon Release of Vasoactive Intestinal Polypeptide in the Mammalian Penis. 
Journal of Endocrinology 1984;100:249-252. 
 169.  Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive 
intestinal polypeptide alone and in combination with other vasoactive agents. Br J 
Urol 1989;64:191-194. 
 170.  Amenta F, Cavallotti C, Derossi M, Ferrante F, Geppetti P. Vasoactive Intestinal 
Polypeptide Levels and Distribution in the Penis of Old Rats. Journal of Neural 
Transmission 1987;70:137-143. 
                                                                                                                     General introduction 
 93 
 171.  Shen ZJ, Lu YL, Chen ZD, Chen F, Chen Z. Effects of androgen and ageing on gene 
expression of vasoactive intestinal polypeptide rat corpus cavernosum. Bju 
International 2000;86:133-137. 
 172.  Crowe R, Lincoln J, Blacklay PF, Pryor JP, Lumley JSP, Burnstock G. Vasoactive 
Intestinal Polypeptide-Like Immunoreactive Nerves in Diabetic Penis - A Comparison 
Between Streptozotocin-Treated Rats and Man. Diabetes 1983;32:1075-1077. 
 173.  Gu J, Lazarides M, Pryor JP, Blank MA, Polak JM, Morgan R, Marangos PJ, Bloom 
SR. Decrease of Vasoactive Intestinal Polypeptide (Vip) in the Penises from Impotent 
Men. Lancet 1984;2:315-318. 
 174.  Lincoln J, Crowe R, Blacklay PF, Pryor JP, Lumley JSP, Burnstock G. Changes in the 
Vipergic, Cholinergic and Adrenergic-Innervation of Human Penile Tissue in Diabetic 
and Nondiabetic Impotent Males. Journal of Urology 1987;137:1053-1059. 
 175.  Steers WD, McConnell J, Benson GS. Anatomical localization and some 
pharmacological effects of vasoactive intestinal polypeptide in human and monkey 
corpus cavernosum. J Urol 1984;132:1048-1053. 
 176.  Willis EA, Ottesen B, Wagner G, Sundler F, Fahrenkrug J. Vasoactive Intestinal 
Polypeptide (Vip) As A Putative Neurotransmitter in Penile Erection. Life Sciences 
1983;33:383-391. 
 177.  Adaikan PG, Kottegoda SR, Ratnam SS. Is Vasoactive Intestinal Polypeptide the 
Principal Transmitter Involved in Human Penile Erection. Journal of Urology 
1986;135:638-640. 
 178.  Wagner G, Gerstenberg T. Intracavernosal Injection of Vasoactive Intestinal 
Polypeptide (Vip) Does Not Induce Erection in Man Per Se. World Journal of Urology 
1987;5:171-172. 
 179.  Roy JB, Petrone RL, Said SI. A clinical trial of intracavernous vasoactive intestinal 
peptide to induce penile erection. J Urol 1990;143:302-304. 
 180.  Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous Self-Injection with 
Vasoactive Intestinal Polypeptide and Phentolamine in the Management of Erectile 
Failure. Journal of Urology 1992;147:1277-1279. 
 181.  Kim YC, Kim JH, Davies MG, Hagen PO, Carson CC. Modulation of Vasoactive 
Intestinal Polypeptide (Vip)-Mediated Relaxation by Nitric-Oxide and Prostanoids in 
the Rabbit Corpus Cavernosum. Journal of Urology 1995;153:807-810. 
 182.  Ding YQ, Takada M, Kaneko T, Mizuno N. Colocalization of Vasoactive Intestinal 
Polypeptide and Nitric-Oxide in Penis-Innervating Neurons in the Major Pelvic 
Ganglion of the Rat. Neuroscience Research 1995;22:129-131. 
 183.  Tamura M, Kagawa S, Kimura K, Kawanishi Y, Tsuruo Y, Ishimura K. Coexistence 
of Nitric-Oxide Synthase, Tyrosine-Hydroxylase and Vasoactive Intestinal 
Polypeptide in Human Penile Tissue - Triple Histochemical and 
Immunohistochemical Study. Journal of Urology 1995;153:530-534. 
Chapter I 
 94 
 184.  Hedlund P, Larsson B, Alm P, Andersson KE. Distribution and function of nitric 
oxide-containing nerves in canine corpus cavernosum and spongiosum. Acta Physiol 
Scand 1995;155:445-455. 
 185.  Hedlund P, Alm P, Andersson KE. NO synthase in cholinergic nerves and NO-
induced relaxation in the rat isolated corpus cavernosum. Br J Pharmacol 
1999;127:349-360. 
 186.  Arvidsson U, Riedl M, Elde R, Meister B. Vesicular acetylcholine transporter 
(VAChT) protein: a novel and unique marker for cholinergic neurons in the central 
and peripheral nervous systems. J Comp Neurol 1997;378:454-467. 
 187.  Edwards AV, Garrett JR. Nitric oxide-related vasodilator responses to 
parasympathetic stimulation of the submandibular gland in the cat. J Physiol 
1993;464:379-392. 
 188.  Modin A, Weitzberg E, Lundberg JM. Nitric oxide regulates peptide release from 
parasympathetic nerves and vascular reactivity to vasoactive intestinal polypeptide in 
vivo. Eur J Pharmacol 1994;261:185-197. 
 189.  Hempelmann RG, Papadopoulos I, Herzig S. Non-synergistic relaxant effects of 
vasoactive intestinal polypeptide and SIN-1 in human isolated cavernous artery and 
corpus cavernosum. Eur J Pharmacol 1995;276:277-280. 
 190.  Kirkeby HJ, Fahrenkrug J, Holmquist F, Ottesen B. Vasoactive intestinal polypeptide 
(VIP) and peptide histidine methionine (PHM) in human penile corpus cavernosum 
tissue and circumflex veins: localization and in vitro effects. Eur J Clin Invest 
1992;22:24-30. 
 191.  Yiangou Y, Christofides ND, Gu J, Blank MA, Polak JM, Bloom SR. Peptide 
histidine methionine (PHM) and the human male genitalia. Neuropeptides 1985;6:133-
142. 
 192.  Hedlund P, Alm P, Hedlund H, Larsson B, Andersson KE. Localization and effects of 
pituitary adenylate cyclase-activating polypeptide (PACAP) in human penile erectile 
tissue. Acta Physiol Scand 1994;150:103-104. 
 193.  Hedlund P, Alm P, Ekstrom P, Fahrenkrug J, Hannibal J, Hedlund H, Larsson B, 
Andersson KE. Pituitary adenylate cyclase-activating polypeptide, helospectin, and 
vasoactive intestinal polypeptide in human corpus cavernosum. Br J Pharmacol 
1995;116:2258-2266. 
 194.  Hauser-Kronberger C, Hacker GW, Graf AH, Mack D, Sundler F, Dietze O, Frick J. 
Neuropeptides in the human penis: an immunohistochemical study. J Androl 
1994;15:510-520. 
 195.  Guidone G, Muller D, Vogt K, Mukhopadhyay AK. Characterization of VIP and 
PACAP receptors in cultured rat penis corpus cavernosum smooth muscle cells and 
their interaction with guanylate cyclase-B receptors. Regul Pept 2002;108:63-72. 
 196.  Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with 
erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334:873-877. 
                                                                                                                     General introduction 
 95 
 197.  Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide 
experience. J Urol 1996;155:802-815. 
 198.  Jeremy JY, Morgan RJ, Mikhailidis DP, Dandona P. Prostacyclin synthesis by the 
corpora cavernosa of the human penis: evidence for muscarinic control and 
pathological implications. Prostaglandins Leukot Med 1986;23:211-216. 
 199.  Roy AC, Adaikan PG, Sen DK, Ratnam SS. Prostaglandin 15-hydroxydehydrogenase 
activity in human penile corpora cavernosa and its significance in prostaglandin-
mediated penile erection. Br J Urol 1989;64:180-182. 
 200.  Daley JT, Brown ML, Watkins T, Traish AM, Huang YH, Moreland RB, De T, I. 
Prostanoid production in rabbit corpus cavernosum: I. regulation by oxygen tension. J 
Urol 1996;155:1482-1487. 
 201.  Daley JT, Watkins MT, Brown ML, Martinez V, Cuevas P, Saenz dT, I. Prostanoid 
production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. J Urol 
1996;156:1169-1173. 
 202.  Azadzoi KM, Kim N, Brown ML, Goldstein I, Cohen RA, Saenz dT, I. Endothelium-
derived nitric oxide and cyclooxygenase products modulate corpus cavernosum 
smooth muscle tone. J Urol 1992;147:220-225. 
 203.  Yang BC, Lawson DN, Mehta JL. Role of eicosanoids in rat aortic ring response to 
agonists and acetylcholine with special reference to the biphasic effects of 
prostacyclin. Eicosanoids 1992;5:135-139. 
 204.  Hedlund H, Andersson KE. Contraction and relaxation induced by some prostanoids 
in isolated human penile erectile tissue and cavernous artery. J Urol 1985;134:1245-
1250. 
 205.  Andersson PO, Bloom SR, Mellander S. Haemodynamics of pelvic nerve induced 
penile erection in the dog: possible mediation by vasoactive intestinal polypeptide. J 
Physiol 1984;350:209-224. 
 206.  Aboseif SR, Breza J, Bosch RJ, Benard F, Stief CG, Stackl W, Lue TF, Tanagho EA. 
Local and systemic effects of chronic intracavernous injection of papaverine, 
prostaglandin E1, and saline in primates. J Urol 1989;142:403-408. 
 207.  Aboseif S, Riemer RK, Stackl W, Lue T, Tanagho E. Quantification of prostaglandin 
E1 receptors in cavernous tissue of men, monkeys and dogs. Urol Int 1993;50:148-
152. 
 208.  Komuro M, Kamiyama M, Furuya Y, Takihana Y, Araki I, Takeda M. Gene and 
protein expression profiles of prostaglandin E2 receptor subtypes in the human corpus 
cavernosum. Int J Impot Res 2006;18:275-281. 
 209.  Lin JS, Lin YM, Jou YC, Cheng JT. Role of cyclic adenosine monophosphate in 
prostaglandin E1-induced penile erection in rabbits. Eur Urol 1995;28:259-265. 
 210.  Derouet H, Eckert R, Trautwein W, Ziegler M. Muscular cavernous single cell 
analysis in patients with venoocclusive dysfunction. Eur Urol 1994;25:145-150. 
Chapter I 
 96 
 211.  Molderings G, Malinowska B, Schlicker E. Inhibition of noradrenaline release in the 
rat vena cava via prostanoid receptors of the EP3-subtype. Br J Pharmacol 
1992;107:352-355. 
 212.  Minhas S, Eardley I, Joyce AD, Morrison JB. The effect of cyclic GMP on rabbit 
corporal smooth muscle tone and its modulation by cyclo-oxygenase products. 
Prostaglandins Leukot Essent Fatty Acids 2000;62:153-160. 
 213.  Fabi F, Argiolas L, Chiavarelli M, Del BP. Nitric oxide-dependent and -independent 
modulation of sympathetic vasoconstriction in the human saphenous vein. Eur J 
Pharmacol 1996;309:41-50. 
 214.  Vo PA, Reid JJ, Rand MJ. Attenuation of vasoconstriction by endogenous nitric oxide 
in rat caudal artery. Br J Pharmacol 1992;107:1121-1128. 
 215.  Cruz MA, Gonzalez C, Gallardo V, Albornoz J, Munoz ME, Lagos M. Endothelial 
modulation of vascular tone and 5-hydroxytryptamine-induced responses in human 
chorionic arteries and veins. Gen Pharmacol 1995;26:1571-1577. 
 216.  Costa G, Jimenez E, Labadia A, Garcia-Pascual A. Endothelial modulation of resting 
and stimulated vascular tone in the pig capsular testicular artery. Pflugers Arch 
1996;433:65-70. 
 217.  Minhas S, Cartledge JJ, Eardley I, Joyce AD, Morrison JF. The interaction of nitric 
oxide and prostaglandins in the control of corporal smooth muscle tone: evidence for 
production of a cyclooxygenase-derived endothelium-contracting factor. BJU Int 
2001;87:882-888. 
 218.  Angulo J, Cuevas P, Fernandez A, Gabancho S, Videla S, Saenz dT, I. Calcium 
dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation 
of human penile resistance arteries. Br J Pharmacol 2003;139:854-862. 
 219.  Prieto D, Simonsen U, Hernandez M, Garcia-Sacristan A. Contribution of K+ 
channels and ouabain-sensitive mechanisms to the endothelium-dependent relaxations 
of horse penile small arteries. Br J Pharmacol 1998;123:1609-1620. 
 220.  Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived 
hyperpolarizing factor : identification and mechanisms of action in human 
subcutaneous resistance arteries. Circulation 2001;103:1702-1708. 
 221.  Angulo J, Cuevas P, Fernandez A, Gabancho S, Allona A, Martin-Morales A, 
Moncada I, Videla S, Saenz dT, I. Diabetes impairs endothelium-dependent relaxation 
of human penile vascular tissues mediated by NO and EDHF. Biochem Biophys Res 
Commun 2003;312:1202-1208. 
 222.  Angulo J, Cuevas P, Gabancho S, Gonzalez-Corrochano R, Videla S, Saenz dT, I. 
Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile 
dysfunction in diabetic rats. J Sex Med 2005;2:341-346. 
 223.  Jack AM, Keegan A, Cotter MA, Cameron NE. Effects of diabetes and evening 
primrose oil treatment on responses of aorta, corpus cavernosum and mesenteric 
vasculature in rats. Life Sci 2002;71:1863-1877. 
                                                                                                                     General introduction 
 97 
 224.  Jin L, Foss CE, Zhao X, Mills TM, Wang MH, McCluskey LP, Yaddanapud GS, 
Falck JR, Imig JD, Webb RC. Cytochrome P450 epoxygenases provide a novel 
mechanism for penile erection. FASEB J 2006;20:539-541. 
 225.  Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial 
dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and 
disease. J Androl 2003;24:S17-S37. 
 226.  Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and 
therapeutic insights. Clin Sci (Lond) 2006;110:153-165. 
 227.  Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 
1994;372:231-236. 
 228.  Walker LA, Nakamoto RK, Somlyo AV, Somlyo AP. RhoA-induced calcium 
sensitization of smooth muscle: Isolation of a 116 kDa RhoA-binding protein. 
Biophysical Journal 1997;72:TH202. 
 229.  Chitaley K, Wingard CJ, Clinton WR, Branam H, Stopper VS, Lewis RW, Mills TM. 
Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent 
pathway. Nat Med 2001;7:119-122. 
 230.  Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO 
availability in rat penile erection. Journal of Andrology 1997;18:110-115. 
 231.  Chitaley K, Webb RC, Mills TM. The ups and downs of Rho-kinase and penile 
erection: upstream regulators and downstream substrates of rho-kinase and their 
potential role in the erectile response. International Journal of Impotence Research 
2003;15:105-109. 
 232.  Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: a novel player in the regulation 
of penile erection. Int J Impot Res 2001;13:67-72. 
 233.  Wilkes N, White S, Stein P, Bernie J, Rajasekaran M. Phosphodiesterase-5 inhibition 
synergizes rho-kinase antagonism and enhances erectile response in male hypertensive 
rats. International Journal of Impotence Research 2004;16:187-194. 
 234.  Chang S, Hypolite J, Changolkar A, Wein AJ, Chacko S, Disanto ME. Increased 
contractility of diabetic rabbit corpora smooth muscle in response to endothelin is 
mediated via Rho-kinase beta. International Journal of Impotence Research 
2003;15:53-62. 
 235.  Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle 
contraction and cytoskeletal reorganization of non-muscle cells. Trends in 
Pharmacological Sciences 2001;22:32-39. 
 236.  Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile 
function in aging male Brown-Norway rats. Journal of Andrology 2005;26:182-188. 
 237.  Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-
kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus 
cavernosum. British Journal of Pharmacology 2001;133:455-458. 
Chapter I 
 98 
 238.  Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, 
Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth 
muscle mediated by a Rho-associated protein kinase in hypertension. Nature 
1997;389:990-994. 
 239.  Weber DS, Webb RC. Enhanced relaxation to the Rho-kinase inhibitor Y-27632 in 
mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 
2001;63:129-133. 
 240.  Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoA-mediated Ca2+ 
sensitization in erectile function. J Biol Chem 2002;277:30614-30621. 
 241.  Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJG, Mills TM, 
Webb RC. Adeno-associated viral gene transfer of dominant negative RhoA enhances 
erectile function in rats. Biochemical and Biophysical Research Communications 
2002;298:427-432. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                     General introduction 
 99 
I.4. Summarising conclusions  
sGC is the only conclusively proven receptor for NO and so intimately involved in a wide 
range of physiological functions, most notably in the cardiovascular system (platelet 
reactivity, vascular tone) and peripheral and central nervous system (neurotransmission). In 
its molecular makeup, sGC exists as an obligatory αβ-heterodimer, of which 2 two isoforms 
for each subunit have been found (α1/α2 and β1/β2). However, only two isoforms (sGCα1β1 
and sGCα2β1) so far have been shown to be physiologically active in which β1 acts as the 
dimerizing partner for both types of α
 
subunits. While sGCα1β1 is ubiquitously expressed in 
mammalian tissue, sGCα1β2 is less widely distributed. The low basal activity of sGC increases 
several hundred-fold when NO binds to the heme prosthetic group, which is associated with 
the N-terminal region of the β1 subunit through a weak histidine 105-iron bond. The histidine-
residue is essential for the stimulation by NO as substitution by phenylalanine leads to a 
heme-deficient enzyme that retains basal cyclase activity but fails to respond to NO. In 
addition to endogenous NO, pharmacological NO-donors (e.g. nitroglycerin, isosorbide 
dinitrate and SNP) and agents such as BAY 41-2272 and YC-1 stimulate sGC, the latter two 
also in an NO-independent way. Upon activation of sGC, GTP is converted to cGMP. Acting 
as a second messenger, cGMP regulates the activity of several enzymes including PKG, CNG 
ion channels and cGMP-regulated phosphodiesterases (e.g. PDE-5) which culminates in a 
reduction of intracellular Ca2+ concentration and a decrease in the sensitivity of the contractile 
system to Ca2+. Both mechanisms ultimately lead to smooth muscle relaxation, which is the 
key event in penile erection and a very important determinant of blood flow and blood 
pressure.  
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II.1. General aim 
The physiological importance of NO/cGMP signaling is now widely appreciated. As the 
predominant intracellular receptor for NO and as cGMP-producing enzyme, sGC plays a 
pivotal role in regulating smooth muscle tone, thereby controlling, among other things, blood 
pressure 1 and penile erection 2. For a long time, the scientific attention for sGC remained 
significantly lower than the focus on NO itself. However, the finding that different sGC 
isoforms (the main sGCα1β1 and minor sGCα2β1) and splice variants exist and that other 
substances besides NO 3 can activate sGC, has led to a renewed interest in the sGC enzyme. 
Nonetheless, the involvement and the specific role of the different sGC isoforms remain 
elusive. This is mainly due to the unavailability of sGC isoform-specific inhibitors. Therefore, 
targeted disruption of the genes encoding the various sGC subunits is a valuable approach to 
study the function of each isoform. In the present study we made use of the advantages of 
sGC subunit knockout/knockin mice to explore the functional importance of the sGC 
subunits in smooth muscle relaxation. Knowledge hereof could allow the development of 
more selective sGC agonists with potentially less-side effects.  
 
II.2. Specific aims 
II.2.1. Relaxation of vascular smooth muscle cells in sGCα1 knockout mice 
(sGCα1-/- mice) 
Known the significance of endothelial NO-signaling, many cardiovascular disorders are 
related with an impairment of the NO/cGMP signaling cascade. Current therapies that involve 
the use of organic nitrates and other NO donors have severe limitations, including 
unpredictable pharmacokinetics of NO, lack of response and the development of tolerance 
following prolonged administration 4 and peroxinitrite formation, which can lead to protein S-
nitrosylation 5, as well as tyrosine nitration 6. Understanding of the functional importance of 
the different sGC isoforms, is of interest in developing improved NO-independent therapeutic 
strategies for the treatment of NO/cGMP signaling pathway-related disease. Therefore, by the 
use of aortic and femoral artery segments isolated from mice deficient for the sGCα1 gene 
(sGCα1-/- mice), we explored the physiological contribution of the sGCα1β1 isoform in 
sGC-regulated vascular smooth muscle relaxation (chapter IV).  
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II.2.2. Relaxation of corpus cavernosum smooth muscle cells in sGCα1-/- mice 
Although there are many neurohumoral factors involved in penile erection, NO is generally 
accepted as the most important to initiate and maintain erection. This is also illustrated by the 
extensive use of therapeutic agents targeting the NO/cGMP pathway for the treatment of 
erectile dysfunction. Today’s most successful therapy, sildenafil citrate (better known as 
Viagra®), is based on the decreased breakdown of cGMP by PDE-5, resulting in increased 
levels of cGMP 7. Because PDE-5 is also present in the systemic vasculature, sildenafil can 
cause a synergistic and potentially life threatening hypotensive response when combined with 
organic nitrates. The co-administration of a nitrate within the first 24 h after a dose of Viagra® 
is therefore absolutely contraindicated 8. Moreover, the efficacy of the treatment with PDE-5 
inhibitors is significantly lower in specific populations such as patients with diabetes 9, 10. 
Therefore, there is a call for alternative therapeutic targets. Especially since ED is worldwide 
estimated to affect more than 150 million men, and that number is expected to exceed 300 
million men by the year 2025 11. In order to determine the possible value of the sGCα1β1 
isoform as pharmacological target, we investigated the sGC-regulated responsiveness of 
corpora cavernosa iolated from sGCα1-/- mice (chapter V).    
 
II.2.3. Relaxation of coporal and vascular smooth muscle cells in sGCβ1 knockin 
mice (sGCβ1ki/ki mice) 
In the vessel and corpus cavernosum preparations isolated from the sGCα1 knockout mice, we 
observed a significantly reduced response to exogenously applied NO and NO-independent 
sGC activators. However, those responses were not completely abolished; there still remained 
a substantial relaxant effect, suggesting that besides the predominant sGCα1β1 isoform, also 
the less abundantly expressed sGCα2β1 isoform and/or an (an) sGC-independent mechanism(s) 
are involved. In order to characterise the mechanism responsible for the remaining response in 
the sGCα1 knockout preparations, the sGC-regulated relaxant properties of vessel and 
corporal tissues isolated from sGCβ1ki/ki mice were investigated (chapter VI). In those 
sGCβ1 knockin mice, the heme-dependent activation of sGC is abolished by the substitution 
of the histidine 105 residue (axial ligand) of the β1 subunit by phenylalanine 12.  
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III.1. Introduction 
Our knowledge on basic pharmacodynamics is mainly based on studies of drugs acting on 
preparations of isolated tissues or blood vessels mounted in organ chambers. Such in vitro 
experiments allow to analyse the influence of local mechanisms, without the interference of 
other competing or compensatory mechanisms being active in in vivo conditions, which 
complicate the correct interpretation of in vivo data.  
 
To study the vasoreactivity of ring segments of isolated large and small arteries, we used a 
wire myograph. In this method, the vessel segments are mounted in an organ bath onto two 
thin wires that are fixed on two holders. One of the holders is connected to a force transducer. 
The length of the ring segment is maintained constant while the force is recorded during 
contraction or relaxation. The mechanical properties of isolated copora cavernosa were 
investigated using a myograph in which the tissues are clasped on two holders, based on the 
same principles of the wire myograph for vessel segments. The strength of this technique is 
that the tension measurements are very sensitive. Those functional studies were supplemented 
with measurements of cGMP concentrations in vascular tissue.  
 
III.2. Mice models 
The sGCα1-/- mice, sGCβ1ki/ki mice and the corresponding control mice, used throughout the 
experiments, were generated, genotyped and bred in the Department of Molecular Biomedical 
Research, Flanders Interuniversity Institute for Biotechnology, Ghent, Belgium. The 
genotyping of the mice was done prior to the experiments by PCR and Southern blot analysis. 
The Mice were treated in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). 
 
III.2.1. sGCα1-/- mice 
In the sGCα1 knockout mice, exon 6 of the sGCα1 gene, which encodes an essential part of the 
conserved catalytic domain, is deleted. The targeting vector was constructed using 4.3 kb 5’ 
and 2.5 kb 3’ sGCα1 homology fragments, isolated from a 129/SvJ lambda FIXII mouse 
genomic library (Stratagene), a neomycine (neo)-resistance cassette (for positive selection) 
and a thymidine kinase cassette (for negative selection). The construct was engineered in that 
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way that exon 6 of the sGCα1 gene and the neomycine-resistance cassette are flanked by loxP-
sites. Embryonic stem (ES) cells, derived from a 129/SvJ strain of mice were electroporated 
with the linearized targeting vector and subjected to positive and negative selection with 
G418 and gancyclovir. To excise the floxed neo cassette (conditional knockout) and/or the 
floxed exon 6 (full knockout), targeted ES cell clones were transiently transfected with a Cre-
expressing plasmid. Chimeras were generated by aggregating ES cell clones, carrying the 
desired deletion with Swiss morula stage embryos, and identified by agouti contribution of the 
ES cells to coat color. Male chimeric mice were mated to Swiss females to check whether the 
ES cells, containing the mutant sGCα1 allele are represented in the gametes. The heterozygous 
offspring, identified by dominant agouti coat coloration and Southern blot analysis, were then 
mated to one another to produce homozygous recombinants.  
 
III.2.2. sGCβ1ki/ki mice 
In the sGCβ1 knockin mice, residue 105, the codon of which is located in exon 5, is converted 
from histidine (His) to phenylalanine (Phe). The targeting construct contains 4.1 kb 5’ and 3 
kb 3’ flanking regions of homology cloned from a 129/SvJ lambda FIXII mouse genomic 
library (Stratagene), a positive and negative selection marker (a floxed neo cassette and a 
thymidine kinase cassette respectively). In addition to the three mutations which replace the 
His with a Phe residue, 5 other silent mutations were introduced to develop a means to 
genotype for the inclusion of Phe during homologous recombination with amplification of a 
PCR fragment making use of primers spanning this region, followed by a restriction digest of 
the fragment with the restriction enzyme SmaI, specifically cleaving only the mutant fragment. 
Also Southern blot (mutation specific restriction) was used to confirm homologous 
recombination. The sGCβ1 knockin mice were generated following the same procedure as the 
sGCα1 knockout mice. But, the recipient blastocyst was derived from a C57BL/6J strain. 
Genotyping of the mutant mice happened by a PCR spanning the region where one LoxP site 
remains after excision of the neo cassette, resulting in 73 extra base pairs in the mutant 
fragment. 
 
III.3. Arteries 
III.3.1. Dissection 
Experiments were performed on arteries isolated from adult male and female mice (age: 10-15 
weeks). After cervical dislocation, the mouse is placed on its side and the skin is removed in 
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the area from the diaphragm to the foreleg. Next, the diaphragm is cut free from the ribs and 
the thorax is opened. The flap of the thoracic wall is turned over, exposing the heart and the 
lungs. Next the lungs are moved aside so that the aorta can be dissected out from the aortic 
arch to the diaphragm (figure III.1). The isolated aorta is then transferred to fresh Krebs-
Ringer-Bicarbonate (KRB) solution and cleansed from surrounding tissue without 
traumatising the vessel wall. Finally, an arterial segment of about 2.5 mm in length is cut and 
ready for mounting in the wire myograph.  
Figure III.1: Thorax and upper part 
of the abdomen of the mouse. The 
arrow indicates the thoracic aorta 
used in the study 
1: liver, 2: stomach, 3: lung, 4: heart, 
5: vena cava, 6: diaphragm, 7: spleen, 
8: ribs, D: dorsal, V: ventral, Cr: 
cranial, C: caudal 
 
 
                 
                                    
 
For the isolation of the femoral artery, the mouse is placed on its back with the legs extended. 
Next, the skin of the groin area of the rear leg is removed and the femoral artery is carefully 
dissected free from the femoral vein (figure III.2). The dissected vessel is then transferred to 
fresh KRB solution and cut into segments of about 2.5 mm in length. After the ring segment 
is slided over the first wire (see mounting of a ring segment), the surrounding tissue is being 
removed 
Figure III.2: Groin area of the 
mouse. The arrow indicates the 
femoral artery used in the study. 1: 
femoral vein (v. femoralis), 2: 
femoral nerve, Cr: cranial, C: caudal 
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III.3.2. Tension measurements 
III.3.2.1. The apparatus 
We have used a manual wire myograph (figure III.3) (based on the automated dual channel 
vessel myograph, model 500A, JP trading, Aarhus, Denmark) constructed by the technical 
staff of our laboratory (Dirk De Gruytere and Cyriel Mabilde). It consists of a 10 ml organ 
bath with two holders in it. One holder is connected to a micrometer which is used to change 
the distance between the two holders and which allows precise measurement of the distance 
between the wires during the normalisation procedure. The other one is connected to a force-
displacement transducer that measures the isometric tension changes. Each ring segment is 
mounted under a dissecting microscope onto two thin stainless steel wires (40 µm diameter) 
that are fixed at those holders.  
 
Figure III.3: A photograph of the 
organ bath of the wire myograph. 
Vessel segments are mounted on two 
thin wires, fixed on the two holders 
in the organ bath. One holder is 
connected to a micrometer which is 
used to change the distance between 
the wires. The other holder is 
connected to a force transducer 
which allows measurement of 
isometric tension changes in the ring 
segment.  
 
 
 
 
 
III.3.2.2. Mounting of a ring segment  
First, a thin wire (40 µm) is cut to length and clamped between the two holders in the organ 
bath (figure III.4B). Then, the far end of the wire is fixed on the left holder with a screw, 
whereas the near end is kept free, pointing towards the operator (figure III.4C).  
 
force 
transducer micrometer 
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Using a pair of tweezers, the ring segment is slided over the free end of the wire (figure 
III.4D). Herewith, care is taken not to damage the endothelium. Next, the holders are set apart, 
and the vessel segment is slided further over the wire until the segment is situated just 
between the holders (figure III.4E). Subsequently, the free end of the wire is fixed with a 
screw to the other side of the left holder (figure III.4F).  
 
Now, the second wire is guided through the lumen of the artery (figure III.4G) and the holders 
are brought together again. Furthermore the ends of the second wire are fixed on the right 
holder (figure III.4H). The wires must be levelled so that both wires are in a single horizontal 
plane (figure III.4I). Finally, the length of the segment (l) is measured with a micrometer 
eyepiece (Zeiss, Germany).  
 
After mounting, the preparations are allowed to equilibrate in a KRB solution at 37°C, pH 7.4 
and oxygenated with 95% O2-5% CO2 for 30 minutes.  
 
 
 
Figure III.4: Schematic representation of the different steps involved in the mounting of an arterial 
segment on two stainless steel wires, fixed on the holders. 
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III.3.2.3. Preparation of the femoral artery segments before the experiment 
Active force development of a muscle cell depends on its length 1, 2. In small arteries, the 
length of the circumferentially oriented smooth muscle cells can be influenced by stretching 
the vessel. It is commonly accepted that the active force development in vascular tissue peaks 
at a certain internal circumference or diameter, which corresponds to a specific length of the 
smooth muscle cell aiming optimal experimental conditions. The vessels should therefore be 
set to their optimal internal diameter at the beginning of each experiment. 
It has been found that the active force production is maximal when the internal circumference 
is 0.9 times the internal diameter a vessel would have in situ when relaxed and under a 
transmural pressure of 100 mm Hg (IC100) 1, 3-5. To calculate the IC100 for a vessel mounted in 
the vessel myograph,
 
we use the normalisation procedure. This allows us to determine the 
position of the holders corresponding to the vessels ideal internal circumference. Also, the 
size of the vessel, normally defined as its size when fully relaxed and under a transmural 
pressure of 100 mm Hg, can be calculated through the normalisation procedure.  
 
*The normalisation procedure 
First of all, the vessel is brought into a resting position corresponding to a force of 0 mN. 
Hence, the holders in the organ bath are brought together until the mounting wires touch and 
the force transducer registers a negative force. Then, the holders are partly pulled back until 
the registered force returns to baseline. At this point, the force registered by the force 
transducer is 0 mN (Y0) and the distance between the two wires is 0 µM (corresponding 
micrometer setting = X0).  
 
During the normalisation procedure, the micrometer is gradually moved to enlarge the 
distance between the wires and subsequently stretch the vessel step by step (figure III.5). One 
minute after each step (i), the corresponding micrometer setting (xi) and force (yi) are 
registered. Finally, the internal circumference (ICi), the wall tension (Ti) and the 
corresponding transmural pressure (Pi), can be calculated from those recorded values.  
 
• Internal circumference (ICi) 
 
The ICi is calculated from the distance between the wires (xi – x0) and the diameter of the 
mounting wires (40 µm) 
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ICi = 2 x ((2π x 20 µm) / 2) + 4 x 20 µm + 2 x (xi – x0) = 205.66 µm + 2 x (xi – x0)  
 
 
 
 
Figure III.5: a schematic representation of the blood vessel after distention i. 
 
• Wall tension (Ti)  
 
The measured force (yi) divided by the wall length equals Ti. The wall length 
corresponds to two times the length of the vessel, since there is both an upper and a lower 
wall. The length of the vessel (l) is measured using a calibrated eyepiece after mounting.  
 
Ti = yi / (2 x l) 
 
• Transmural pressure (Pi) 
 
The calculation of Pi is based on the law of Laplace, which states that in a cylinder, wall 
tension (Ti) is proportional to the pressure times the radius of the cylinder. Since the 
radius (r) can be computed from the ICi (ICi = 2π r), the Pi can be determined with the 
following formula:  
 
Pi = Ti / (ICi / 2π) 
 
It should be noted that the calculated pressure is only an approximation for the intraluminal 
pressure that would be necessary to expand the vessel to the measured ICi .  
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For each pair of xi and corresponding yi, the matching pressure is calculated. The stepwise 
stretching of the vessel segments is stopped when the pressure exceeds 100 mm Hg (= 13.3 
kPa). Then, an exponential curve is constructed, showing the relation between the internal 
circumference and the equivalent pressure. On this graph, the point corresponding with a 
pressure of 100 mmHg denotes IC100. With this value, the ideal position of the holders to 
obtain an internal circumference of 90 % of the IC100, can be calculated by inserting this value 
in the formula for ICi. Finally, the holders are set in this position and the experiment can be 
started. Additionally, the diameter the ring segment would have when exposed to a transmural 
pressure of 100 mm Hg can be deduced from the IC100 value (IC = 2π r).  
 
*A detailed example of a normalisation procedure
.  
This example demonstrates the successive steps in the normalisation procedure for a mouse 
femoral artery with a length of 2.40 mm. 
 
Step (i) xi (µm) yi (mN) 
0 4245 0.00 
1 4654 2.10 
2 4773 6.48 
3 4845 9.98 
4 4919 16.10 
 
1 minute after the first distension: 
 
IC1 = 205.66 µm + (2 x (x1- x0)) µm = 205.66 µm + (2 x (4654 – 4245)) µm = 1023.66 µm 
 
T1 = y1/ (2 x l) = 2.1 mN / (2 x 2.40 mm) = 0.438 mN/mm 
 
P1 = T1 / (IC1 / 2π) = 0.438 mN/mm / (1.02366 mm / 2π) = 2.69 kPa 
 
After the same calculations were made for the following distensions, the internal 
circumference is expressed in function of the pressure. On this curve (figure III.6), the point 
corresponding with a pressure of 13.3 kPa corresponds with an IC100 of 1521.66 µm. With 
this value, the ideal position of the holders and the size of the artery can be calculated: 
The ideal internal circumference IC90 = 0.9 x IC100 = 1369.50 µm 
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The ideal micrometer setting (x1’) yielding the IC90 can be computed with the following 
formula: IC90 = 205.66 µm + (2 x (x1’- x0)) µm 
 
 x1’ = ((IC90 – 205.66 µm) / 2) + x0 µm = ((1369.50 µm − 205.66 µm) / 2) + 4245 µm =     
              4826.92 µm 
 
The diameter of the ring segment, when it would be exposed to a transmural pressure of 
13.3 kPa (l100) equals IC100 / π = 484.36 µm 
 
Before the start of the experiment, the micrometer is set at 4827 µm. 
 
Figure III.6: Relation between 
the internal circumference of the 
ring segment (X-as) and the 
intraluminal pressure that would 
be necessary to extend the vessel 
to this internal circumference (Y-
axis). From this exponential 
curve, the internal circumference 
that the vessel would have under 
a transmural pressure of 100 mm 
Hg (13.3 kPa) can be deduced.  
 
III.3.2.4. Preparation of the aortic segments before the experiment 
When studying ring segments of larger arteries such as the mouse aorta, the ring segments are 
gradually stretched until a fixed stable preload is obtained. In mouse aorta a preload of 0.5 g 
is used, as it has been shown that this resulted in a maximum response.  
 
III.3.3. cGMP measurements 
After cervical dislocation, the thoracic aorta was rapidly dissected and transferred to cooled 
KRB solution. Subsequently two aortic ring segments of equal length were prepared, which 
were incubated for 30 minutes in 10 ml KRB solution at 37°C, bubbled with 95% O2-5% CO2 
(pH 7.4). Next, the aortic rings were treated with 30 µmol/L PGF2α for 10 minutes. Then, the 
segments were treated with SNP (10 µmol/L) or vehicle for 1 minute, which was terminated 
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by a quick freeze with liquid nitrogen. In the other set of experiments, the segments were 
treated for 20 minutes with ODQ (1 µmol/l) or vehicle together with PGF2α. Subsequently, the 
relaxation reaction was initiated by SNP (10 µmol/L) and 1 minute later terminated by snap 
freezing in liquid nitrogen. Frozen tissues were stored at -80°C until further processing. 
Different homogenizing strategies were performed in order to optimize the measurement of 
cGMP in the mouse aorta. A few samples were homogenized in ice cold trichloroacetic acid 
(TCA) (6% w v-1) with a glass-Teflon homogenizer at 4°C. In another set of samples, the 
Teflon pestle was replaced by a glass one. Besides the potter homogenizers, also a polytron 
homogenizer at 3000 r.p.m. was used to grind the ring segments. All those methods were not 
able to fully scatter the aorta, which is a very though tissue due to the large amount of elastic 
fibres. A more homogenous solution was obtained by pulverizing the frozen segments by a 
Mikrodismembrator U (B-braun Biotech International, Germany) and subsequently dissolving 
the tissue debris in ice-cold trichloroacetic acid. However, this process is very labour-
consuming and not very practical. Considering the degree of homogenization and the practical 
feasibility, the best results were obtained by crushing the frozen segments by hand prior to the 
addition of TCA. Immediately after the tissue was transferred to a cooled 15 ml Falcon tube, a 
few tight thrusts were applied on the tissue. For that purpose, we used a pestle made of Teflon 
which was designed to perfectly fit the Falcon tube. Subsequently, the tissue homogenates 
were centrifuged at 1500 x g for 10 minutes at 4°C. The resulting pellets were used for a 
protein assay according to the Bradford method 6 with bovine serum albumin (BSA) as 
standard. The supernatant fractions were extracted 4 times with 5 volumes of water-saturated 
diethyl ether and dried in a Speed-Vac centrifuge. Further processing of the samples for 
acetylation and subsequent determination of cGMP was carried out according to the 
manufacturer’s instructions using a commercially available non-radioactive enzyme 
immunoassay kit (Cayman Chemical, Ann Arbor, MI). This assay, performed in duplicate, is 
based on the competition between unlabelled cGMP and a fixed quantity of peroxidase-
labeled cGMP for a limited number of binding sites on a cGMP-specific antibody. With fixed 
amounts of antibody and peroxidase-labeled cGMP, the amount of peroxidase-labeled ligand 
bound by the antibody was inversely proportional to the concentration of added unlabeled 
ligand. The absorbance was measured with a 96-well plate reader at 405 nm and the arterial 
cGMP content was expressed as femptomoles per microgram protein.  
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III.4. Corpora cavernosa 
III.4.1. Dissection 
Experiments were performed on corpora cavernosa isolated from sexually mature male mice 
(age: 10-15 weeks). After cervical dislocation, the mouse is placed on its back with the legs 
extended. Then the skin in the uro-genital area and the underlying adipose tissue is cut away 
(figure III.7A). Next the connective and adventitial tissue along the shaft of the penis is 
removed, followed by the dorsal arteries, dorsal vein and the corpus spongiosum with the 
urethra (figure III.7B). After, the glans penis is cut off, the corpora cavernosa are separated by 
cutting the fibrous septum between them (figure III.7C). Finally, the corpora cavernosa are 
excised at the base (figure III.7D) and transferred to fresh KRB solution.  
Figure III.7: Different steps involved in the isolation of the mice corpora cavernosa.  
1: fat, 2: penis, 3: seminal vesicle, 4: testis, 5: cauda epididymis, 6: superficial vein, 7: glans penis, 8: 
corpora cavernosa, Cr: cranial, C: caudal 
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III.4.2. The apparatus
 
We have used a manual myograph (figure III.8) constructed by the technical staff of our 
laboratory (Mr. Dirk De Gruytere and Mr. Cyriel Mabilde). It contains two holders which are 
placed in an organ bath (10 ml capacity). One holder is connected to a micrometer that is used 
to change the distance between the two holders. The other one is connected to the lever of a 
force-displacement transducer that measures the isometric tension changes. Between those 
holders, each corpus cavernosum is fixed horizontally (figure III.8A).  
 
Figure III.8: A photograph of the organ bath of the adapted myograph: A. top view; B. lateral view. 
Corpora cavernosa are horizontally fixed on the two holders in the organ bath of the myograph. One 
holder is connected to a micrometer which is used to change the distance between the holders. The 
other holder is connected to a force transducer which allows measurement of isometric tension 
changes in the corporal tissues.  
 
III.4.3. Mounting of the penile tissue 
First, the screw of the left holder is loosened so that one end of the tissue can be placed 
between the clasping parts of the holder. Then by tightening the screw, the tip of the corpus 
cavernosum is fixed on the left holder. Next the holders are brought together so that in a 
similar way, the other end of the penile tissue can be fixed on the right holder. 
 
After mounting, the preparations are allowed to equilibrate in a KRB solution at 37°C, pH 7.4 
and oxygenated with 95% O2-5% CO2 for 30 minutes.  
 
A B 
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III.4.4. Preparation of the tissue before the experiment.   
During an equilibration of 60 min, tension is adjusted until a fixed stable tension was obtained. 
To investigate the optimal preload for this tissue a preliminary study was performed, in which 
the preload was augmented in several steps (beginning with 0.05 g and increasing by 0.05 g). 
After each increase in preload, the contractile response to 5 µmol/l norepinephrine was 
registered. Subsequently the CC was washed and allowed to relax to the imposed basal tone. 
This stepwise procedure was stopped when maximum contractile effect was obtained with 
norepinephrine. From those measurements, a curve that represents the relationship between 
the preload and the subsequent norepinephrine-induced contraction was constructed (figure 
III.9).  The point on the curve corresponding with the maximal response to norepinephrine 
(95.10 mN) then denotes the optimal preload (0.45 g), applied in all further experiments on 
penile tissue.  
 
 
 
Figure III.9: Relation between the preload and subsequent contraction elicited by 5 µmolL 
norepinephrine (n=4). From this curve, the optimal preload which results in a maximal contraction was 
deduced (0.45 g). 
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IV.1. Abstract and keywords 
OBJECTIVE: Soluble guanylyl cyclase (sGC), the predominant receptor for nitric oxide 
(NO), exists in 2 active isoforms (α2β1 and α1β1). In vascular tissue sGCα1β1 is believed to be 
the most important. The aim of our study was to investigate the functional importance of the 
sGCα1-subunit in vasorelaxation.  
METHODS: Aortic and femoral artery segments from male and/or female sGCα1-/- mice and 
wild type mice were mounted in a small vessel myograph for isometric tension recording. 
This was supplemented with biochemical measurements of the cGMP concentration and sGC 
enzyme activity.  
RESULTS: The functional importance of sGCα1β1 was demonstrated by the significantly 
decreased relaxing effects of acetylcholine (ACh), sodium nitroprusside (SNP), S-nitroso-N-
acetylpenicillamine (SNAP), NO-gas, YC-1, BAY 41-2272 and T-1032 in the sGCα1-/- mice 
of both genders. Moreover, the basal and SNP-stimulated cGMP levels and basal sGC activity 
were significantly lower in the sGCα1-/- mice. However, the relaxing effects of NO, BAY 41-
2272 and YC-1 seen in blood vessels from sGCα1-/- mice indicate a role for an sGCα1β1-
independent mechanism. The increase in sGC activity after addition of BAY 41-2272 and the 
inhibition of the ACh-, SNP-, SNAP and NO-gas-induced response by the sGC-inhibitor 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) in the sGCα1-/- mice, are observations 
suggesting that also the sGCα2β1 isoform is functionally active. However, the non-significant 
increase in cGMP in response to SNP and the non-upregulated sGCα2 expression level in the 
sGCα1-/- mice, rather suggest the involvement of (an) sGC-independent mechanism(s). 
CONCLUSIONS: We conclude that sGCα1β1 is involved in the vasorelaxations induced by 
NO-dependent and NO-independent sGC activators in both genders. However the remaining 
relaxation seen in the sGCα1-/- mice, suggests that besides sGCα1β1 also the minor isoform 
sGCα2β1 and/or (an) sGC-independent mechanism(s) play(s) a substantial role. 
 
Key words: arteries, nitric oxide, endothelial function, second messengers, 
vasoconstriction/dilatation 
 
Preliminary reports of these findings have been presented at the International Conference on 
cGMP, Potsdam1. 
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IV.2. Introduction 
Soluble guanylyl cyclase (sGC) is considered to be the predominant intracellular receptor for 
nitric oxide (NO) and hence a very important enzyme for the physiological regulation of 
vascular tone and blood pressure. The heterodimeric hemoprotein is composed of a larger α 
and a smaller β subunit, both necessary for catalytic activity 2. Two isoforms for each subunit 
(α1/α2 and β1/β2) have been identified in various species 3. Theoretically, the association of α 
and β subunits could give rise to at least four different isoforms, but only the α2β1 and α1β1 
isoforms are reported to be active 4. In the brain, the levels of both isoforms are comparable 
but in all other tissues, including vascular tissue, the α1β1 isoform is predominant 5.  
The most important endogenous activator of sGC is NO. In addition to endogenous NO, 
pharmacological NO-donors (e.g. nitroglycerin, isosorbide dinitrate and SNP) and agents such 
as BAY 41-2272 and YC-1 stimulate sGC, the latter two also in an NO-independent way 6. 
The resulting rise in the intracellular cGMP concentration induces vascular smooth muscle 
relaxation by lowering the intracellular Ca2+ concentration and by desensitization of the 
contractile apparatus to Ca2+ 7.  
Dysfunction of the endothelial NO/cGMP signaling pathway contributes to the 
pathophysiology of a variety of cardiovascular disorders including hypertension, thrombosis, 
atherosclerosis, myocardial infarction and angina pectoris 8. This makes the different isoforms 
of sGC, as effector molecule for NO, attractive therapeutic targets for the treatment of the 
above mentioned conditions and drugs aiming to target sGC isoforms are currently in 
development 9. However, due to the lack of sGC isoform-specific inhibitors, little is known 
about the specific role and relative importance of the sGC isoforms on vascular tissue 
response to endogenous and exogenous sGC stimulators. The recently developed knockout 
mice for the sGCα1 gene 10 allow to unravel this. In the present study the functional 
importance of the sGCα1-subunit in the vascular system was analysed using aortic and 
femoral artery segments isolated from soluble guanylyl cyclase alpha 1 knockout (sGCα1-/-) 
mice. Experiments were performed on preparations from both genders as it was found that 
male but not female animals develop hypertension 10. 
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IV.3. Materials and methods 
IV.3.1. Animals and tissue collection 
All experiments were performed on male and/or female homozygous soluble guanylyl cyclase 
alpha 1 knockout (sGCα1-/-) mice, bred in the Department of Molecular Biomedical Research, 
Flanders Interuniversity Institute for Biotechnology, Ghent, Belgium (age: 10-15 weeks; 
genetic background: mixed Swiss-129), using sGCα1+/+ mice as control 10. The animals were 
treated in accordance with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The 
sGCα1-/- mice lack exon 6 of the sGCα1 gene, which codes for an essential part in the catalytic 
domain. After cervical dislocation, the thoracic aorta and femoral artery were carefully 
removed from the animals and transferred to cooled Krebs-Ringer bicarbonate (KRB) 
solution.  
 
IV.3.2. Tension measurements 
Artery preparations and general experimental protocol  Ring segments of the collected 
arteries (internal diameter: aorta: 978.0±39.5 µm (n=9); femoral artery: 424.7±11.8 µm 
(n=15)) were mounted in a small-vessel myograph with a tissue chamber filled with 10 ml of 
KRB solution and were cleansed from adhering tissue. Two stainless steel wires (40 µm 
diameter) were guided through the lumen of the segments. One wire was fixed to a force-
displacement transducer and the other was connected to a micrometer. After mounting, the 
preparations were allowed to equilibrate for 30 min in the KRB solution bubbled with 95% 
O2-5% CO2 (pH 7.4) at 37 °C. The aortic rings were gradually stretched until a stable preload 
of 0.5 g was obtained, whereas the femoral arteries were set to their normalized internal 
diameter 11. In short, the arteries were stretched in progressive steps. From the passive wall-
tension-internal circumfences relationship obtained by these measurements, the artery was 
stretched to a diameter corresponding to 90% of the diameter the vessel would have under a 
transmural pressure of 100 mm Hg.  
After applying the optimal resting tension, the preparations were contracted 3 times with a 
KRB solution containing 120 mmol/L K+ and 5 µmol/L norepinephrine (NOR), washed, and 
allowed to relax to basal tension before starting the protocol. Precontraction was elicited with 
30 µmol/L prostaglandin (PGF2α) or 5 µmol/L NOR. When a stable contraction plateau was 
obtained, relaxation responses were examined in a cumulative manner by increasing the 
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concentration in log increments, once the response to the previous concentration had 
stabilized. Segments of sGCα1-/- and sGCα1+/+ mice were always tested in parallel. 
 
Specific experimental protocols  First, the relaxation responses to acetylcholine (ACh) (1 
nmol/L–10 µmol/L), sodium nitroprusside (SNP) (1 nmol/L–10 µmol/L), S-nitroso-N-
acetylpenicillamine (SNAP) (1 nmol/L–10 µmol/L) and NO-gas (1 µmol/L–100 µmol/L) 
were measured in varying order. These relaxing substances were also tested in the presence of 
the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (1 
µmol/L for ACh, SNP and SNAP or 10 µmol/L for NO-gas; 20 minutes preincubation) or the 
NO-synthase (NOS) inhibitor Nω-nitro-L-arginine (L-NA) (0.1 mmol/L; 10 minutes 
preincubation). Besides vasodilators with NO as active metabolite, also NO-independent sGC 
stimulators such as BAY 41-2272 (1 nmol/L–10 µmol/L) and YC-1 (10 nmol/L–10 µmol/L) 
were tested. Also the influence of 1 µmol/L ODQ on the BAY 41-2272-induced response was 
measured. The influence of accumulation of cGMP formed under basal conditions was 
investigated by addition of the PDE-5 inhibitor, T-1032 (1 nmol/L–10 µmol/L). sGC-
independent relaxation was assessed using the KATP-channel opener levcromakalim (Lev) (1 
nmol/L–10 µmol/L) and the cGMP-analogue 8-(4-chlorophenylthio)-guanosine 3’,5’-cyclic 
monophosphate (8-pCPT-cGMP) (100 nmol/L–100 µmol/L). 
 
IV.3.3. Measurement of cGMP levels in thoracic aortic rings 
After 30 minutes of equilibration in a KRB solution at 37°C, bubbled with 95% O2-5% CO2 
(pH 7.4), the thoracic aorta segments were precontracted with 30 µmol/L PGF2α. In the first 
series of experiments, a single concentration of either SNP (10 µmol/L) or vehicle was added 
to the preparations 10 minutes after the addition of PGF2α 1 minute later, the reaction was 
stopped by snap freezing in liquid nitrogen. In the second series of experiments, 1 µmol/L 
ODQ or vehicle was added together with PGF2α. After 20 minutes, the ring segments were 
exposed to a single concentration of SNP (10 µmol/L) for 1 minute, before being rapidly 
frozen in liquid nitrogen. 
The collected segments were kept at -80°C until further processing. The frozen aortic rings 
were pulverized, homogenized in 6 % w v -1 trichloroacetic acid, followed by centrifugation at 
1,500 x g for 10 minutes at 4°C. The resulting pellets were used for total protein 
determination according to the method of Bradford 12. The supernatants were extracted 4 
times with 5 volumes of water-saturated diethyl ether before being dried in a Speed-Vac 
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centrifuge. The redissolved samples were acetylated and cyclic GMP concentration was 
determined using a non-radioactive enzyme immunoassay kit (Cayman Chemical, Ann Arbor, 
MI). Assays were performed in duplicate and the amount of cGMP in each blood vessel ring 
was expressed as fmol µg-1 protein.  
 
IV.3.4. Measurement of sGC activity in femoral artery preparations 
sGC enzyme activity was measured as described by Bloch et al. 13. After collecting, the 
femoral artery tissues were homogenized in buffer containing 50 mmol/L 
tris(hydroxymethyl)aminomethane (Tris).HCl (pH 7.6), 1 mmol/L EDTA, 1 mmol/L 
dithiothreitol, and 2 mmol/L phenylmethylsulfonyl fluoride. After centrifugation at 20,000 x g 
for 1h at 4°C, the supernatants were incubated for 10 min at 37°C in a reaction mixture 
containing 50 mmol/L Tris.HCl (pH 7.5), 4 mmol/L MgCl2, 0.5 mmol/L 1-methyl-3-
isobutylxanthine, 7.5 mmol/L creatine phosphate, 0.2 mg/ml creatine phosphokinase, 1 
mmol/L L-NAME and 1 mmol/L GTP with or without 100 µmol/L BAY 41-2272. The 
reaction was terminated by the addition of 0.9 ml of 0.05 mol/L HCl and the cGMP content in 
the reaction mixture was measured using a commercial radioimmunoassay (Biomedical 
Technologies, Stoughton, MA). sGC enzyme activity is expressed as pmol of cGMP produced 
per minute per milligram of protein in femoral artery extract supernatant. 
 
IV.3.5. Drugs 
The experiments were performed in a KRB solution of the following composition (mmol/L): 
NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), acetylcholine 
chloride, T-1032, YC-1, 8-(4-chlorophenylthio)-guanosine 3’,5’-cyclic monophosphate (8-
pCPT-cGMP), trichloroacetic acid, norepinephrine bitartrate, dithiothreitol, 
phenylmethylsulfonyl fluoride, tris(hydroxymethyl)aminomethane (Tris).HCl, 1-methyl-3-
isobutylxanthine, creatine phosphate, creatine phosphokinase, Nω-nitro-L-arginine (L-NA), Nω 
nitro-L-arginine methyl ester (L-NAME) and GTP were obtained from Sigma-Aldrich 
(St.Louis, MO); sodium nitroprusside from Merck (Darmstadt, Germany); BAY 41-2272 and 
S-nitroso-N-acetylpenicillamine from Alexis (San Diego, USA) and prostaglandin F2α 
(Dinolytic) from Upjohn (Puurs, Belgium). ODQ, T-1032, SNAP, YC-1 and BAY 41-2272 
were dissolved in dimethylsulfoxide and acetylcholine in 50 mmol/L potassium hydrogen 
phtalate buffer, pH 4.0. The other drugs were dissolved in distilled water. Saturated NO 
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solution was prepared from gas (Air liquide, Belgium) as described by Kelm & Schrader 14. 
All concentrations are expressed as final molar concentrations in the organ bath. The final 
concentration of dimethylsulfoxide in the organ bath never surpassed 0.1%. 
 
IV.3.6. Calculations and statistics 
Data are presented as mean values ± SEM; n represents the number of arteries (each obtained 
from a different mouse). Statistical significance was evaluated by using Student’s t-test for 
paired and unpaired observations (SPSS, version 12) or with two-way ANOVA with 
Bonferroni post hoc test (GraphPad Prism, version 4), when appropriate. P<0.05 was 
considered as significant.  
 
IV.4. Results 
IV.4.1. NO-dependent sGC-induced relaxations 
IV.4.1.1. Effect of ACh  
Responses to stimulated release of endothelium-derived NO were determined by recording 
concentration-relaxation curves to ACh in the aorta (figure IV.1A) and femoral artery (figure 
IV.1B) from male and female sGCα1-/- and sGCα1+/+ mice. The results were essentially similar 
in both genders. ACh-induced concentration-dependent relaxation was nearly abolished in the 
aortic rings of the sGCα1-/- mice (10 µmol/L ACh: female: 67.8%±3.5 vs. 16.4%±5.2 (n=6), 
P<0.05)). Also in the femoral artery segments of the sGCα1-/- mice, the ACh-induced response 
was significantly reduced compared to the sGCα1+/+ mice (10 µmol/L ACh: female: 89.0%± 
2.9 vs. 43.1%±10.7 (n=6, P<0.05)). 
A second relaxation curve to ACh was established in the presence of the sGC inhibitor ODQ. 
ODQ inhibited the ACh-induced response in the aorta (figure IV.1A) (10 µmol/L ACh: 
female: 67.8%±3.5 vs. 28.8%±3.0 (n=6, P<0.05)) and femoral artery (figure IV.1B) (10 
µmol/L ACh: female: 89.0%±2.9 vs. 50.3%±10.9 (n=6, P<0.05)) from control mice. As the 
response to ACh in the sGCα1-/- aortic rings was very small, the reducing effect of ODQ was 
also confined (10 µmol/L ACh: female: 16.4%±5.2 vs. 2.6%±1.3 (n=6, P>0.05)). After 
treatment with ODQ, the maximal relaxation in the femoral arteries of sGCα1-/- mice, was 
approximately reduced by 74% and 52% (43.1%±10.7 vs. 20.9%±9.9 (n=6, P<0.05)) 
respectively in male and female sGCα1-/- mice. 
                                                                   Role of sGCα1 in vascular smooth muscle relaxation 
 131 
In order to evaluate the involvement of non-nitric oxide vasodilating substances such as the 
endothelium-derived hyperpolarising factor (EDHF) in the ACh-induced response, the effect 
of the NOS inhibitor L-NA was investigated in femoral arteries isolated from male sGCα1+/+ 
mice (figure IV.1G). In those arteries, the vasorelaxing influence of ACh was almost 
completely abolished by L-NA (10 µmol/L ACh: female: 77.9%±8.0 vs. 7.0%±1.9 (n=4, 
P<0.05)).  
 
IV.4.1.2. Effect of SNP  
In this series of experiments, the relaxant effects of increasing concentrations of the NO-
donor SNP were compared on precontracted aortas (figure IV.1C) and femoral arteries (figure 
IV.1D; figure IV.2A,B) from male and female sGCα1-/- and sGCα1+/+ mice. The results were 
essentially the same in both genders. The cumulative addition of SNP resulted in a 
concentration-dependent response in the ring segments of both sGCα1-/- and sGCα1+/+ mice. 
However, the relaxing effect of SNP was significantly reduced in the preparations of the 
sGCα1-/- mice (10 µmol/L SNP: female: aorta: 77.9%±4.0 vs. 48.6%±3.6 (n=15, P<0.05); 
femoral artery: 89.9%±1.8 vs. 70.3%±5.1 (n=14, P<0.05)).  
Following preincubation with ODQ, the relaxing effect of SNP was significantly reduced in 
the aorta and femoral artery of both sGCα1-/- and sGCα1+/+ mice (10 µmol/L SNP: female: 
aorta: 77.9%±4.0 vs. 36.8%±2.6 (n=15, P<0.05); femoral artery: 89.9%±1.8 vs. 49.5%±3.9 
(n=14, P<0.05)). The relaxing effect of 10 µmol/L SNP was reduced by approximately 85% 
in male aortic rings (figure IV.1C) of sGCα1-/- mice and 80% (48.6%±3.6 vs. 9.8%±1.9 (n=15, 
P<0.05)) in the corresponding female segments. Also in the femoral artery preparations 
(figure IV.1D) of the sGCα1-/- mice, approximately 70% (female: 70.3%±5.1 vs. 20.5%±1.9 
(n= 14, P<0.05)) of the response to SNP was eliminated by ODQ.  
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Figure IV.1: Relaxation effect of ACh (A, B), SNP (C, D) and NO-gas (E, F) on precontracted (30 
µmol/L PGF2α (ACh, NO-gas,) and 5 µmol/L NOR (SNP)) aortas (A, C, E) and femoral arteries (B, D, 
F) from male sGCα1+/+ and sGCα1-/- mice in control conditions (▲ and ∆) and in the presence of ODQ 
(● and ○) (1 µmol/L (ACh, SNP) and 10 µmol/L (NO-gas)). G, effect of L-NA (■) (0.1 mmol/L) on 
the ACh-induced response in the femoral artery of male sGCα1+/+ mice. *(sGCα1+/+ vs. sGCα1-/-), 
+(sGCα1+/+ ODQ vs. sGCα1-/- ODQ): P<0.05, (n=7-15); #(control conditions vs. presence of L-NA): 
P<0.05, (n=4). 
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IV.4.1.3. Effect of SNAP  
In these experiments, we investigated the relaxant effect of the NO-donor SNAP on aortic 
rings of female female sGCα1-/- and sGCα1+/+ mice. The concentration-dependent relaxant 
effect of SNAP was nearly abolished in the ring segments of the sGCα1-/- mice compared to 
the sGCα1+/+ mice (10 µmol/L SNAP: 64.4%±4.5 vs. 7.0%±3.6 (n=6, P<0.05)). 
Treatment of the aortic rings with ODQ, resulted in a large, significant reduction of the 
SNAP-induced response in the sGCα1+/+ aortic rings. In those preparations, the 10 µmol/L 
SNAP-induced relaxation was reduced by approximately 94% (64.4%±4.5 vs. 3.8%±2.1 (n=6, 
P<0.05)). Since SNAP had a very small effect in the aortic rings of the sGCα1-/- mice, the 
influence of ODQ was rather negligible (7.0%±3.6 vs. 0.7%±0.7 (n=6, P>0.05)). 
 
IV.4.1.4. Effect of NO-gas 
The relaxing effect of exogenous NO delivered as gas was also examined on the aorta (figure 
IV.1E) and femoral artery (figure IV.1F) from male and female sGCα1-/- and sGCα1+/+ mice. 
The results were essentially similar in both genders. In the ring segments of both sGCα1+/+ and 
sGCα1-/- mice, NO-gas showed a concentration-dependent relaxing effect. The response to 
NO-gas was significantly reduced in the aorta (100 µmol/L NO-gas: female: 58.0%±3.5 vs. 
33.0%±3.0 (n=7, P<0.05)) and femoral artery (100 µmol/L NO-gas: female: 86.4%±2.7 vs. 
56.35%±6.3 (n=7, P<0.05)) of the sGCα1-/- mice.  
Preincubation with ODQ before adding NO-gas caused a rightward shift of the concentration-
response curve in the aorta (figure IV.1E) and femoral artery (figure IV.1F) of both sGCα1-/- 
and sGCα1+/+ mice (100 µmol/L: female: aorta: 58.0%±3.5 vs. 36.9%±3.1; femoral artery: 
86.4%±2.7 vs. 75.8%±4.7 (n=7, P<0.05)). The relaxation induced by 100 µmol/L NO-gas on 
male and female sGCα1-/- aortas was reduced by respectively 68% and 56% (33.0%±3.0 vs. 
14.6%±3.4 (n=7, P<0.05)), while 24% and 32% (56.4%±6.3 vs. 38.1%±7.5 (n=7, P<0.05)) for 
respectively male and female sGCα1-/- femoral artery segments. 
 
IV.4.1.5. Effect of basal NO 
We also analysed the effect of ODQ on the contraction elicited by 5 µmol/L NOR in the aorta 
(figure IV.3F) and femoral artery (data not shown) of male and female sGCα1-/- and sGCα1+/+ 
mice. The results were similar for both genders. Addition of ODQ elicited a small rise or even 
no rise in the precontraction level of the femoral arteries, while in the aortic rings the 
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contraction to norepinephrine was substantially increased by ODQ. This ODQ-induced 
increase in vascular tone was significantly smaller in the aortas of the sGCα1-/- mice.  
 
 
 
Figure IV.2: Original tracings showing a concentration-response curve to SNP in the femoral artery 
of a male sGCα1+/+ (A) and sGCα1-/- mouse (B) and to BAY 41-2272 in the aorta of a male sGCα1+/+ 
(C) and sGCα1-/- mouse (D). 
 
IV.4.2. NO-independent sGC-induced relaxations 
IV.4.2.1. Effect of YC-1  
YC-1 stimulates sGC in an NO-independent way and sensitizes it to NO 6. To find out which 
sGC isoform is involved in the vasodilating effect of YC-1, cumulative concentration-
response curves to YC-1 were obtained in the aorta (figure IV.3A) and femoral artery (figure 
IV.3B) from male sGCα1-/- and sGCα1+/+ mice. YC-1 induces a concentration-dependent 
relaxing effect in the ring segments of both sGCα1-/- and sGCα1+/+ mice. However, the YC-1-
induced response was significantly reduced in the preparations of the sGCα1-/- mice.  
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Figure IV.3: Relaxation effect of YC-1 (A,B) and BAY 41-2272 (C,D) on precontracted (30 µmol/L 
PGF2α) aortas (A,C) and femoral arteries (B,D) from male sGCα1+/+ (▲) and sGCα1-/- mice (∆) (n=7-
9). E, influence of ODQ (1 µmol/L) on the BAY 41-2272-induced response in the aorta of female 
sGCα1+/+ mice (n=4). F, effect of ODQ (1 µmol/L) on the contraction elicited by 5 µmol/L NOR in the 
aorta of male and female sGCα1+/+ and sGCα1-/- mice (n=13-15). * P<0.05 
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IV.4.2.2. Effect of BAY 41-2272 
BAY 41-2272, another NO-independent type of sGC stimulator 9 was added to aortic (figure 
IV.2C,D; figure IV.3C) and femoral artery (figure IV.3D) ring segments of male and female 
sGCα1-/- and sGCα1+/+ mice. This resulted in a relaxing response that was concentration-
dependent in the femoral arteries of sGCα1-/- and sGCα1+/+ mice. In the aorta, however, the 
BAY 41-2272-induced response was only clearly concentration-dependent in the sGCα1+/+ 
preparations. In the aortic rings from sGCα1-/- mice, a substantial relaxation was only obtained 
with a concentration of 10 µmol/L (female: 96.3%±1.4 vs. 66.5%±5.6 (n=8, P<0.05)). Also in 
the femoral arteries of sGCα1-/- mice, the relaxing effect of BAY 41-2272 was significantly 
impaired (female: 90.2%±3.6 vs. 61.5%±4.4 (n=8, P<0.05)). The results were similar for both 
genders.  
The treatment of sGCα1+/+ aortic rings with ODQ (figure IV.3E) shows that ODQ had a strong 
inhibitory influence on the BAY 41-2272-induced response, except on the highest BAY 41-
2272 concentration (10 µmol/L). 
 
IV.4.3. Relaxation induced by PDE-5 inhibition  
The influence of the PDE-5 inhibitor T-1032 was explored in the aorta (figure IV.4A) and 
femoral artery (figure IV.4B) of female sGCα1-/- and sGCα1+/+ mice. Increasing concentrations 
of T-1032 induced a concentration-dependent relaxation which was almost completely 
abolished in the aortas isolated from sGCα1 knockout mice. Also in the femoral artery 
segments of the sGCα1-/- mice, the T-1032-induced response was significantly reduced 
compared to the control mice.  
 
IV.4.4. sGC-independent relaxations 
IV.4.4.1. Effect of 8-pCPT-cGMP    
Concentration-response curves to 8-pCPT-cGMP, a cell membrane permeable cGMP-
analogue, were recorded in the aorta (figure IV.4C) and femoral artery (figure IV.4D) from 
male sGCα1-/- and sGCα1+/+ mice. The concentration-dependent responses to 8-pCPT-cGMP 
were not significantly altered in the aorta and femoral artery of sGCα1-/- mice compared to 
sGCα1+/+ preparations. 
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Figure IV.4: Relaxation effect of T-1032 on precontracted (30 µmol/L PGF2α) aortas (A) and femoral 
arteries (B) from female sGCα1+/+ (▲) and sGCα1-/- mice (∆) (n=6) in control conditions. Relaxation 
effect of 8-pCPT-cGMP on precontracted (30 µmol/L PGF2α) aortas (C) and femoral arteries (D) from 
male sGCα1+/+ (▲) and sGCα1-/- mice (∆) (n=5-8) in control conditions. Relaxation effect of Lev on 
precontracted (30 µmol/L PGF2α) aortas (E) and femoral arteries (F) from female sGCα1+/+ (▲) and 
sGCα1-/- mice (∆) (n=6-9) in control conditions. * P<0.05. 
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IV.4.4.2. Effect of levcromakalim 
In these experiments, relaxation curves were obtained by addition of cumulative 
concentrations of the KATP channel opener Lev to the aorta (figure IV.4E) and femoral artery 
(figure IV.4F) of female sGCα1-/- and sGCα1+/+ mice. There was no significant difference in 
the concentration-dependent response to Lev between the preparations of sGCα1-/- and 
sGCα1+/+ mice. 
 
IV.4.5. cGMP-measurements in thoracic aorta rings 
Figure IV.5A shows that the basal cGMP content in aortic rings isolated from sGCα1-/- mice 
was significantly smaller than in rings from sGCα1+/+ mice. In the sGCα1+/+ ring segments 
stimulated with SNP (10 µmol/L), the cGMP levels increased 100-fold above basal values. 
Those isolated from sGCα1-/- mice showed only a non-significant two-fold increase upon 
stimulation with SNP.  
In another series of experiments, the effect of ODQ on the SNP-induced cGMP increase was 
assessed in aortic segments of female sGCα1-/- and sGCα1+/+ mice. The results (figure IV.5B) 
demonstrate that ODQ significantly reduced the cGMP content of the SNP-treated aortic rings 
in both sGCα1-/- and sGCα1+/+ mice. 
 
IV.4.6. sGC enzyme activity levels in femoral artery rings 
In the femoral arteries isolated from male and female sGCα1-/- mice, the basal sGC activity 
was significantly smaller compared to sGCα1+/+ mice. Upon stimulation with 100 µmol/L 
BAY 41-2272, the sGC activity level increased approximately 50-fold above basal values in 
the ring segments of the sGCα1+/+ mice. The corresponding sGCα1-/- preparations showed only 
a 3-fold increase (figure IV.5C). 
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Figure IV.5: A, Increase of cGMP elicited by SNP (10 µmol/L) in aortic rings of male and female 
sGCα1+/+ and sGCα1-/- mice (n=6-9). #(vehicle vs. SNP), *(wild type vs. knockout): P<0.001. B, 
Influence of ODQ (1 µmol/L) on the increase in cGMP elicited by SNP (10 µmol/L) in aortic rings of 
female sGCα1+/+ and sGCα1-/- mice (n=9). #(SNP vs. SNP+ODQ), *(sGCα1+/+ vs. sGCα1-/-): P<0.001. 
C, Baseline and BAY 41-2272-stimulated sGC enzyme activity in femoral rings from male and female 
sGCα1+/+ and sGCα1-/- mice (n=11-14). #(baseline vs. BAY 41-2272), *(sGCα1+/+ vs. sGCα1-/-): 
P<0.001. Data from male and female animals were pooled. 
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IV.5. Discussion 
The physiological relevance of the sGC isoforms is of great importance to validate sGC 
subunits as potential pharmacological targets for the treatment of various diseases. In vascular 
tissue the sGCα1 subunit is predominantly found 5. However, our results demonstrate that 
sGCα1β1 is not the only target of both NO-dependent and NO-independent sGC stimulators.  
The importance of the sGCα1 subunit in vasorelaxations induced by endogenous and 
exogenous NO is illustrated by the significantly reduced responses to ACh, SNP, SNAP and 
NO-gas in the arteries from sGCα1-/- mice. The relaxant response to ACh (release of 
endogenous NO from the endothelium) and SNAP (release of exogenous NO upon 
nonreductive decomposition) was nearly abolished in the aortic rings of sGCα1-/- mice, 
whereas SNP (release of exogenous NO upon biotransformation) and NO-gas (represents 
exogenous NO as such) still elicited relaxation. Femoral arteries of sGCα1-/- mice showed a 
substantial response to all three NO-delivering substances (SNAP was not tested).  
Besides NO, the endothelium may release other relaxing substances including prostacyclin 
(PGI2) and EDHF depending on the vascular bed studied. In mouse aorta, Chataigneau et al. 
demonstrated that the ACh-induced response is completely blocked by Nω-nitro-L-arginine 
(L-NA), indicating that NO is the sole endothelium-derived vasodilator 15. The same 
conclusion can be made from analogous experiments we performed in the femoral arteries of 
sGCα1+/+ mice.  
The continuous release of basal NO keeps the cardiovascular system in a state of constant 
active vasodilation and plays a substantial role in regulating blood flow and blood pressure 16. 
The increase in vascular tone elicited by the sGC-inhibitor ODQ on precontracted 
preparations was significantly smaller in the aorta from sGCα1-/- mice. This suggests that 
basally released NO acts predominantly through activation of sGCα1β1.  
T-1032 causes an accumulation of the basally produced cGMP by inhibiting 
phosphodiesterase type 5. In comparison to the femoral arteries of the sGCα1+/+ mice, the 
corresponding arteries of the sGCα1-/- mice showed significantly less relaxation in response to 
T-1032. This is in line with the significantly lower basal sGC activity we found in the sGCα1-/- 
femoral artery preparations, using a biochemical technique. In the aorta of sGCα1-/- mice, the 
relaxant effect of T-1032 is almost abolished and a significantly lower basal cGMP content is 
found. All these data suggest a diminished basal influence of sGC in blood vessels of sGCα1-/- 
mice. 
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Because of their sGC-stimulating effect, there is a great interest in molecules such as YC-1 
and BAY 41-2272 6 as potential new drugs for the treatment of cardiovascular pathologies 9. 
Our results confirm that BAY 41-2272 is approximately 30-fold more potent as a vasodilator 
than YC-1 9. The finding that the relaxations in response to YC-1 and BAY 41-2272 were 
significantly diminished in the arteries from male sGCα1-/- mice, suggests that YC-1 and BAY 
41-2272 mainly act through activation of sGCα1β1. However YC-1 and BAY 41-2272 still 
induce a response in the sGCα1-/- mice.  
The finding that the arteries from both sGCα1-/- and sGCα1+/+ mice responded in a similar way 
to the cGMP-analogue, 8 pCPT-cGMP, and the KATP channel opener Lev, excludes that 
mechanisms downstream of the cGMP formation are affected by knocking out sGCα1.  
All observations demonstrate the functional importance of the sGCα1 subunit as was expected 
from its predominant presence in vascular tissue. However, the surprising observation that 
NO, BAY 41-2272 and YC-1 still elicit a relaxing effect in sGCα1-/- mice, indicates that 
activation of sGCα1β1 is not the sole mechanism responsible for these relaxations. It should 
however be mentioned that besides their stimulatory effect on sGC, at higher concentrations 
BAY 41-2272 and YC-1 also increase intravascular cyclic GMP by inhibition of cGMP 
breakdown through phosphodiesterase type 5, the major cGMP-degrading enzyme in vascular 
smooth muscle cells 17. Despite the fact that the NO-donor drugs, SNP and SNAP release the 
same NO species (NO●, NO+ and NO-) 18, the SNP-induced response in the aortic rings of the 
sGCα1-/- mice is far more pronounced. This could be due to the fact that SNP also decomposes 
to other bioactive compounds, such as cyanide and iron ions 19, leading to an enhanced 
oxidative stress and vasorelaxation 20.  
Recently Mergia et al. 21 also showed the substantial role of an sGCα1-dependent mechanism 
in NO-related vasorelaxations. However, possible gender and regional differences were not 
explored in that study. The potential gender difference could be relevant considering that male 
but not female sGCα1-/- mice develop hypertension from the age of 14 weeks due to an 
increase in peripheral resistance 10. Because of this remarkable gender dependency, we 
performed experiments on both female and male sGCα1-/- and sGCα1+/+ mice. No gender 
differences of sGCα1 deletion were observed in the response to ACh, SNP, NO-gas and BAY 
41-2272 indicating that this is not the underlying cause for the development of hypertension 
in male sGCα1-/- mice. Potential regional variations were also addressed by studying two 
different types of arteries: the aorta as an elastic artery and the femoral artery as a muscular 
artery. Overall, similar results were obtained in both vessel types.  
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The fact that there is still a substantial relaxation in response to several sGC-stimulators in the 
sGCα1-/- mice, indicates that besides sGCα1β1 another mechanism is involved; either activation 
of the sGCα2β1 isoform or activation of (an) sGC-independent mechanism(s) or a combination 
of these. Arguments in favour of both hypotheses are obtained in the present study. 
Our finding that there is still an increase in sGC activity of sGCα1-/- femoral arteries after 
addition of BAY 41-2272 is in line with the contribution of the sGCα2β1 isoform in the BAY 
41-2272-induced response. The possible contribution of the sGCα2β1 isoform in the NO-
induced relaxations seen in sGCα1-/- mice is also suggested by the observations that ODQ, 
which inhibits both sGC
 
isoforms, had a strong inhibitory influence on NO-induced 
relaxations in both the aorta and femoral artery preparations of the sGCα1-/- mice and that the 
cGMP production by SNP was significantly reduced in the sGCα1-/- aortic rings in the 
presence of ODQ. From their observations Mergia et al. suggest that sGCα1-independent 
relaxation is mediated by sGCα2 and that the limited activity of sGCα2 is enough to elicit a 
response in sGCα1-/- mice 21. It should however be mentioned that there is an important 
difference between the transgenic mouse model developed by Mergia et al. and the one used 
in the present study. We isolated arteries from sGCα1-/- mice expressing a mutant sGCα1 
protein that is catalytically inactive 10. This avoids alterations in phenotype due to potential 
enzyme structural functions as has recently been demonstrated for PI3Kγ knockout mice 22. 
Conversely, Mergia et al. generated sGCα1-deficient mice with complete abrogation of sGCα1 
expression 21. Therefore, the possible influence on the phenotype of non-catalytic sGCα1 
effects,
 
such as complex formation with e.g. AGAP1 23, can not be ruled out in that model. 
Several observations suggest that also (an)other sGC-independent mechanism(s) might be 
involved in the remaining relaxation response in sGCα1-/-. If sGCα2β1 is the sole isoform 
responsible for the vasorelaxation seen in sGCα1-/- mice, one would expect a significant 
increase in cGMP in the sGCα1-/- mice upon stimulation with NO. However, the sGCα1-/- 
aortic ring segments showed only a two-fold, non-significant increase in cGMP in response to 
SNP. It is questionable that this small increase in cGMP is sufficient to elicit a substantial 
relaxation (SNP 10 µmol/L: 63.23%±3.38 and 48.59%±3.55 in respectively male and female 
sGCα1-/- aortas). Under the assumption that the cGMP-relaxation relation in rat aorta 24 is 
similar to that of mouse aorta, the level of cGMP we observed in the aorta from sGCα1-/- mice 
upon stimulation by SNP, would be able to elicit a relaxation of only 10%. This would imply 
that the rise of cGMP induced by SNP in the sGCα1-/- aortas is too small to explain a 50% 
relaxation. This questions a substantial role of the sGCα2β1 isoform in NO-induced 
relaxations. It should however be mentioned that this reasoning is purely hypothetical. More 
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convincing are the QPCR-measurements showing no higher expression of the sGCα2 subunit 
in the ring segments of sGCα1-/- mice 10.  
In addition to the sGCα2β1 isoform, perhaps (an) sGC-independent mechanism(s) 
contribute(s) to the substantial relaxation seen in the sGCα1-/- mice. Various sGC/cGMP-
independent actions of NO have been described, including the activation of (i) calcium- and 
voltage-dependent potassium channels in vascular smooth muscle cells 25, 26, (ii) 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 27, and (iii) vascular Na+/K+-ATPase 28. 
They have not only been reported for NO-donors but also for authentic NO 29 and endogenous 
NO synthesized from inducible NO synthase 30. Also the observation that ODQ failed to 
inhibit the relaxant effect of 10 µmol/L BAY 41-2272 in the sGCα1+/+ aortic ring, suggests the 
involvement of (a) cGMP-independent mechanism(s) rather than sGCα2 activation. There are 
reports on cGMP-independent mechanisms underlying BAY 41-2272 and YC-1 induced 
vasorelaxation, including inhibition of Ca2+ entry 31 and activation of K+ channels 32 and Na+-
K+-ATPase 33. 
 
IV.6. Conclusions 
From the present study we can conclude that the predominant sGC isoform in the aorta and 
femoral artery, sGCα1β1, is indeed involved in the vasorelaxations induced by NO-dependent 
and NO-independent sGC activators in both genders. However the remaining relaxation seen 
in the sGCα1-/- mice, may indicate that besides sGCα1β1 also the less abundantly expressed 
isoform sGCα2β1 and/or (an) sGC-independent mechanism(s) play(s) a very important role. 
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V.1. Abstract and keywords 
Soluble guanylyl cyclase (sGC) is the major effector molecule for NO, and as such an 
interesting therapeutic target for the treatment of erectile dysfunction. To assess the functional 
importance of the sGCα1β1 isoform in corpus cavernosum (CC) relaxation, CC from male 
sGCα1-/- and wild type mice were mounted in organ baths for isometric tension recording. The 
relaxation to endogenous NO (from acetylcholine, bradykinin and electrical field stimulation) 
was nearly abolished in the sGCα1-/- CC. In the sGCα1-/- mice, the relaxing influence of 
exogenous NO (from sodium nitroprusside and NO-gas), BAY 41-2272 (NO-independent 
sGC-stimulator) and T-1032 (phosphodiesterase type 5 inhibitor) were also significantly 
decreased. The remaining exogenous NO-induced relaxation seen in the sGCα1-/- mice was 
significantly decreased by the sGC-inhibitor ODQ. The specificity of the impairment of the 
sGC-related responses was demonstrated by the unaltered relaxations seen with forskolin 
(adenylyl cyclase activator) and 8-pCPT-cGMP (cGMP-analogue). In conclusion, the 
sGCα1β1 isoform is involved in corporal smooth muscle relaxation in response to NO and 
NO-independent sGC-stimulators. The fact that there is still some effect of exogenous NO in 
the sGCα1-/- mice, suggests the contribution of (an) additional pathway(s).  
 
key words: penile erection, nitric oxide, soluble guanylyl cyclase, vasodilatation, impotence 
 
V.2. Introduction 
Penile erection is a complex, neurally regulated physiologic event that involves increased 
blood filling of the corporal tissue and restricted venous outflow, both resulting from corporal 
smooth muscle relaxation 1. Nitric oxide (NO) is widely accepted as the principal mediator of 
the erectile response. It is produced by neuronal NO synthase (nNOS) in non-adrenergic, non-
cholinergic (NANC) nerves, innervating the penis 2. Although also sinusoidal and vascular 
endothelial cells release NO in response to mechanical 3 and chemical stimuli 1, 4, neurogenic 
NO is generally considered as the primary source required for penile erection. However, the 
importance of NO produced by eNOS for penile erection is becoming increasingly recognized 
5
. Regardless of the source, NO binds to the heme component of soluble guanylyl cyclase 
(sGC), leading to a 300-fold increase in the catalytic conversion of guanosine-5’-triphosphate 
(GTP) to cyclic guanosine-3’, 5’-monophosphate (cGMP) and pyrophosphate 6. This high 
amount of cGMP conveys signals through activation of cGMP-dependent protein kinase I, 
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eventually leading to smooth muscle relaxation 7, 8. sGC is a heterodimer composed of two 
subunits, α and β 9, both essential for catalytic activity 10. Two isoforms for each subunit 
(α1/α2 and β1/β2) have been described 11-13, but only the α1β1 and α2β1 heterodimers are found 
active 14. sGCα1β1 is the predominantly expressed isoform in most tissues except in the brain, 
in which the levels of both isoforms are comparable 15. Various diseases, including 
hypertension 16, 17, hypercholesterolemia 18, diabetes mellitus 19 and renal failure 20, that cause 
erectile dysfunction (ED) are highly associated with impairments of the NO/cGMP signaling 
pathway. The central role of this pathway is demonstrated by the phosphodiesterase type-5 
inhibitor sildenafil as today’s most successful therapy for the treatment of ED. However, 
since some side effects and limitations for use have been reported 21, 22, there is an increasing 
interest for alternative therapeutic measures. sGC is, as the predominant intracellular receptor 
of NO, a promising therapeutic target. The aim of the present study was therefore to analyse 
the functional importance of the sGCα1β1 isoform in penile smooth muscle relaxation using 
soluble guanylyl cyclase alpha 1 knockout (sGCα1-/-) mice. 
 
V.3. Materials and methods 
V.3.1. Animals  
All experiments were performed on male homozygous soluble guanylyl cyclase alpha 1 
knockout (sGCα1-/-; n= 6-9) mice and sGCα1+/+ (n= 6-11) mice (genetic background: mixed 
Swiss-129) 23, bred in the Department of Molecular Biomedical Research, Flanders 
Interuniversity Institute for Biotechnology, Ghent, Belgium. The animals were treated in 
accordance with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). On the day of 
experiment, the mice were sexually mature (age: 10-15 weeks) and euthanized by cervical 
dislocation. 
 
V.3.2. Tissue collection  
The penile tissue was dissected free by removal of connective and adventitial tissues along the 
shaft of the penis, the dorsal arteries, dorsal vein, corpus spongiosum, urethra and glans penis. 
Then, the corpora cavernosa (CC) were separated by cutting the fibrous septum between them 
and were excised at the base. They were kept in cooled Krebs-Ringer bicarbonate (KRB) 
solution until mounting. 
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V.3.3. Tension measurements 
Of each mouse, one corpus cavernosum was mounted horizontally in a myograph with one 
end fixed to a force-displacement transducer and the other to a micrometer. The tissue 
chambers contained 10 ml KRB solution at 37 °C (pH 7.4) equilibrated with 95% O2-5% 
CO2. The preparations were preloaded with 0.45 g of tension and allowed to equilibrate for 60 
minutes in bath fluid that was frequently replaced with fresh KRB solution. The preparations 
were 3 times contracted with 5 µmol/L norepinephrine (NOR), washed, and allowed to relax 
to resting tension before starting the protocol. When the pre-contraction response reached a 
stable level, electrical field stimulation (EFS: train duration 20s or 40s; frequency: 1,2,4 and 8 
Hz; pulse duration: 5 ms; 80 V), delivered by a Grass stimulator via two parallel platinum 
electrodes, was applied to the tissue or various vasodilating substances were added to the bath 
medium. In some experiments, increasing concentrations of NOR were added at a stable 
resting tension to analyse the contractile response. EFS was repeated after incubation with 
atropine (1 µmol/L) and guanethidine (4 µmol/L) for 30 minutes to eliminate responses 
mediated by cholinergic and noradrenergic nerves, respectively. The influence of the soluble 
guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (1 µmol/L, 20 
min preincubation) was investigated on EFS and drug-induced effects. Between response-
curves, the CC were washed and allowed to recover for 20-30 min. At the end of the 
experiments, tissues were lightly patted dry and weighed.  
 
V.3.4. Drugs 
The experiments were performed in a KRB solution of the following composition (mmol/L): 
NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), acetylcholine 
chloride (ACh), bradykinin acetate (BK), Nω-nitro-L-arginine, forskolin, 8-(4-
chlorophenylthio)-guanosine 3’,5’-cyclic monophosphate (8-pCPT-cGMP), atroprine, 
guanethidine and norepinephrine bitartrate were obtained from Sigma-Aldrich (St.Louis, 
MO), BAY 41-2272 from Alexis (San Diego, USA) and sodium nitroprusside (SNP) from 
Merck (Darmstadt, Germany). ODQ and BAY 41-2272 were dissolved in dimethylsulfoxide 
and acetylcholine in 50 mmol/L potassium hydrogen phtalate buffer, pH 4.0. The other drugs 
were dissolved in distilled water. Saturated NO solution was prepared from gas (Air liquide, 
Belgium) as described by Kelm & Schrader 24. All concentrations are expressed as final molar 
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concentrations in the organ bath. The final concentration of dimethylsulfoxide in the organ 
bath never surpassed 0.1%. 
 
V.3.5. Calculations and statistics 
Data are presented as mean values ± SEM; n represents the number of corpora cavernosa 
(each obtained from a different mouse). Relaxations are expressed as a percentage of the tone 
developed by the addition of NOR. Contractions are expressed in mN. 
Statistical significance was evaluated using Student’s t-test for paired and unpaired 
observations (SPSS, version 12). P < 0.05 was considered as significant.  
 
V.4. Results 
The weight of the CC preparations did not significantly differ between sGCα1-/- and sGCα1+/+ 
mice (13.54 mg ± 0.80 (n=9) vs. 12.77 mg ± 0.77 (n=11, P>0.05)).  
In response to increasing concentrations of NOR (10 nmol/L−10 µmol/L), the penile tissue 
isolated from sGCα1-/- mice, developed an equal force per mg tissue compared with the 
sGCα1+/+ preparations (figure V.1). 
 
 
 
Figure V.1: Cumulative concentration-contraction curve to NOR in CC from sGCα1+/+ (▲; n=11) and  
sGCα1-/- (∆; n=9) mice. 
 
The ability to relax NOR-contracted CC preparations through release of endothelial NO was 
tested by addition of ACh (10 µmol/L) and BK (50 µmol/L). ACh relaxed the sGCα1+/+ 
preparations, whereas it contracted the tissues of sGCα1-/- mice (figure V.2). Inhibition of sGC 
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by ODQ, resulted in a contractile effect of ACh in both sGCα1-/- and sGCα1+/+ CC tissues 
(figure V.2). BK had a relaxant effect in the CC of both sGCα1-/- and sGCα1+/+ mice, though 
the response in the sGCα1-/- preparations was significantly reduced (4.55% ± 2.80 in sGCα1-/- 
vs. 26.82% ± 2.86 in sGCα1+/+ (n=6 each, P<0.05)).  
 
 
 
Figure V.2: Relaxation effect of ACh on precontracted (5 µmol/L NOR) CC from sGCα1+/+ (n=7) and  
sGCα1-/- (n=7) mice in control conditions (-ODQ) and in the presence of ODQ (+ODQ). *(sGCα1+/+ vs.  
sGCα1-/-), #(-ODQ vs. +ODQ): P<0.05. 
 
The effect of neuronal NO was examined by stimulating the intrinsic nerves with EFS. EFS 
relaxed the tissues of sGCα1+/+ mice in a frequency-dependent manner (figure V.3A), whereas 
the response in the sGCα1-/- preparations was nearly abolished (figures V.3B and V.4A). 
Following preincubation with ODQ, the relaxations induced by EFS in the sGCα1+/+ 
preparations were completely blocked and resulted even in a small contractile response of 
EFS at 8 Hz (figure V.4A). As the response to EFS in the CC of the sGCα1-/- mice was very 
small, the influence of ODQ was negligible. The presence of guanethidine and atropine, 
significantly reduced relaxation by EFS on the sGCα1+/+ CC (figure V.4B). The very limited 
EFS-induced response in the sGCα1-/- preparations was unaltered by guanethidine and 
atropine even after increasing the stimulation period from 20s to 40s (data not shown). 
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Figure V.3: Original tracing showing a response curve to EFS (Hz) (A, B) and to SNP (-log mol/L)  
(C, D) in CC from a sGCα1+/+ (A, C) and a sGCα1-/- (B, D) mouse.  
 
 
 
Figure V.4: Effect of EFS on precontracted (5 µmol/L NOR) CC from sGCα1+/+ (n=6) and sGCα1-/-  
(n=6) mice in control conditions and in the presence of ODQ (A) or guanethidine (GUA) and atropine  
(ATR) (B). *(sGCα1+/+ vs. sGCα1-/-), +(sGCα1+/+ vs. sGCα1-/- both in the presence of GUA+ATR), #(- 
ODQ or -GUA+ATR vs. +ODQ or +GUA+ATR for sGCα1+/+ mice), §(-GUA+ATR vs. +GUA+ATR  
for sGCα1-/- mice): P<0.05. 
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Administration of increasing concentrations of the endothelium-independent NO-donor 
compound SNP (1 nmol/L–10 µmol/L) resulted in a concentration-dependent relaxation of the 
sGCα1+/+ (figure V.3C) and sGCα1-/- (figure V.3D) CC preparations that was significantly 
reduced in the sGCα1-/- mice as compared to sGCα1+/+ mice (figure V.5A). The maximal 
relaxation to SNP in the CC from sGCα1-/- mice was decreased by approximately 38%. 
Preincubation of the CC tissues with ODQ strongly inhibited the SNP-induced responses in 
both sGCα1+/+ and sGCα1-/- mice (figure V.5A). 
Exogenous NO delivered as gas (1 µmol/L–100 µmol/L) and added non-cumulatively, was 
able to relax the CC preparations of both sGCα1-/- and sGCα1+/+ mice in a concentration-
dependent way. However, the response to NO-gas was significantly reduced in the penile 
tissues of the sGCα1-/- mice as compared to those of sGCα1+/+ mice (figure V.5B). The 
maximum response to NO-gas was significantly diminished in sGCα1-/- CC by approximately 
36% compared to control. Treatment with ODQ significantly reduced the relaxant effect of 
NO-gas in both sGCα1+/+ and sGCα1-/- CC preparations (figure V.5B). 
 
 
 
Figure V.5: Relaxation effect of SNP (A) and NO-gas (B) on precontracted (5 µmol/L NOR) CC from  
sGCα1+/+ and sGCα1-/- mice in control conditions (▲ and ∆) and in the presence of ODQ (● and ○).  
*(sGCα1+/+ vs. sGCα1-/-), +(sGCα1+/+ ODQ vs. sGCα1-/- ODQ): P<0.05, (n=6-7). 
 
The inhibition of phosphodiesterase type 5 by T-1032 25 (1 nmol/L–10 µmol/L), resulted in a 
concentration-dependent relaxant response in the penile tissue from both sGCα1-/- and 
sGCα1+/+ mice. This response was however significantly smaller in the sGCα1-/- mice than in 
sGCα1+/+ mice (figure V.6A). 
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Addition of BAY-41-2272, an NO-independent sGC-stimulator 26 (1 nmol/L–10 µmol/L), 
produced a concentration-dependent relaxation in the CC preparations of both sGCα1-/- and 
sGCα1+/+ mice. However BAY 41-2272 had a significantly smaller effect in the sGCα1-/- 
preparations compared to sGCα1+/+ penile tissue (figure V.6B). 
There was no difference in the concentration-dependent response to the cell membrane 
permeable cGMP-analogue, 8-pCPT-cGMP (100 nmol/L–10 mmol/L) between the sGCα1-/- 
and sGCα1+/+ preparations (figure V.6C). 
Also forskolin (1 nmol/L–10 µmol/L), an adenylyl cyclase-stimulator, induced an identical 
concentration-dependent response in the sGCα1-/- and sGCα1+/+ preparations (figure V.6D). 
 
 
 
Figure V.6: Relaxation effect of T-1032 (A), BAY 41-2272 (B), 8-pCPT-cGMP (C) and Forskolin  
(D) on precontracted (5 µmol/L NOR) CC from sGCα1+/+ (▲; n=6) and sGCα1-/- (∆; n=7) mice.  
*(sGCα1+/+ vs. sGCα1-/-): P<0.05.  
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V.5. Discussion 
It is generally accepted that sGC, as major effector molecule for NO, plays a very important 
role in penile smooth muscle cell relaxation. An understanding of the functional importance 
of the sGC isoforms in penile erection is necessary to validate the sGC subunits as therapeutic 
targets for the treatment of ED. It has been shown that the main isoform of sGC expressed in 
the corpora cavernosa is sGCα1β1 27. By the present study, this notion is translated in its 
functional importance, as the response to endogenous NO from endothelial origin is nearly 
abolished in the CC preparations of sGCα1-/- mice compared to the sGCα1+/+ CC tissues. 
Cavernosum from sGCα1-/- mice developed even contractions in response to ACh and showed 
significantly less relaxation in response to BK. This indicates that endothelium-derived NO 
exerts its effect through activation of the sGCα1 subunit. These observations are in line with 
our observations on aorta and femoral arteries 28. This is an interesting finding for the 
development of new therapies for ED, as the role of endothelial NO in penile erection is 
becoming more significant than originally thought 5. Moreover, our data suggest the 
involvement of endothelium-derived NO induced by ACh released from parasympathetic 
nerve fibers 29, as atropine inhibited the EFS-induced relaxation in the CC of sGCα1+/+ mice. 
Those EFS-induced relaxations are completely mediated by NO/sGC, as they were 
completely abolished by the sGC-inhibitor ODQ. In the CC preparations of the sGCα1-/- mice, 
the response to EFS was completely abolished, even after prolonged stimulation (40 seconds), 
indicating that sGCα1β1 also functions as the predominant target for neuronal NO. 
Furthermore, this finding does not support the putative role of the vasoactive intestinal 
peptide (VIP) as inhibitory neurotransmitter in penile erection 30. VIP, which is present in the 
nerves of murine corpora cavernosa, as well as other species, stimulates adenylyl cyclase 
(AC) and subsequently elevates the cAMP-dependent protein kinase 31. As it has been shown 
that there are cross-modulatory functions between the sGC/cGMP- and AC/cAMP-signaling 
pathways 32, one could suggest that the latter has a complementary role in the control of 
cavernous smooth muscle tone. However, we show that the AC-activator, forskolin relaxes 
the CC preparations of both sGCα1-/- and sGCα1+/+ mice to a similar extent. Therefore, there is 
no evidence for an upregulation and possible compensatory effect of the AC/cAMP-
transduction pathway in the sGCα1-/- mice. Furthermore, this unaltered forskolin-induced 
response in the sGCα1-/- mice demonstrates that the reduced sGC-related responses in this 
study are not due to an aspecific impairment of relaxation related to structural damage. 
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Our data not only illustrate the functional importance of the sGCα1β1 isoform in 
vasorelaxations induced by endogenous NO but also by exogenous NO, since the response to 
SNP and NO-gas were significantly reduced in the CC of the sGCα1-/- mice. However, in the 
sGCα1-/- preparations, SNP (release of exogenous NO upon biotransformation) and NO-gas 
(represents exogenous NO as such) still elicit a relaxing effect, indicating that sGCα1β1 is not 
the sole mechanism responsible for those relaxations. ODQ, which inhibits both sGC 
isoforms, had a strong inhibitory effect on the exogenous NO-induced relaxations observed in 
the sGCα1-/- mice. Therefore, we suggest that also the minor sGCα2β1 isoform participates in 
the responses to SNP and NO-gas. Additionally, we suggest that also (an) sGC-independent 
mechanism(s) may be involved, as the relaxing effect of exogenous NO in the sGCα1-/- CC is 
not completely abolished by ODQ. It has been shown that, by stimulation of Na+/K+-ATPase 
activity, NO (derived from SNP) relaxes human corpus cavernosum smooth muscle cells 
independently of its ability to increase the intracellular cGMP concentration 33. The ability of 
NO to directly activate calcium-dependent potassium channels or sarcoplasmic/endoplasmic 
reticulum Ca2+-ATPase, as described for vascular smooth muscle cells 34, might be involved.  
The administration of T-1032, which blocks the hydrolysis of cGMP by phosphodiesterase 
type 5, resulted in a relaxation that is significantly reduced in the sGCα1-/- penile tissue as 
compare to sGCα1+/+ penile tissue. This observation suggests a smaller basal sGC-activity in 
the sGCα1-/- mice. Molecules such as BAY 41-2272, that stimulate sGC without the need of 
NO 26, are of particular interest for ED-patients who respond less well to phosphodiesterase 
type 5 inhibitors because of severe endothelial and/or nerve dysfunction 35. The finding that 
the response to BAY-41-2272 was significantly diminished but not completely abolished in 
the sGCα1-/- preparations, implies that besides sGCα1β1, also sGCα2β1 and/or (an) sGC-
independent mechanism(s) participate(s) in those relaxation. BAY 41-2272 has been shown to 
activate both sGC-isoforms 36 and also to exert some cGMP-independent actions 37.  
In the sGCα1-/- mice, the signaling cascade downstream of sGC functions normal because the 
cGMP-analogue 8-pCPT-cGMP relaxed CC of the sGCα1-/- mice to the same extent as the 
sGCα1+/+ preparations.  
 
V.6. Conclusions 
The present study demonstrates the involvement of the predominantly expressed isoform, 
sGCα1β1, in murine CC smooth muscle relaxation in response to NO and NO-independent 
sGC-stimulator. However, as some responsiveness to exogenous NO (SNP and NO-gas) and 
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an sGC-stimulator (BAY 41-2272) remains in the sGCα1-/- mice, also the less abundantly 
expressed isoform, sGCα2β1 and/or (an) sGC-independent mechanism(s) are suggested to 
participate.  
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VI.1. Abstract and keywords 
The binding of nitric oxide (NO) to the heme group of soluble guanylyl cyclase (sGC), results 
in a burst of cGMP, which in turn mediates vascular and corporal smooth muscle relaxation. 
The sGCα1β1 and sGCα2β1 heterodimer are reported to be physiologically active, in which the 
β1 subunit acts as dimerizing partner for both α subunits. As the histidine (His) residue at 
position 105 of the β1 subunit functions as axial ligand for the heme prosthetic group, 
substitution of His by phenylalanine (Phe) will abolish the heme-dependent activation of sGC. 
This is the case in the sGCβ1ki/ki mice from which artery segments (aorta and femoral artery) 
and corpora cavernosa (CC) were isolated and mounted on a myograph for isometric tension 
recording. In comparison with the preparations isolated from the wild type mice, the response 
to endogenous NO (released from the endothelium in response to acetylcholine (ACh)) and 
exogenous NO (from the NO-donor sodium nitroprusside (SNP)) were completely abolished 
in the aortic rings from the sGCβ1ki/ki mice. In the sGCβ1ki/ki femoral arteries, on the other 
hand, both NO-releasing substances still had a relaxing effect. In the CC from the sGCβ1ki/ki 
mice, the response to endogenous NO, which is induced by ACh and electrical field 
stimulation (EFS) (neuronal derived NO), was completely abolished, whereas SNP could still 
induce a response. The relaxing influence of the NO-independent sGC stimulator BAY 41-
2272 was significantly reduced in the arteries and CC from the sGCβ1ki/ki mice, though it was 
not completely abolished. The arteries from the sGCβ1ki/ki mice showed a higher response to 
NOR. Moreover, the responses to methoxamine (specific α1-adrenoreceptor agonist), 
prostaglandin (prostanoid receptor agonist) and potassium (K+) were significantly higher in 
the aortic rings from the sGCβ1ki/ki mice, but not in the corresponding femoral arteries. In the 
presence of the Rho kinase inhibitor HA-1077, the response to NOR was still significantly 
higher in the aortic rings from the sGCβ1ki/ki mice, whereas in the femoral arteries, the 
difference in the NOR-induced contraction between the sGCβ1ki/ki and sGCβ1+/+ mice was 
abolished. The influx of Ca2+ induced by tetraethylammonium chloride (a non-selective K+-
channel blocker) and BAY k 8644 (L-type Ca2+-channel agonist) resulted in a significantly 
higher force development in the aortic rings, but not in the femoral arteries from the sGCβ1ki/ki 
mice. All those data indicate that in the sGCβ1ki/ki aortic rings, the contractile response is 
rather unselective, whereas in the corresponding femoral arteries it is less marked and rather 
specific for NOR. The administration of the sGC-inhibitor ODQ resulted in a significant, 
comparable increase of the NOR-induced tone in the aorta and femoral artery from C57BL/6J 
mice. This suggests that the enhanced contractile activity of the sGCβ1ki/ki preparations is at 
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least in part due to the abolished vasorelaxing influence of basal endothelial NO. In previous 
studies 1, 2, where we characterised mice which are deficient for the sGCα1 gene, we found 
that the responses to SNP and BAY 41-2272 were significantly reduced but not completely 
abolished in the preparations of the sGCα1-/- mice. Apart from the CC, also ACh still had a 
relaxing effect in the sGCα1-/- mice. From those data, together with the present data, we can 
conclude that in the aortic rings, sGC is the sole target for NO, whereas in the femoral arteries 
and CC, also (an) sGC-independent mechanism(s) play(s) a substantial role. In the CC, the 
predominant sGCα1β1 isoform is the main target for NO, as well as for BAY 41-2272. This is 
also the case for the response to endogenous NO and BAY 41-2272 in the arteries, whereas 
exogenously applied NO mainly activates the less abundantly expressed sGCα2β1 isoform.  
 
Key words: arteries, corpora cavernosa, soluble guanylyl cyclase, nitric oxide, 
vasoconstriction/dilatation 
 
VI.2. Introduction 
Soluble guanylyl cyclase (sGC) plays a pivotal role in the transduction of cellular signals 
conveyed by the messenger molecule nitric oxide (NO). By the formation of cGMP, this 
enzyme mediates NO-elicited actions, particularly smooth muscle relaxation, thereby 
controlling blood flow, blood pressure 3, and erectile function 4. The cloning of sGC from 
various species has revealed that the protein is a heterodimer composed of a larger α and a 
smaller β subunit 5, required for catalysis 6. Although two α (α1 and α2) and two β (β1 and β2) 
subunits have been identified so far 7-9, only the α1β1 and α2β1 heterodimers have been shown 
to occur in vivo 10. The α1β1 isoform predominates in most tissues except the brain, in which 
relatively high levels of the α2β1 isoform are expressed 11.  
The low basal activity of sGC increases several hundred-fold upon the binding of NO to the 
heme prosthetic group, which is associated with the N-terminal region of the β1 subunit 
through a weak histidine (His) 105-iron bond. Wedel et al. showed that histidine 105 of the β1 
subunit is essential for the stimulation by NO since substitution by phenylalanine yielded an 
enzyme that was catalytically active but insensitive to NO 12. Upon activation of sGC, the 
accumulating intracellular cGMP targets principally cGMP-dependent protein kinase I (PKG 
I) to bring about smooth muscle relaxation 13. Due to its ubiquitous nature, the pathogenesis 
of various disease states has been linked to inappropriate activation of sGC 14. The different 
isoforms of sGC are therefore very attractive as potential new therapeutic targets for the 
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treatment of among others cardiovascular diseases and erectile dysfunction. In previous 
studies we used sGCα1-/- mice to analyse the functional importance of the sGCα1 subunit in 
vascular 1 and penile 2 smooth muscle relaxation. We found that besides the predominant 
sGCα1β1 isoform, also the less abundantly expressed sGCα2β1 and/or (an) sGC-independent 
mechanism(s) are involved in the NO- and NO-independent sGC mediated smooth muscle 
relaxation. To assess the relative contribution of sGCα2β1 and (an) sGC-independent 
mechanism(s), we examined the responsiveness of vessel segments and corpora cavernosa 
isolated from mice, that express NO-insensitive sGC (sGCβ1ki/ki mice), to NO and an NO-
independent sGC activators.  
 
VI.3. Materials and methods 
VI.3.1. Animals  
Almost all experiments were performed on male and/or female homozygous soluble guanylyl 
cyclase beta 1 knockin (sGCβ1ki/ki) mice and sGCβ1+/+ mice (genetic background: mixed 
129/SvJ-C57BL/6J), developed and bred in the Department of Molecular Biomedical 
Research, Flanders Interuniversity Institute for Biotechnology, Ghent, Belgium. The Sixth 
series of experiments were performed on female C57BL/6J mice (Janvier). The animals were 
treated in accordance with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The mice 
were euthanized by cervical dislocation.  
 
VI.3.2. Blood vessel study 
VI.3.2.1. Tissue collection  
The thoracic aorta and femoral artery were carefully removed from the animals and 
transferred to cooled Krebs-Ringer bicarbonate (KRB) solution.  
 
VI.3.2.2. Tension measurements 
Ring segments of the collected arteries were mounted in a small-vessel myograph with a 
tissue chamber filled with 10 ml of KRB solution and were cleansed from adhering tissue. 
Two stainless steel wires (40 µm diameter) were guided through the lumen of the segments. 
One wire was fixed to a force-displacement transducer and the other was connected to a 
micrometer. After mounting, the preparations were allowed to equilibrate for 30 min in the 
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KRB solution bubbled with 95% O2-5% CO2 (pH 7.4) at 37 °C. The aortic rings were 
gradually stretched until a stable preload of 0.5 g was obtained, whereas the femoral arteries 
were set to their normalized internal diameter15. In short, the arteries were stretched in 
progressive steps. From the passive wall tension-internal circumference relationship obtained 
by these measurements, the artery was stretched to a diameter corresponding to 90% of the 
diameter the vessel would have under a transmural pressure of 100 mm Hg.  
After applying the optimal resting tension, the preparations were contracted (1 till 3 times) 
with a KRB solution containing 120 mmol/L K+ and 5 µmol/L norepinephrine (NOR), 
washed, and allowed to relax to basal tension before starting the protocol. Precontraction was 
elicited with prostaglandin (30 µmol/L PGF2α, unless mentioned otherwise). When a stable 
contraction plateau was obtained, cumulative concentration-response curves were obtained by 
increasing the concentration in log increments, once the response to the previous 
concentration had stabilized. Relaxation responses to Acetylcholine (ACh), Sodium 
nitroprusside (SNP), BAY 41-2272, 8-pCPT-cGMP and forskolin were examined in varying 
order. The concentration-response curves to ACh and SNP were repeated on vessel segments 
in which a comparable level of precontraction was obtained in preparations from the sGCβ1+/+ 
and sGCβ1ki/ki mice. Therefore, a concentration-response curve to PGF2α was obtained on the 
sGCβ1ki/ki and sGCβ1+/+ vessel segments from which the adequate concentration was deduced. 
To analyse the differences in contractile responses between preparations from sGCβ1+/+ and 
sGCβ1ki/ki mice, a single dose (tetraethylammonium chloride (TEA)) or increasing 
concentrations (NOR, PGF2α, methoxamine and Bay k 8644) of the vasoconstrictor were 
added to the preparations at a stable resting tension. The cumulative concentration-response 
curves to NOR, PGF2α, methoxamine and Bay k 8644 were determined by a stepwise increase 
in the concentration of the contractile substance as soon as a steady response to the preceding 
concentration had been obtained. The concentration-response curve to NOR was repeated in 
the presence of HA-1077 (10 µmol/L, 15 minutes preincubation) or ODQ (1 µmol/L, 20 
minutes preincubation). The cumulative concentration-response curve to K+ was made by 
replacing the KRB solution by a modified KRB solution containing 30, 60 or 120 mmol/l K+ 
(changes in the KCl concentration of the KRB solution were compensated by equimolar 
adjustment of the NaCl concentration). Segments of sGCβ1ki/ki and sGCβ1+/+ mice were 
always tested in parallel. 
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VI.3.3. Corpora cavernosa study 
VI.3.3.1. Tissue collection  
The penile tissue was dissected free by removal of connective and adventitial tissues along the 
shaft of the penis, the dorsal arteries, dorsal vein, corpus spongiosum, urethra and glans penis. 
Then, the corpora cavernosa (CC) were separated by cutting the fibrous septum between them 
and were excised at the base. They were kept in cooled Krebs-Ringer bicarbonate (KRB) 
solution until mounting. 
 
VI.3.3.2. Tension measurements 
Of each mouse, one corpus cavernosum was mounted horizontally in a myograph with one 
end fixed to a force-displacement transducer and the other to a micrometer. The tissue 
chambers contained 10 ml KRB solution at 37 °C (pH 7.4) equilibrated with 95% O2-5% 
CO2. The preparations were preloaded with 0.45 g of tension and allowed to equilibrate for 60 
minutes in bath fluid that was frequently replaced with fresh KRB solution. The preparations 
were 3 times contracted with 5 µmol/L norepinephrine (NOR), washed, and allowed to relax 
to resting tension before starting the protocol. When the pre-contraction response (5 µmol/L 
NOR) reached a stable level, electrical field stimulation (EFS: train duration 20s or 40s; 
frequency: 1,2,4 and 8 Hz; pulse duration: 5 ms; 80 V), delivered by a Grass stimulator via 
two parallel platinum electrodes, was applied to the tissue. Additionally, the relaxant response 
to a single concentration of ACh and cumulative concentration-response curves to SNP, NO 
gas, HA-1077 and 8-pCPT-cGMP were investigated after NOR-induced precontraction. The 
contractile effect of NOR was assessed by adding increasing concentrations of NOR at a 
stable resting tension. In between the concentration-response curves, the CC were washed and 
allowed to recover for 20-30 min. Corporal tissues of sGCβ1ki/ki and sGCβ1+/+ mice were 
always tested in parallel. At the end of the experiments, tissues were lightly patted dry and 
weighed. 
 
VI.3.4. Drugs 
The experiments were performed in a KRB solution of the following composition (mmol/L): 
NaCl, 135; KCl, 5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and 
EDTA, 0.026 in H2O. Acetylcholine chloride (ACh), forskolin, 8-(4-chlorophenylthio)-
guanosine 3’,5’-cyclic monophosphate (8-pCPT-cGMP), methoxamine hydrochloride, HA-
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1077 dihydrochloride, tetraethylammonium chloride (TEA), Bay k 8644, 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and norepinephrine bitartrate (NOR) were 
obtained from Sigma-Aldrich (St.Louis, MO), BAY 41-2272 from Alexis (San Diego, USA) 
and sodium nitroprusside (SNP) from Merck (Darmstadt, Germany). BAY 41-2272 and ODQ 
were dissolved in dimethylsulfoxide, Bay k 8644 in ethanol and ACh in 50 mmol/L potassium 
hydrogen phtalate buffer, pH 4.0. The other drugs were dissolved in distilled water. Saturated 
NO solution was prepared from gas (Air liquide, Belgium) as described by Kelm & Schrader 
16
. All concentrations are expressed as final molar concentrations in the organ bath. The final 
concentration of dimethylsulfoxide or ethanol in the organ bath never surpassed 0.1%. 
 
VI.3.5. Calculations and statistics 
Data are presented as mean values ± SEM; n represents the number of preparations (each 
obtained from a different mouse). In the figures, relaxations are expressed as a percentage of 
the pre-contraction tone developed by the addition of the precontractile agent, whereas in the 
results section, relaxations are expressed in terms of percentage decrease of the pre-
contraction tone. Contractions are expressed in mN. The reduction or the remaining part of a 
response in the preparations of the transgenic mice is expressed in term of percentage 
relatively compared to the response in the preparations of the corresponding control mice.  
Statistical significance was evaluated using Student’s t-test for paired and unpaired 
observations (SPSS, version 12). P < 0.05 was considered as significant. The estimated 
maximum relaxation (Emax) and the negative logarithm of the concentration producing 50% of 
the maximal effect (pEC50) were calculated using nonlinear regression curve fit (GraphPad 
Prism, version 4).  
 
VI.4. Results 
VI.4.1. Blood vessel study 
VI.4.1.1. First set of experiments 
In a first series of experiments, the relaxing effect of ACh, SNP en BAY 41-2272 were 
investigated on precontracted (30 µmol/L PGF2α) aortic (ACh: Fig. VI.1A; SNP: Fig. VI.1C; 
BAY 41-2272: Fig. VI.1E) and femoral artery rings (ACh: Fig. VI.1B; SNP: Fig. VI.1D; 
BAY 41-2272: Fig. VI.1F) isolated from male sGCβ1+/+ and sGCβ1ki/ki mice.  
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The endothelium-dependent vasodilator ACh (1 nmol/L–10 µmol/L) elicited a 
concentration-dependent response in the sGCβ1+/+ vessel segments, whereas in the aortic rings 
of the sGCβ1ki/ki mice, this response was completely abolished. Also in the sGCβ1ki/ki femoral 
artery segments, the ACh-evoked response was markedly impaired (the response induced by 
10 µmol/L ACh was reduced by 61.05 %) compared to the femoral artery rings from the 
sGCβ1+/+ mice.  
When added cumulatively to the bathing medium, the NO-donor SNP (1 nmol/L–10 µmol/L) 
elicited a concentration-dependent relaxation in the aortic and femoral artery rings of the 
sGCβ1+/+ mice. In the aorta from sGCβ1ki/ki mice, the relaxant effect of SNP was completely 
eliminated, while in the corresponding femoral artery rings a significantly reduced response to 
SNP was observed (the response induced by 10 µmol/L SNP was reduced by 56.37%).  
The cumulative addition of BAY 41-2272 (1 nmol/L–10 µmol/L), an NO-independent sGC-
stimulator, resulted in a concentration-dependent response in the aortic and femoral artery 
rings of the sGCβ1+/+ mice. In the sGCβ1ki/ki aortic rings, only a concentration of 10 µmol/L 
BAY 41-2272 had a minor relaxing influence. The femoral artery from the sGCβ1ki/ki mice, 
showed a reduced sensitivity as compared to sGCβ1+/+ preparations (pEC50: 7.57±0.48 for 
sGCβ1+/+ vs. 6.06±0.24 for sGCβ1ki/ki (n=4, P<0.05)). The estimated maximal response to 
BAY 41-2272 in both sGCβ1+/+ and sGCβ1ki/ki femoral arteries was comparable (Emax: 94.8%± 
3.17 for sGCβ1+/+ vs. 97.18%±2.82 for sGCβ1ki/ki (n=4, P>0.05).  
Additionally, we examined the NOR-induced constriction in the aortic and femoral artery 
rings of male sGCβ1+/+ and sGCβ1ki/ki mice (data not shown). The concentration-response 
curve to NOR (10 nmol/L–10 µmol/L) showed a remarkable upward shift (indicated by an 
increase in estimated maximal contractile response: 1.57 mN±0.7 for sGCβ1+/+ vs. 23.52 
mN±1.47 for sGCβ1ki/ki (n=5, P<0.05)) in the aortic rings from the sGCβ1ki/ki mice in 
comparison to the corresponding sGCβ1+/+ rings. Also the femoral artery rings of the 
sGCβ1ki/ki mice showed an increased contractile response to NOR (10 µmol/L NOR: 2.94 
mN±0.19 vs. 8.27 mN±1.17 (n=3, p<0.05)). This increased contractile responsiveness of the 
sGCβ1ki/ki mice was also observed in the contractions that are elicited by the combination of a 
KRB solution containing 120 mmol/L K+ and 5 µmol/L NOR applied repeatedly on the 
vessel segments before starting the protocol. The first as well as the third time, the contractile 
response was significantly higher in the aorta and femoral artery from the sGCβ1ki/ki mice 
compared to the matching sGCβ1+/+ rings. The difference in contraction level between 
sGCβ1+/+ and sGCβ1ki/ki mice was significantly more pronounced in the aortas than in the 
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femoral arteries (first response to K120 and 5 µmol/L NOR: 2.03 mN±1.13 for the femoral 
artery vs.12.89 mN±1.25 for the aorta; third response to K120 and 5 µmol/L NOR: 2.3 
mN±0.96 for the femoral artery vs.17.67 mN±2.31 for the aorta (n=4-6, P<0.05)).  
 
 
 
Figure VI.1: Relaxation effect of ACh (A, B), SNP (C, D) and BAY 41-2272 (E, F) on precontracted 
(30 µmol/L PGF2α) aortas (A, C, E) (n=6) and femoral arteries (B, D, F) (n=4) from male sGCβ1+/+ and 
sGCβ1ki/ki mice. *(sGCβ1+/+ vs. sGCβ1ki/ki): P<0.05.  
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VI.4.1.2. Second set of experiments 
In a separate series of experiments, the relaxing influence of ACh (1 nmol/L–10 µmol/L), 
SNP (1 nmol/L–10 µmol/L) and the cell permeable cGMP analogue 8-pCPT-cGMP (100 
nmol/L–0.1 mmol/L) (were examined on aortic (ACh: Fig. VI.2A; SNP: Fig. VI.2C; 8-pCPT-
cGMP: Fig. VI.7A) and femoral artery (ACh: Fig. VI.2B; SNP: Fig. VI.2D; 8-pCPT-cGMP: 
Fig. VI.7B) segments in which the concentration of PGF2α was adjusted to obtain a similar 
precontraction level in female sGCβ1ki/ki and sGCβ1+/+ vessel segments (precontraction level 
of the concentration-response curve to ACh : aortic rings: 19.64 mN±0.57 for sGCβ1+/+ vs. 
19.43 mN±1.68 for sGCβ1ki/ki (n=4, P>0.05), femoral artery: 14.74 mN±0.93 for sGCβ1+/+ vs. 
13.48 mN±0.87 for sGCβ1ki/ki (n=4, P>0.05); precontraction level of the concentration-
response curve to SNP : aortic rings: 18.59 mN±0.56 for sGCβ1+/+ vs. 20.34 mN±1.66 for 
sGCβ1ki/ki (n=4), P>0.05), femoral artery: 13.65 mN±1.1 for sGCβ1+/+ vs. 13.30 mN±1.01 for 
sGCβ1ki/ki (n=4), P>0.05). The ACh and SNP-induced concentration-dependent relaxation 
was completely abolished in the aortic rings of the sGCβ1ki/ki mice and nearly completely 
abolished in the femoral artery rings of the sGCβ1ki/ki mice.  
8-pCPT-cGMP induced a concentration-dependent relaxation of the femoral arteries and 
aorta from female sGCβ1+/+ and sGCβ1ki/ki mice. The sGCβ1+/+ and sGCβ1ki/ki femoral arteries 
responded to 8-pCPT-cGMP in a similar way (pEC50: 5.81±0.47 for sGCβ1+/+ vs. 5.03±0.12 
for sGCβ1ki/ki (n=4, P>0.05); Emax: 89.82%±6.10 for sGCβ1+/+ vs. 94.63%±4.22 for sGCβ1ki/ki 
(n=4, P>0.05)), whereas in the aortic rings, the 8-pCPT-cGMP-induced response was 
somewhat reduced in the sGCβ1ki/ki mice (pEC50: 5.27±0.59 for sGCβ1+/+ vs. 4.30±0.17 for 
sGCβ1ki/ki (n=4, P>0.05); Emax: 84.28%±10.39 for sGCβ1+/+ vs. 64.54%±13.89 for sGCβ1ki/ki 
(n=4, P>0.05)).  
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Figure VI.2: Relaxation effect of ACh (A, B), SNP (C, D) on precontracted (adjusted concentration of 
PGF2α) aortas (A, C) (n=4) and femoral arteries (B, D) (n=4) from female sGCβ1+/+ and sGCβ1ki/ki mice 
(similar precontraction level between sGCβ1+/+ and sGCβ1ki/ki arteries). *(sGCβ1+/+ vs. sGCβ1ki/ki): 
P<0.05.  
 
VI.4.1.3. Third set of experiments 
In another subset of experiments the contractile effect of NOR, PGF2α, K+ and methoxamine 
were investigated on aortic (NOR: Fig. VI.3A; methoxamine: Fig. VI.3B; PGF2α: Fig. VI.3C; 
K+: Fig. VI.3D) and femoral artery rings (NOR: Fig. VI.4A; methoxamine: Fig. VI.4B; 
PGF2α: Fig. VI.4C; K+: Fig. VI.4D) from male (data not shown) and female sGCβ1+/+ and 
sGCβ1ki/ki mice. Additionally, the response to 10 µmol/L ACh was assessed in these 
preparations.  
Rings from both sGCβ1+/+ and sGCβ1ki/ki mice responded to NOR (aorta: 1 nmol/L–1 µmol/L; 
femoral artery: 1 nmol/L–10 µmol/L) in a concentration-dependent way. The NOR-induced 
concentration-response curve in the sGCβ1ki/ki aortic rings was shifted to the left as compared 
with the aortic segments of the sGCβ1+/+ mice. Consequently, pEC50 was significantly higher 
in the aortic segments of the sGCβ1ki/ki mice (Table VI.1). In the aortic rings of the female 
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sGCβ1ki/ki mice also the estimated maximum response to NOR was significantly higher (Table 
VI.1). Also in the femoral artery rings of sGCβ1ki/ki mice, the contractile effect of NOR was 
significantly enhanced (response induced by 10 µmol/L NOR was augmented with 34.72% 
and 44.67% in males and females respectively). The results were essentially similar in both 
genders.  
The α1-receptor agonist methoxamine (10 nmol/L–0.1 mmol/L) increased the tone of the 
sGCβ1+/+ and sGCβ1ki/ki preparations in a concentration-dependent way. The methoxamine-
induced concentration-response curve of the sGCβ1ki/ki aortic rings was shifted to the left with 
a significant higher pEC50 (Table VI.1). Also the estimated maximal response to methoxamine 
was significantly higher in the sGCβ1ki/ki aortic rings (Table VI.1). Contractions in response to 
methoxamine were comparable in the femoral arteries from female sGCβ1+/+ and sGCβ1ki/ki 
mice. The results were essentially similar in both genders. 
PGF2α (aorta: 100 nmol/L–10 µmol/L; femoral artery: 100 nmol/L–30 µmol/L) had a 
concentration-dependent contractile effect in the vessel segments of sGCβ1+/+ and sGCβ1ki/ki 
mice. But, the aortic rings of sGCβ1ki/ki mice exhibited a greater sensitivity to PGF2α 
compared with sGCβ1+/+ mice, with a significant higher pEC50 (Table VI.1). The estimated 
maximum response to PGF2α was however comparable between the aortas of sGCβ1+/+ and 
sGCβ1ki/ki mice (Table VI.1). In the femoral arteries of sGCβ1ki/ki mice, the concentration-
response curve to PGF2α was not significantly altered as compared to the sGCβ1+/+ 
preparations. No differences in the response to PGF2α were obtained between male and female 
preparations. 
Administration of increasing concentrations of K+ (30, 60 and 120 mmol/L) resulted in a 
concentration-dependent contraction of the sGCβ1+/+ and sGCβ1ki/ki preparations. Yet, in the 
sGCβ1ki/ki aortic rings, the contractile effect of 30 mmol/L K+ was significantly enhanced with 
46.11% and 56.61% in male and female mice respectively. Moreover, in the aortic segments 
of the female sGCβ1ki/ki mice, the responses to 60 and 120 mmol/L were also significantly 
increased. The femoral artery rings of both sGCβ1+/+ and sGCβ1ki/ki mice responded to K+ in a 
similar way. The contractile activity of K+ was essentially similar in both genders. 
The addition of a single concentration of ACh (10 µmol/L) resulted in a minor relaxation of 
the sGCβ1ki/ki femoral arteries as compared to the sGCβ1+/+ preparations (response to 10 
µmol/L ACh: male: 60.54% ±3.13 for sGCβ1+/+ vs. 18.67% ±14.44 for sGCβ1ki/ki (n=5, 
p<0.05); female: 88.60%±3.59 for sGCβ1+/+ vs. 15.09% ±6.63 for sGCβ1ki/ki (n=6, p<0.05)), 
whereas in the aortic rings of the sGCβ1ki/ki mice, no response was obtained. No differences in 
the ACh-induced response were observed between the male and female preparations. 
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Table VI.1: pEC50 and Emax for NOR, PGF2α and methoxamine in the aorta of sGCβ1+/+ and sGCβ1ki/ki 
mice. 
 
 
 
Figure VI.3: Cumulative concentration-response curve to NOR (A), methoxamine (B), PGF2α 
(C) and K+ (D) in aortas from female sGCβ1+/+ and sGCβ1ki/ki mice *(sGCβ1+/+ vs. sGCβ1ki/ki): 
P<0.05, (n=5-6). 
 pEC50  Emax (mN) 
 sGCβ1+/+ sGCβ1ki/ki  sGCβ1+/+ sGCβ1ki/ki 
NOR 7.35 ± 0.05 (n=6) 
8.27 ± 0.09 * 
(n=6) 
 13.53 ± 2.48 
(n=6) 
21.12 ± 1.02 * 
(n=5) 
PGF2α 5.64 ± 0.09 (n=6) 
6.31 ± 0.1 *  
(n=5) 
 23.05 ± 1.01  
(n=6) 
23.43 ± 1.26  
(n=5) ♀ 
Methoxamine 5.09 ± 0.23 (n=6) 
6.38 ± 0.09 * 
(n=6) 
 15.76 ± 1.28  
(n=6) 
21.14 ± 0.87 * 
(n=6) 
NOR 7.33 ± 0.17 (n=5) 
8.13 ± 0.07 * 
(n=6) 
 13.51 ± 2.98 
(n=5) 
19.68 ± 0.75  
(n=6) 
PGF2α 5.7 ± 0.07 (n=6) 
6.22 ± 0.03 * 
(n=6) 
 21.73 ± 1.37 
(n=6) 
21.6 ± 1.02  
(n=6) ♂ 
Methoxamine 5.32 ± 0.18 (n=6) 
6.16 ± 0.06 * 
(n=5) 
 15.81 ± 1.98 
(n=6) 
19.56 ± 1.01  
(n=5) 
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Figure VI.4: Cumulative concentration-response curve to NOR (A), methoxamine (B), PGF2α (C) and 
K+ (D) in femoral arteries from female sGCβ1+/+ and sGCβ1ki/ki mice *(sGCβ1+/+ vs. sGCβ1ki/ki): P<0.05, 
(n=6). 
 
VI. 4.1.4. Fourth set of experiments 
In this series of experiments, we explored the influence of the Rho kinase inhibitor HA-
1077 on the contractile effect of NOR in the aortic (Fig. VI.5A) and/or femoral artery rings 
(Fig. VI.5B) from male and/or female sGCβ1+/+ and sGCβ1ki/ki mice (male and female mice 
were pooled). In addition, increasing concentrations of the L-type Ca2+-channel agonist Bay 
k 8644 (Fig. VI.5C) and a single dose of the K+-channel blocker TEA were added to the 
aortic (TEA: Fig. VI.6C) and/or femoral artery rings (TEA: Fig. VI.6D) from male and/or 
female sGCβ1+/+ and sGCβ1ki/ki mice (male and female mice were pooled). 
Preincubation with HA-1077, resulted in a significant reduction of the NOR-induced response 
in the aortic and femoral artery preparations from both sGCβ1+/+ and sGCβ1ki/ki mice. 
Moreover, in the sGCβ1ki/ki femoral arteries, the significantly higher contractile effect of NOR 
observed in control conditions, is abolished in the presence of HA-1077.  
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Bay k 8644, an agonist of L-type Ca2+-channels, almost failed to induce a contraction in the 
aortic rings from the sGCβ1+/+ mice, whereas in the sGCβ1ki/ki aortic rings, Bay k 8644 elicited 
a strong and concentration-dependent contractile effect.  
The addition of 1 mmol/L TEA to the aortic rings from sGCβ1+/+ and sGCβ1ki/ki mice (male 
and female mice were pooled) at a stable resting tension, resulted in a sustained contraction of 
both sGCβ1+/+ and sGCβ1ki/ki aortic rings. However, the TEA-induced response was 
significantly higher in the aortic segments of the sGCβ1ki/ki mice compared to the sGCβ1+/+ 
aortas (response to 1 mmol/L TEA: 1.4 mN±0.49 for sGCβ1+/+ vs. 14.61 mN±0.55 for 
sGCβ1ki/ki (n=6, P<0.05)). In the femoral arteries, TEA induced a transient augmentation of 
the basal tone, with a similar peak contraction in both sGCβ1+/+ and sGCβ1ki/ki mice.  
 
 
 
Figure VI.5: Cumulative concentration-response curve to NOR in the aorta (A) (n=5) and femoral 
artery (B) (sGCβ1+/+: n=3 and sGCβ1ki/ki: n=5) from male and female sGCβ1+/+ and sGCβ1ki/ki mice in 
control conditions (▲and ∆) and in the presence of HA-1077 (● and ○). Cumulative concentration-
response curve to Bay k 8644 in aortas (C) (n=6) from male and female sGCβ1+/+ and sGCβ1ki/ki mice.  
*(sGCβ1+/+ vs. sGCβ1ki/ki), +(sGCβ1+/+ vs. sGCβ1ki/ki both in the presence of HA-1077), #(-HA 1077  
vs. +HA-1077 for sGCβ1+/+ mice), §(-HA-1077 vs. +HA-1077 for sGCβ1ki/ki mice): P<0.05. 
Data from male and female animals were pooled. 
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Figure VI.6: Contractile effect of TEA (1 mmol/L) on aortic rings (A, C) and femoral arteries (B, D)  
from male and female sGCβ1+/+ and sGCβ1ki/ki mice. *(sGCβ1+/+ vs. sGCβ1ki/ki): P<0.05, (n=5-6). Data  
from male and female animals were pooled. 
 
VI.4.1.5. Fifth set of experiments 
sGC-independent vasorelaxation was explored with a concentration-response curve to 8-
pCPT-cGMP (see second set of experiments and Fig. VI.7A, B). Additionally, the relaxing 
influence of forskolin, which stimulates adenylyl cyclase and increases the concentration of 
cAMP, was examined on aortic rings (Fig. VI.7C) and femoral arteries (Fig. VI.7D) from 
male and/or female sGCβ1+/+ and sGCβ1ki/ki mice (male and female mice were pooled).  
Forskolin produced concentration-dependent relaxations in the aortic and femoral artery 
preparations from sGCβ1+/+ and sGCβ1ki/ki mice. In the aortic rings from the sGCβ1ki/ki mice, 
10 µmol/L forskolin had a biphasic vasorelaxing effect: an initial fast phase of relaxation with 
an average duration of 8.4 ±0.52 minutes (n=4), followed by a slow phase. For the sGCβ1ki/ki 
aortic rings, the concentration-response curve to forskolin is in case of the highest 
concentration, drawn up with the data from the first, fast phase. The concentration-response 
curve to forskolin is significantly shifted to the right in the aortic rings from the sGCβ1ki/ki 
mice compared to the sGCβ1+/+ aortas, as indicated by the significantly reduced pEC50 and 
estimated maximum response in the former (pEC50: 6.7±0.07 vs. 6.22±0.11 (n=5, P<0.05); 
Emax: 96.91%±1.0 vs. 58.53%±10.16 (n=5, P<0.05)). In the femoral artery segments, the 
forskolin-induced response is not significantly reduced in the sGCβ1ki/ki mice. On the contrary, 
de concentration-response curve to forskolin is slightly shifted to the left in the femoral artery 
rings from the sGCβ1ki/ki mice, with a significant higher response in the sGCβ1ki/ki femoral 
arteries at a concentration of 100 nmol/l forskolin. 
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Figure VI.7: Relaxation effect of 8-pCPT-cGMP (A, B) (n=4) and forskolin (C, D) (n=5) on 
precontracted 30 µmol/L PGF2α) aortas (A, C) and femoral arteries (B, D) from female (8-pCPT-
cGMP) (data from male and female animals were pooled in case of forskolin) sGCβ1+/+ and sGCβ1ki/ki 
mice.
 
*(sGCβ1+/+ vs. sGCβ1ki/ki): P<0.05, (n=7-15). 
 
VI.4.1.6. Last set of experiments 
We explored the influence of the sGC inhibitor ODQ on the concentration-response curve to 
NOR (1 nmol/L–10 µmol/L) in the aorta (Fig. VI.8A) and femoral artery (Fig. VI.8B) isolated 
from female mice with a C57BL/6J background. The preincubation with ODQ resulted in a 
significant increase in tone in the aorta (10 µmol/L NOR: 3.06mN±1.16 for -ODQ vs. 
12.83mN±1.28 for +ODQ (n=6, P<0.05) and femoral artery (10 µmol/L NOR: 6.24mN±0.95 
for -ODQ vs. 13.85mN±0.86 for +ODQ (n=6, P<0.05)). This increase in contraction level was 
comparable in both vessels (∆ (-ODQ vs. +ODQ) 10 µmol/L NOR: 9.78mN±0.74 for aorta 
vs. 7.61mN±0.86 for femoral artery (n=6, P>0.05)). 
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Figure VI.8: Effect of ODQ (1 µmol/L) on the concentration-response curve to NOR in the aorta (A) 
and femoral artery (B) of female C57BL/6J mice. *(control conditions vs. the presence of ODQ): 
P<0.05, (n=6). 
 
VI.4.2. Corpora cavernosa study 
The vasorelaxing influence of endothelium-derived NO was examined by the addition of 10 
µmol/L ACh (Fig. VI.9A) to the NOR-contracted CC preparations of sGCβ1+/+ and sGCβ1ki/ki 
mice. ACh substantially relaxed CC tissues from the sGCβ1+/+ mice, but contracted the CC 
tissues from the sGCβ1ki/ki mice. 
Neuronal NO was released by stimulation of the intrinsic nerves by EFS (Fig. VI.9B) (1, 2, 4 
and 8 Hz). In the sGCβ1+/+ CC preparations, EFS generated frequency-dependent relaxant 
responses. No relaxation in response to EFS was observed in the NOR-contracted CC 
preparations from sGCβ1ki/ki mice. In contrast, contractions were observed, starting from a 
frequency of 4 Hz.  
Exogenously derived NO from the NO-donor SNP (1 nmol/L–10 µmol/L) (Fig. VI.9C), 
relaxed the CC tissues from both sGCβ1+/+ and sGCβ1ki/ki mice in a concentration-dependent 
way. The SNP-induced response was significantly reduced in the CC preparations of the 
sGCβ1ki/ki mice.  
Addition of NO-gas (1 µmol/L–0.1 mmol/L) (Fig. VI.9D) induced concentration-dependent 
and rapid relaxations in NOR-contracted preparations from both sGCβ1+/+ and sGCβ1ki/ki mice. 
But, in the sGCβ1ki/ki CC preparations, the relaxation evoked by NO-gas was significantly 
impaired.  
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BAY 41-2272 (1 nmol/L–10 µmol/L) (Fig. VI.10A), stimulating sGC in a NO-independent 
way, produced concentration-dependent relaxations in the sGCβ1+/+ and sGCβ1ki/ki CC tissues. 
In the sGCβ1ki/ki CC, the relaxant effect of BAY 41-2272 is slightly but significantly 
attenuated.  
The concentration-dependent relaxation induced by the cGMP analogue, 8 pCPT-cGMP 
(Fig. 10C) was not different in CC from sGCβ1+/+ and sGCβ1ki/ki mice.  
HA-1077, a Rho-kinase inhibitor (Fig. VI.10D), produced concentration-dependent 
relaxations with similar potency in NOR-contracted CC preparations from sGCβ1+/+ and 
sGCβ1ki/ki mice.  
The concentration-response curve to NOR (Fig. VI.10B) was not significantly altered in the 
CC from the sGCβ1ki/ki mice (pEC50: 6.83±0.13 for sGCβ1+/+ vs. 5.82±0.21 for sGCβ1ki/ki (n=5, 
P>0.05); Emax: 1.89mN±0.43 for sGCβ1+/+ vs. 1.79mN±0.46 for sGCβ1ki/ki (n=5, P>0.05)). 
 
 
 
Figure VI.9: Relaxation effect of ACh (A), EFS (B), SNP (C) and NO-gas (D) on precontracted (50 
µmol/L NOR)
 
CC from sGCβ1+/+ and sGCβ1ki/ki mice. *(sGCβ1+/+ vs. sGCβ1ki/ki): P<0.05, (n=8).  
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Figure VI.10: Relaxation effect of BAY 41-2272 (A), 8-pCPT-cGMP (C) and HA-1077 (D) on 
precontracted (50 µmol/L NOR)
 
CC from sGCβ1+/+ and sGCβ1ki/ki mice. Cumulative concentration-
response curve to NOR (B) in CC from sGCβ1+/+ and sGCβ1ki/ki mice. *(sGCβ1+/+ vs. sGCβ1ki/ki): 
P<0.05, (n=5-8).  
 
VI.5. Discussion 
As NO receptor, sGC plays an important role in numerous physiological processes, thus 
representing a very attractive pharmacological target. Moreover, the presence of two 
physiologically active isoforms of sGC, offers a potentially more selective therapeutical 
approach. Therefore, a quantification of the physiological importance of the different sGC 
isoforms is of substantial interest. In previous studies, using sGCα1-/- mice 1, 2, we established 
that in vascular and penile smooth muscle relaxation the predominant sGCα1β1 isoform is a 
very important, though not the only target of NO-dependent and NO-independent sGC 
activators. The involvement of the less abundantly expressed sGCα2β1 isoform as well as (an) 
sGC-independent mechanisms could be argued. In the present study, in which we used NO-
insensitive sGC mutant mice, the issue whether sGCα2β1 and/or (an) sGC-independent 
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mechanisms participate in vascular and penile smooth muscle relaxation, was further 
unravelled.  
In the aortic rings from the sGCβ1ki/ki mice, the response to endogenous (induced by ACh) and 
exogenous NO (induced by SNP) was completely abolished, indicating that in the aorta sGC 
is the sole receptor for NO. This observation, allows us to conclude that the remaining effect 
of ACh (remaining effect of 10 µmol/L ACh: 23.24% 1) and of SNP (remaining effect of 10 
µmol/L SNP: 73.45% 1) in the sGCα1-/- aortic rings, is due to the activation of sGCα2β1. In 
contrast with the aortic rings,
 
the femoral arteries from the sGCβ1ki/ki mice showed a 
significantly reduced but not completely blocked response to endogenous and exogenous NO, 
suggesting that NO in this preparation also signals via an alternative, sGC-independent target. 
The response to ACh is slightly more impaired in the femoral arteries from the sGCβ1ki/ki mice 
compared to the sGCα1-/- mice (impairment of the response to 10 µmol/L ACh: 43.75% for 
sGCα1-/- 1 vs. 61.05% for sGCβ1ki/ki), whereas the relaxant effect of SNP is considerably more 
reduced in the femoral arteries from the sGCβ1ki/ki mice compared to the sGCα1-/- mice 
(impairment of the response to 10 µmol/L SNP: 13.89% for sGCα1-/- 1 vs. 56.37% for 
sGCβ1ki/ki). This suggests that activation of sGCα2β1 is more significant in the response to 
exogenous NO than in the response to endogenous NO. 
The involvement of (an) sGC-independent mechanism(s) is not only suggested by the 
observations on femoral arteries but also by the response to exogenous NO in the CC. This 
suggestion is based on the fact that a substantial effect of SNP and NO-gas remains in the CC 
from the sGCβ1ki/ki mice compared to the CC in sGCβ1+/+ mice. The responses to SNP and 
NO-gas are more impaired in the sGCβ1ki/ki CC than in the CC from the sGCα1-/- mice 
(impairment of the response to 10 µmol/L SNP: 38.3% for sGCα1-/- 2 vs. 58.67% for 
sGCβ1ki/ki; 100 µmol/L NO-gas: 36.29% for sGCα1-/- 2 vs. 64.01% for sGCβ1ki/ki), suggesting 
that the response to exogenous NO is partly mediated by the sGCα2β1 isoform. In contrast to 
the response induced by exogenous NO, CC smooth muscle relaxation induced by 
endogenous NO is completely mediated through activation of sGC, as shown by the total loss 
of response to ACh and EFS in the sGCβ1ki/ki CC. This finding is in line with the suggestion 
of our study on sGCα1-/- mice where we found that in the CC, sGCα1β1 is the sole receptor for 
endogenously produced NO 2. 
During our experiments it became apparent that the sGCβ1ki/ki arteries exhibited a significant 
stronger response to NOR compared to the sGCβ1+/+ preparations. In order to exclude a 
possible influence of the higher precontraction tone of the sGCβ1ki/ki arteries on the NO-
mediated vasorelaxation, concentration-response curves to ACh and SNP were obtained in 
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which the precontraction of preparations from sGCβ1+/+ and sGCβ1ki/ki mice was set to a 
similar supramaximal level. Under these conditions, the vasorelaxing influence of ACh and 
SNP was completely abolished in both the aortic and femoral artery rings from the sGCβ1ki/ki 
mice. These data on the femoral arteries did not correspond with the observations in our first 
series of experiments and reject the conclusion of sGC-independent effect of NO in those 
vessels. It should however be mentioned that besides the precontraction level, there were also 
other differences between these series of experiments. The first NO-induced responses were 
examined on vessel segments from male sGCβ1+/+ and sGCβ1ki/ki mice of 7 to 10 weeks old, 
whereas for the following concentration-response curves only older mice (12 to 13 weeks) of 
the female sex were used. Moreover, the younger animals had a weaker state of health and 
related to this a higher mortality at early age. Because of the age and gender variations 
between the mice used to explore the vasorelaxing effect of NO, the response to 10 µmol/L 
ACh was reassessed on aortic and femoral artery rings from sGCβ1+/+ and sGCβ1ki/ki mice of 
both genders and with a broader range of age (9 to 12 weeks). ACh was not able to relax the 
aortic rings from those sGCβ1ki/ki mice, whereas the sGCβ1ki/ki femoral arteries still showed a 
minor response to ACh. Those data confirm our first suggestion that is that in the aorta, sGC 
is the only target of NO regulating vasorelaxation, whereas in the femoral artery also (an) 
sGC-independent mechanism(s) participate in the NO-induced smooth muscle relaxation. 
Activation of Ca2+- and voltage-dependent potassium channels 17, 18, sarcoplasmic reticulum 
Ca2+-ATPase 19 and Na+/K+-ATPase 20 have been described as sGC-independent vasorelaxing 
actions of NO. Still, the remaining response to ACh in the femoral arteries could also point to 
the participation of the endothelium-derived hyperpolarising factor (EDHF), particularly since 
this non-prostanoid, non-nitric oxide factor has been reported to be play an important role in 
the endothelium-dependent relaxation of femoral arteries isolated from mice with a C57BL/6J 
background 21. No gender differences in the ACh-induced response were obtained, indicating 
that this is not the underlying cause for the variations in the responsiveness of the sGCβ1ki/ki 
femoral arteries towards NO.  
NO-independent sGC stimulators like BAY 41-2272 are emerging as valuable tools for the 
treatment of numerous pathologies caused by the reduced bioavailability and/or 
responsiveness to endogenously produced NO 22. Despite the fact that the sGC-activating 
effect of BAY 41-2272 is dependent on the presence of the reduced prosthetic heme moiety of 
sGC 23, BAY 41-2272 could still elicit a substantial response in the femoral arteries and CC 
isolated from the sGCβ1ki/ki mice. This suggests that in those tissues, BAY 41-2272 partly 
exerts its relaxant effect through (an) sGC-independent mechanism(s). BAY 41-2272 has 
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been reported to induce vasorelaxation independently from cGMP-production through 
activation of the Na+-K+-ATPase 24 and inhibition of the Ca2+-entry 25. As abolition of the 
sGCα1 subunit or of the NO-stimulated sGC activity decreased the response to BAY 41-2272 
in a similar way (response to 10 µmol/l BAY 41-2272: 18.28% 1 vs. 15.45%), only the 
sGCα1β1 isoform is suggested to be responsible for the sGC-dependent vasorelaxing effect of 
BAY 41-2272. This is also suggested by the observations with BAY 41-2272 on the CC, 
where similar results were obtained in the preparations from sGCβ1ki/ki and sGCα1-/- mice 
(impairment of the response to 10 µmol/L BAY 41-2272: 25.05% 2 vs. 29.78%). A significant 
part of the relaxing influence of BAY 41-2272 in the CC can be attributed to (an) sGC-
independent mechanism(s), since BAY 41-2272 elicited a substantial response in the 
sGCβ1ki/ki CC. The sGCβ1ki/ki aortic rings, on the other hand, only slightly responded to 10 
µmol/L BAY 41-2272. This was also the case in the aortic rings from the sGCα1-/-, however 
the 10 µmol/L BAY 41-2272-induced relaxation was less impaired in the sGCα1-/- aortas 
(impairment of the response to 10 µmol/L BAY 41-2272: 36.83% 1 vs. 82.81%). This 
indicates that at a concentration of 10 µmol/L, BAY 41-2272 mainly activates the sGCα2β1 
isoform whereas at lower concentrations, sGCα1β1 is the main target for BAY 41-2272. As in 
the sGCβ1ki/ki mice, the basal sGC-activity is not abrogated and BAY 41-2272 is known to 
inhibit the PDE-5 mediated hydrolysis of cGMP at concentrations of 10 µmol/L or higher 26, 
the remaining effect of BAY 41-2272 in the sGCβ1ki/ki preparations may be in part due to the 
accumulation of basally produced cGMP.  
The specificity of the impaired responses we found in the sGCβ1ki/ki preparations was assessed 
by a concentration-response curve to the cell permeable cGMP-analogue 8-pCPT-cGMP, to 
forskolin, which acts via activation of AC and/or to HA-1077, an Rho kinase inhibitor. The 
femoral artery and CC preparations from both sGCβ1+/+ and sGCβ1ki/ki mice responded to 8-
pCPT-cGMP in a similar way, indicating that the signaling cascade downstream of sGC 
functions normally. This can not be concluded for the aortic rings as the 8-pCPT-cGMP-
induced response is somewhat reduced in the sGCβ1ki/ki aortic rings. Moreover, the 
vasorelaxing effect of forskolin is also significantly impaired in the aortic rings from the 
sGCβ1ki/ki mice, whereas in the femoral arteries the response to forskolin is not altered. In 
addition, HA-1077 relaxed the CC preparations from both sGCβ1+/+ and sGCβ1ki/ki mice to a 
similar extent.  
The marked contractile activity of the sGCβ1ki/ki aortic rings, which will be discussed next, 
may be responsible for the somewhat impaired sGC-independent relaxation seen in the 
sGCβ1ki/ki aortas.  
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A number of reports to date have described the effect of the genetic background on the results 
of transgenesis and targeted gene disruption 27-29. Therefore, possible strain-specific 
differences between the sGCα1-/- (mixed background: Swiss-129/SvJ) and sGCβ1ki/ki (mixed 
background: 129/SvJ-C57BL/6J) mice must be considered for a correct interpretation and 
comparison of the data obtained from the two mice models.  
The absence of sGC that can be activated by NO, significantly influences the contractile 
activity of vascular smooth muscle. In the different subset of experiments, contraction 
induced by NOR, was significantly greater in both the aorta and femoral artery from male and 
female sGCβ1ki/ki mice, but not in CC. Particularly in the sGCβ1ki/ki aortic rings, the increased 
sensitivity towards NOR was very pronounced. NOR is known to induce arterial 
vasoconstriction through interaction with a mixed population of postjunctional vascular α1- 
and α2-adrenergic receptors. Stimulation of α2-adrenergic receptors can induce either an 
increase or decrease of vascular tone depending on the kind of vessel 30, 31 and on the location 
of the receptors 32. Since activation of endothelial α2-adrenergic receptors can induce the 
release of NO 33, 34, it could be that the augmented NOR-induced tone in the sGCβ1ki/ki 
preparations is due to the fact that NO produced in response to NOR, can no longer exert its 
sGC-dependent vasorelaxing influence in the sGCβ1ki/ki mice. Moreover, contractions to NOR 
in the aortic rings from α2A/D-adrenoreceptor knockout mice have been shown to be 
significantly increased 35. However, this can not be the sole cause as also the response to the 
selective α1-adrenoreceptor agonist methoxamine was significantly increased in the aortic 
rings of the sGCβ1ki/ki mice. This observation is in line with the fact that the α1-adrenergic 
receptors play a predominant role in the NOR-induced contraction of large noninnervated 
conductance arteries 36, 37 as well as small innervated vessels 38. Whatsoever, the significant 
higher NOR-evoked contraction in the sGCβ1ki/ki aortic rings can not be selectively linked to 
the α1-adrenergic receptors, as the sGCβ1ki/ki aortic rings are also more sensitive to PGF2α. 
Additionally,
 
depolarization of the vascular smooth muscle cells by increasing the external K+ 
concentration, also resulted in a significantly higher tone of the sGCβ1ki/ki aortic rings 
compared to the sGCβ1+/+ preparations. In contrast to the aortic rings, the femoral arteries 
from both sGCβ1+/+ and sGCβ1ki/ki mice responded to methoxamine, PGF2α and K+ in a similar 
way. Hence, the α2-adrenoreceptor-mediated NO release and relaxation is more likely to be 
involved in the NOR specific higher force development of the sGCβ1ki/ki femoral arteries. 
However, the fact that following treatment with the Rho-kinase inhibitor HA-1077, the 
contractile response to NOR in sGCβ1ki/ki femoral arteries closely resembled that of the 
sGCβ1+/+ femoral arteries, suggests a higher activity of the Ca2+ sensitization pathway as 
Chapter VI 
 188 
underlying case for the increased NOR-induced contraction in the sGCβ1ki/ki femoral arteries. 
However, as prostanoid receptor agonists like PGF2α have been reported to be preferentially 
involved in Ca2+ sensitization through activation of RhoA 39, 40, one would expect then that 
also the PGF2α-induced response is significantly higher in the femoral arteries from the 
sGCβ1ki/ki mice. Since this is not the case, the hypothesis of a higher Ca2+ sensitization 
pathway in sGCβ1ki/ki femoral arteries remains debatable. The data of the aorta rings, on the 
other hand, are more consistent. Preincubation with HA-1077 resulted in a stronger reduction 
of the NOR-induced contraction in the sGCβ1+/+ aortic rings compared to the sGCβ1ki/ki aortic 
rings, which does not support the involvement of the Ca2+ sensitization pathway. This is in 
line with the smaller efficiency of α-adrenoreceptor agonists compared to prostanoid receptor 
agonists to activate RhoA and thereby to induce Ca2+ sensitization of MLC20 phosphorylation 
39, 40
. Moreover, this corresponds with the finding that the increased tone of the sGCβ1ki/ki 
aortic rings compared to the sGCβ1+/+ aortic rings, is more pronounced in response to NOR 
than in response to PGF2α.  
When a receptor coupled to a heterotrimeric GTP binding protein is activated, Ca2+ 
sensitization as well as Ca2+ mobilization occurs. The Ca2+ reactivity of the sGCβ1ki/ki 
preparations was explored with the L-type Ca2+ channel agonist Bay k 8644 and by the TEA-
induced depolarization. Both substances provoke the influx of extracellular Ca2+ through 
voltage dependent Ca2+ channels. Bay k 4486 as well as TEA elicited significantly greater 
contractions in the sGCβ1ki/ki aortic rings than in the sGCβ1+/+ aortic rings, suggesting that the 
sGCβ1ki/ki aortic rings are more sensitive to cytosolic Ca2+. In contrast with the aortic rings, 
the femoral arteries do not show an indication towards an increased Ca2+ sensitivity as the 
femoral arteries from both sGCβ1+/+ and sGCβ1ki/ki mice responded to TEA in a similar way. 
Those data are not completely in line with the effect of HA-1077 on the NOR-induced 
contraction, from which we suggested that the sGCβ1ki/ki femoral arteries exhibited a higher 
RhoA kinase activity and the sGCβ1ki/ki aortic rings a lower. Besides Rho kinase also protein 
kinase C (PKC) is a major determinant for the Ca2+ sensitization in vascular smooth muscles 
41
. Therefore it can be hypothesized that the PKC-pathway is responsible for an enhanced 
contractile activity of the sGCβ1ki/ki aortic rings. However, our data indicate that in the 
sGCβ1ki/ki aortic rings, the contractile response is rather unselective, whereas in the 
corresponding femoral arteries it is less marked and rather specific for NOR. This discrepancy 
is perhaps related to the variable importance of basally released NO among vessel types. 
There are literature data on C57BL/6J mice showing that basal NO is massively produced in 
the aorta 42 and carotid artery, whereas in the femoral artery it is far less pronounced 21. 
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Knowing that there is cross talk between cAMP and cGMP 43, this higher amount of 
spontaneously released NO in the aortic rings could also explain the impaired forskolin-
induced response we have observed in the sGCβ1ki/ki aortic rings. In vitro, basal NO was 
shown to decrease the sensitivity towards NO-donors and its impact appeared to decline over 
time 21. Therefore, its possible influence on the vasomotor responses we have investigated 
should be considered. Still, preincubation of aortic rings and femoral artery segments (isolated 
from C57BL/6J mice) with ODQ, resulted in a comparable increase of the NOR-induced 
response in both vessel types, which is not completely in line with the findings on the 
heterogeneity in basal NO 21, 42. Furthermore, the findings on C57BL/6J mice can not be fully 
converted to our sGCβ1ki/ki mice, which have a mixed background (129/SvJ-C57BL/6J). 
Hence, we suggest that the enhanced contractile activity of the sGCβ1ki/ki preparations can not 
completely attributed to the abolished vasorelaxing influence of basal NO.  
 
VI.6. Conclusions 
This study provides evidence that in the aortic rings the response to NO is completely sGC-
dependent, whereas in the femoral arteries, also (an) sGC-independent mechanism(s) are 
involved. In contrast to endogenous NO and the NO-independent sGC stimulator BAY 41-
2272, that mainly activate the predominant sGCα1β1 isoform, exogenous NO mainly activates 
the minor sGCα2β1 isoform. In the CC, on the other hand, sGCα1β1 is the main target for 
endogenous NO, BAY 41-2272 as well as exogenous NO. Furthermore, we found that the 
arteries from the sGCβ1ki/ki mice exhibited a higher contractile activity, which to some extent 
could be explained by the incapability to respond to basal endothelial NO. 
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VII.1. General discussion and future perspectives 
Although both sGC and its product cGMP, were identified in the 1960’s, it has been only 
within the last 15 years that the outline of the NO/cGMP signaling pathway has been 
understood. Ever since, many good examples of signal transduction by this system have 
emerged. They appeared to be most notably in the cardiovascular system (smooth muscle 
relaxation and blood pressure regulation 1, platelet aggregation and disaggregation 2) and the 
nervous system (neurotransmission both peripherally, in non-adrenergic-non-cholinergic 
nerves 3 and centrally in the process of long-term potentiation and depression 4). However, 
also light transduction in the retina 5, kidney function 6, suppression of leukocyte adhesion 7 
and vascular remodelling 8 may be put on the list of NO/cGMP mediated physiological 
processes. This extensive record implies of course that impairment of the NO/cGMP system is 
the underlying cause for many diseases. Despite decades of research, many aspects of sGC, 
including the physiological relevance of its two isoforms remain to be revealed. The capital 
aim of this thesis was to gain more insight into the importance of the sGCα1β1 and sGCα2β1 
isoforms in vascular and corpora cavernosa smooth muscle relaxation in order to validate the 
isoforms as potential pharmacological targets. Because of the lack of sGC subunit or isoform 
specific inhibitors, we made use of genetically engineered mice with a targeted deletion of 
one of the sGCα genes or a mutation of the sGCβ gene to obtain our goal.  
Two isoforms for each sGC subunit have been described, but only the predominantly 
expressed heterodimer α1β1 and the less profusely expressed heterodimer α2β1 have been 
reported to be physiologically active 9. Because the α1β1 isoform represents the largest part of 
the total sGC content in most tissues 10, we first focussed our research on the sGCα1-/- mice in 
which the α1β1 isoform is no longer functionally active. In the CC as well as in the aorta 
isolated from the sGCα1-/- mice, we found that the response to endogenous NO was 
completely or almost completely abolished, which reflects the principal role of the α1β1 
isoform. In order to evaluate the correlation between this functional alteration in the CC and 
erectile dysfunction, one of the future perspectives would be to determine the erectile 
hemodynamics of the sGCα1-/- mice in response to drugs or nerve stimulation by ICP 
measurements. In contrast with the CC and aorta, the femoral arteries isolated from the 
sGCα1-/- mice, still showed a substantial response to ACh, suggesting that besides the 
sGCα1β1 isoform, also the sGCα2β1 isoform and/or (an) sGC-independent mechanism(s) are 
involved. In addition to NO, ACh is known to induce the release of prostacyclin (PGI2) and of 
the endothelium-derived hyperpolarising factor (EDHF) 11. However, the contribution of these 
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endothelium-derived substances could be excluded by the fact that the relaxing influence of 
ACh was completely blocked by the NO-synthase inhibitor Nω-nitro-L-arginine (L-NA). 
Furthermore, this finding suggests that the remaining effect of ACh seen in the sGCα1-/- mice 
is completely mediated by NO. To investigate whether this effect of NO is sGC-dependent, 
we explored the response to ACh in sGCβ1ki/ki mice, in which the NO-mediated activation of 
sGC is abolished. The data obtained from these mice gave us also conclusive information on 
the involvement of the sGCα2β1 isoform. As compared with the sGCα1-/- mice, ACh had less 
effect in the sGCβ1ki/ki femoral arteries. This suggests that the minor sGC isoform, α2β1, is 
also activated by endogenous NO in this preparation. However, endogenous NO is also able 
to exert a sGC-independent relaxant effect, since vasorelaxation induced by ACh is not 
completely abolished in the sGCβ1ki/ki femoral arteries. On the other hand, also EDHF could 
be responsible for the remaining endothelium-dependent relaxation of those arteries. In 
contrast to our findings in mice with a 129/SvJ-Swiss background, there is evidence in 
literature that EDHF is an important endothelium-dependent vasodilator in femoral arteries of 
C57BL/6J mice 12.  
It should however be noted that the responsiveness to ACh as well as to the NO-donor 
SNP were characterised by some variability, as in one third of the preparations, the relaxant 
effect of the NO-related substances was completely abolished in the sGCβ1ki/ki femoral 
arteries. We suggest that this variation is due to variation in the available sGCβ1ki/ki mice. At 
the beginning only young mice were available because most of the sGCβ1ki/ki mice died at an 
early age. Later on, the survival rate of the sGCβ1ki/ki mice increased due to an adapted diet. A 
study performed by the research unit of Prof. Dr. P. Brouckaert of the Department of 
Molecular Biomedical Research and Flanders Interuniversity Institute of Biotechnology, who 
bred the genetically engineered mice, demonstrated that the lifespan of the sGCβ1ki/ki mice 
markedly increased when they receive expanded food, with a higher dose of vitamins.  
Besides the diet, also the mixed background of the sGCβ1ki/ki mice can have influenced 
the results. The sGCβ1 knockin was created in a 129/SvJ-derived embryonic stem (ES) cell 
line and crossed to C57BL/6J mice to test the germ line transmission. C57BL/6J x 129/SvJ F2 
mice were then intercrossed to produce the homozygous mutant mice. Subsequently the 
sGCβ1 mutant strain was being backcrossed to a more uniform inbred strain (C57BL/6J 
strain), in order to eliminate phenotypic variations caused by the mixed background and thus 
to more accurately evaluate the specific gene phenotype. However, the time involved to create 
fully backcrossed congenic strains, defined as 10 generations of backcrossing 13, combined 
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with scientific curiosity, led to characterization of sGCβ1ki/ki mice with a background that was 
still segregating for genes from the progenitor strains. Numerous reports illustrate the 
importance of an appropriate genetic background 14. Heterozygous insulin receptor knockout 
mice for example, showed a variable hyperinsulinemia on a mixed background, a mild 
hyperinsulinemia on a C57BL/6 congenic background and a severe hyperinsulinemia on a 
129S6 background 15.  
Like the sGCβ1ki/ki mice, also the sGCα1-/- mice were generated on a mixed 
background; targeted ES cells derived from a 129/SvJ strain were injected into Swiss 
blastocysts to form the chimeric mice. The vascular as well as the cavernosal responsiveness 
of the sGCα1-/- mice was obtained on this mixed background. As illustrated above, this creates 
a potential source of variability in the results 16, especially since the Swiss strain is known as 
an outbred strain (in contrast to the 129/SvJ and C57BL/6J strains). Still, these F2 mice 
obtained by crossing the chimera to Swiss and then intercrossing their heterozygous offspring, 
offered a reasonable compromise between the demands of time for scientific progress on the 
one hand and the rigorous control of background on the other hand. In the long term, it is 
however recommended that mutants are analysed on a more defined background 17. Therefore, 
we also characterised sGCα1-/- mice which were successfully backcrossed to a pure C57BL/6J 
background (see caption VIII.2: Influence of the genetic background on the phenotype of the 
sGCα1-/- mice). The aortic ring segments of these mice, showed a significantly reduced 
response to ACh, though the remaining effect of ACh in these arteries was more than twice as 
big compared with the remaining effect of ACh in the aortic rings of the sGCα1-/- mice on the 
mixed background. This phenotypic difference has severe implications for the interpretation 
of our results, as the sGCα1β1 and the sGCα2β1 isoform are physiologically more important in 
respectively the sGCα1-/- mice on the mixed background and the sGCα1-/- mice on the pure 
background. The exclusive sGC-dependency of endogenous NO was suggested by the 
complete absence of ACh-induced relaxation in the aortic rings from the sGCβ1ki/ki mice. 
Furthermore, this clearly shows that for a correct comparison of the data obtained from the 
sGCα1-/- and sGCβ1ki/ki mice, both mutant mice should be characterised when fully 
backcrossed to the same inbred strain. Moreover, to identify genetic modifiers of the gene of 
interest, minimum two congenic strains of every mutation should be examined 17. In this 
perspective, it could be interesting to examine the vascular and cavernosal responsiveness in 
sGCα1-/- mice on a pure 129/SvJ background and in the sGCβ1ki/ki mice on a C57BL/6J and 
129/SvJ background. Additionally, the phenotypic evaluation of a tissue-specific targeted 
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disruption (e.g. in the smooth muscle cells) of the sGCα1 gene, may provide more detailed 
information on the role of the sGCα1β1 isoform in smooth muscle relaxation. Furthermore, a 
temporal regulation of the sGCβ1 mutation can perhaps circumvent the developmental 
retardation of the sGCβ1ki/ki mice and in that way lead to an increased life span.  
Under physiological conditions, the endothelium acts as an inhibitory regulator of 
vascular contraction through the continuous release of basal NO 18. We suggest that in the 
aorta, sGCα1β1 is the predominant target for basally produced NO. After all, the aortic rings 
isolated from the sGCα1-/- mice were characterised by a significant lower basal cGMP level, 
an almost completely abolished response to the phosphodiesterase type 5 inhibitor T-1032 and 
a significant smaller increase of the precontraction tonus upon addition of the sGC-inhibitor 
ODQ. In the sGCα1-/- femoral arteries and CC, on the other hand, more basally produced 
cGMP was accumulated as T-1032 still had a substantial relaxant effect in these preparations. 
This suggests that besides sGCα1β1, also sGCα2β1 is a target for basally released NO.  
A lot of diseases, in which an impaired bioavailability and/or responsiveness to 
endogenous NO has been implicated, are currently treated with organic nitrates and other NO-
donor drugs that release NO by spontaneous decomposition or bioconversion 19. Given its 
clinical relevance, we examined the responsiveness towards exogenously applied NO in both 
sGCα1-/- and sGCβ1ki/ki mice. First of all, SNP, which releases exogenous NO upon 
biotransformation and NO-gas, which represents the purest form of exogenous NO, still had a 
substantial relaxing effect in the aortic and femoral artery segments isolated from the sGCα1-/- 
mice. Furthermore, the sGC inhibitor ODQ had a strong inhibitory influence on the 
exogenous NO-induced vasorelaxation and on the SNP-induced cGMP production. ODQ is 
described as a potent and highly selective inhibitor of sGC and has therefore been used widely 
to probe for the involvement of cGMP in a given pharmacological response and to 
discriminate between cGMP-dependent and -independent effects of NO. However, there are 
also reports on the influence of ODQ on the redox state of other heme containing proteins 
such as the cytochrome P-450 system, thereby inhibiting the reductive bioactivation of 
organic nitrates and SNP and thus vasorelaxation induced by these compounds 20. Moreover, 
as targets for ODQ, myoglobin and hemoglobin can positively (e.g. in the aorta 21) or 
negatively (e.g. in cardiomyocytes 22) influence the effectiveness of ODQ depending on their 
concentrations in the tissues. Therefore, a transgenic approach, such as the NO-insensitive 
sGC mutation is of great value. Whatsoever, our results obtained with ODQ are in line with 
the results obtained from the sGCβ1ki/ki mice. In the femoral arteries of the sGCβ1ki/ki mice, the 
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response to SNP was far more reduced compared to the SNP-induced response in the sGCα1-/- 
femoral arteries. Moreover, the aortic rings of the sGCβ1ki/ki mice did not respond to SNP at 
all. Even though all those findings favour the sGCα2β1 isoform as an important target for 
exogenous NO, the cGMP-measurements in the sGCα1-/- aortic rings are not convincing, since 
there is only a small, not significant increase in the production of cGMP upon addition of 
SNP. Moreover, the absence of the sGCα1 subunit is not compensated by an upregulation of 
the sGCα2 subunit as suggested by the QPCR measurements in the ring segments of both 
sGCα1-/- and sGCα1+/+ mice. However, the study of Mergia et al. in which the role of the sGC 
isoforms was explored using sGCα1-/- and sGCα2-/- mice, suggests that the small amount of 
cGMP produced by the sGCα2β1 isoform, would be sufficient to exert a profound effect on 
vascular tone 23. They claim that the sGCα1β1 isoform has a predominant role in NO-induced 
vasorelaxation, but that the less abundantly expressed sGCα2β1 isoform is able to induce an 
equivalent response, although higher NO concentrations are needed. As the transgenic mouse 
models used in the study of Mergia et al. were developed on a mixed 129/SvJ-C57BL6/J 
background it is not surprising that their observations are more in line with our data from the 
sGCα1-/- mice on the C57BL/6J background (see caption VIII.2: Influence of the genetic 
background on the phenotype of the sGCα1-/- mice) than those of the sGCα1-/- mice on the 
129/SvJ-Swiss background. This also suggests that the NO origin-dependent difference we 
observed in sGCα1-/- vasorelaxation is related to the Swiss background of the sGCα1-/- mice. 
Overall, we can state that despite its lower expression, the sGCα2β1 isoform, plays a very 
important role in NO-mediated vasorelaxation. To know whether the vasorelaxing effect of 
sGCα2β1 is a compensation for the absence of the sGCα1β1 isoform or the sGCα2β1 is actually 
the main physiologically target for NO, NO-induced vasorelaxation should be explored in 
sGCα2-/- mice. Such experiments were scheduled in our work program, but sGCα2-/- mice are 
not yet available due to problems with the germline transmission of the mutation and 
infertility of the chimeric mice. As in the Transgene Core Facility of the research unit of Prof. 
Dr. P. Brouckaert from the Department of Molecular Biomedical Research and Flanders 
Interuniversity Institute of Biotechnology, the sGCα2 knockout generation has been restarted 
from newly electroporated ES, it could perhaps be possible to characterise those mice in the 
future. Notwithstanding, Mergia and collaborators already explored the responsiveness to NO 
in sGCα2-/- mice, it would still be interesting, as there are some important differences between 
the transgenic mouse models, and this can lead to variable results as was observed with the 
sGCα1-/- mice.  
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In contrast with the aortic rings in which the sGCα1-independent relaxation is 
proposed to be completely mediated by sGCα2β1, our observations on the femoral arteries and 
CC demonstrate the participation of sGC-independent mechanisms in the response to 
exogenous NO. Although many actions of NO have been attributed to its ability to activate 
sGC and to increase cGMP, also cGMP-independent effects of NO have been described. One 
of the proposed mechanisms underlying cGMP-independent reduction of the intracellular 
Ca2+ concentration by NO is the opening of potassium channels 24-26 in the cell membrane, 
resulting in membrane hyperpolarisation and subsequent closure of the voltage-gated Ca2+-
channels. Additionally, NO has also been shown to extrude Ca2+ from the cell by directly 
stimulating the Na+/K+ ATPase activity 27, 28. Moreover, it accelerates the sequestration of 
Ca2+ into the internal stores by activating the sarco-endoplasmic reticulum Ca2+-pumping 
ATPase (SERCA) 29. Especially in the CC, only exogenously applied NO seems to have an 
sGC-independent effect. It is possible that the route of administration of NO may influence 
the actions of NO and thus also the involvement of an sGC-independent effect. After all, NO 
has direct effects on the endothelium 30 and differential responses to luminal versus adluminal 
application of NO have been reported 31. Thus, endogenous NO released at the smooth 
muscle/ endothelium interface and exogenous NO administrated to the whole vessel may have 
different effects. Moreover, also the type of NO-donor and related with that the form of NO 
generated may play a role. NO can exist in a variety of forms, viz. as free radical (NO•) or as 
the ions nitroxyl (NO-) or nitrosium (NO+), and the form(s) predominating may vary 
depending on the source of NO 32.  
Besides its direct cGMP-independent actions, NO may also regulate ion channels and 
transporters by S-nitrosylation 33 or S-glutathiolation 34 of reactive thiols, through the 
secondary generation of reactive oxygen species. Adachi at al. showed that NO and 
superoxide anion, through the formation of peroxynitrite, activate SERCA by reversible S-
glutathiolation 35. Additionally, various other proteins involved in metabolism, signaling, cell 
shape and DNA transcription may be regulated by NO through S-glutathiolation 36. These 
non-specific interactions are, together with the development of tolerance 37 and insufficient 
biometabolism 38, severe limitations associated with the use of NO releasing drugs for the 
treatment of NO/cGMP implicated pathologies. Additionally, cGMP-specific 
phosphodiesterase inhibitors used for the treatment of erectile dysfunction have been shown 
to be significantly less potent in patients with a reduced bioavailability of endogenously 
produced NO 39. Because of these limitations, it was of interest to determine the physiological 
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relevance of the different sGC isoforms in smooth muscle relaxation, in order to provide 
information needed for the development of more selective drugs.  
Also substances like BAY 41-2272 that can activate sGC in a NO-independent way, 
might offer considerable therapeutic advantages over the NO-based therapies 19. Knocking out 
the sGCα1β1 isoform caused a significant reduction of the response to BAY 41-2272 in the 
femoral arteries and CC; elimination of the heme-dependent activation of both sGC isoforms 
did however, not further reduce this BAY 41-2272-induced response. This suggests that in the 
femoral artery and CC, sGCα1β1 is the only sGC-dependent target of BAY 41-2272. In the 
aortic rings, on the other hand, only the highest concentration of BAY 41-2272 we applied 
could induce a substantial relaxation in the sGCα1-/- mice. In the sGCβ1ki/ki aortic rings, the 
remaining effect of 10 µmol/L BAY 41-2272 was significantly smaller, suggesting that at 
higher concentrations also sGCα2β1 is being activated. Furthermore, from its relaxant effect in 
the sGCβ1ki/ki mice, we can conclude that in neither of the tissues explored, BAY 41-2272 
exerts its effect only through the activation of sGC, at least, if the sGC-activating quality of 
BAY 41-2272 is completely heme-dependent. It is known that BAY 41-2272 can inhibit Ca2+ 
entry by mechanisms that do not involve cGMP 40. Furthermore, Mullerhausen et al. 
demonstrated a PDE-5 inhibitory action of BAY 41-2272 41. However, this has been refuted 
by a study of Bischoff and Stasch, who observed that BAY 41-2272 was devoid of any 
inhibitory effect on PDE-5 42.  
From the comparable reaction in sGCα1-/- and sGCα1+/+ mice towards the cGMP-
analogue 8-pCPT-cGMP and the cAMP-producing substance forskolin, we concluded that the 
impaired responses we observed in the sGCα1-/- preparations are related to sGC. This could 
not be concluded for the sGCβ1ki/ki mice, at least not in aortic ring segments. In contrast with 
the femoral arteries and CC, the aortic ring segments from the sGCβ1ki/ki mice showed a 
significantly reduced response to 8-pCPT-cGMP, pointing to an additional mechanism 
beyond the level of sGC as underlying cause for the reduced relaxations. Moreover, also the 
AC-activator forskolin did not show an equal relaxant effect in the aortic rings from both 
sGCβ1ki/ki and sGCβ1+/+.  
Another difference with the sGCα1-/- mice, is that the arteries of the sGCβ1ki/ki mice 
showed a significant higher response to NOR than the corresponding sGCβ1+/+ preparations. 
The elevated sensitivity towards NOR was most pronounced in the aortic rings and its 
relevance was confirmed by a high reproducibility. These surprising observations were 
however not reported in the sGCβ1-/- mice, generated by the research group of Koesling and 
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coworkers 43, who also generated sGCα1-/- and sGCα2-/- mice 23. It should however be noted 
that in their sGCβ1 transgenic mice model, the expression of NO-sensitive sGC is completely 
abrogated, whereas in the sGCβ1 mutant mice we characterised, the sGC enzyme is present, 
yet without a prosthetic heme-group. This is also the case for the sGCα1-/- mice, as the model 
we used expressed a catalytically inactive sGCα1 protein, whereas in the one of Mergia et al., 
sGCα1 expression was completely eliminated 23. This implies that in the knockout mice 
generated by Koesling and coworkers, the influence of enzyme structural functions on the 
phenotype, as demonstrated for the PI3Kγ knockout mice 44, can not be ruled out.  
Further explorations of the higher NOR-induced response in the sGCβ1ki/ki arteries, 
revealed that this effect is rather specific for NOR in the femoral arteries. The addition of 
other contractile substances such as the selective α1-adrenoreceptor agonist methoxamine, the 
prostanoid receptor agonist prostaglandin F2α (PGF2α) and K+ did not result in a higher 
response of the sGCβ1ki/ki femoral arteries. In the aortic rings, on the other hand, all tested 
contractile agents induced a significant higher response in the sGCβ1ki/ki preparations, 
although with a different extent. The sGCβ1ki/ki aortic rings had a greater sensitivity towards 
PGF2α, although the maximum response was not significantly increased. The contractile effect 
of a G-protein coupled receptor agonist has been shown to result from Ca2+ sensitization as 
well as Ca2+ mobilization 45. The importance of both processes was explored in the contractile 
responsiveness of the sGCβ1ki/ki preparations.  
As preincubation with the Rho kinase inhibitor HA-1077, abolished the difference in 
the NOR-induced response between the sGCβ1ki/ki and sGCβ1+/+ femoral arteries, we suggest 
that the Ca2+ sensitization pathway, in which Rho kinase plays a key role, has a more 
profound action in the sGCβ1ki/ki mice . However, in the aortic rings from the sGCβ1ki/ki mice, 
the Rho kinase activity is not suggested to be enhanced, as even in the presence of HA-1077, 
the NOR-induced response was still significantly higher in the sGCβ1ki/ki preparations. Still, 
this does not exclude a possible higher sensitivity towards Ca2+, as besides Rho kinase, also 
protein kinase C (PKC) is a major determinant for the Ca2+ sensitization in vascular smooth 
muscles 46. The influx of extracellular Ca2+ induced by Bay k 8644 (an L-type Ca2+ channel 
agonist) and/or TEA (a non-selective K+ channel inhibitor), caused a significant higher force 
development in the aortic rings, but not in the femoral arteries from the sGCβ1ki/ki mice. As in 
contrast with the sGCβ1ki/ki arteries, the vessel segments from the sGCα1-/- mice showed an 
equal contractile activity compared with the sGCα1+/+ mice, we hypothesize that in these mice, 
the presence of the sGCα2β1 isoform suppresses the NOR-induced contraction. As this 
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compensation by the sGCα2β1 isoform is not possible in the sGCβ1ki/ki arteries, one would 
speculate that the insensitivity towards basal endothelium-derived NO of the sGCβ1ki/ki vessel 
segments is responsible for their higher contractile activity. The stimulating effect of ODQ on 
the NOR-induced response in C57BL/6J mice also points into that direction. The importance 
of basally released NO has been shown to depend on the vessel type studied 12, 47. However, 
this heterogeneity does not explain the discrepancy in contractile activity between the 
sGCβ1ki/ki aorta and sGCβ1ki/ki femoral artery as we could not observe a significant difference 
in the ODQ-induced increase in tone between the C57BL/6J aorta and femoral artery. 
Therefore, we suggest that besides basal endothelium-derived NO, also other mechanisms are 
responsible for the higher tone of the sGCβ1ki/ki arteries. Additional experiments should 
further address this issue, for example simultaneous measurements of [Ca2+]i and force. 
 
VII.2. Conclusions 
Our results show that the sGCα1β1 isoform, which represents the largest fraction of the total 
sGC protein concentration, is the main target for NO and NO-independent sGC stimulators, 
like BAY 41-2272. However, the sGCα2β1 isoform can despite its limited expression, produce 
sufficient cGMP to largely compensate for the lack of the sGCα1β1 isoform. Contrary to the 
aorta, in which sGC is the sole NO-receptor, the femoral artery and corpora cavernosa, also 
support the participation of cGMP-independent mechanisms. The latter can also be concluded 
from our experiments with BAY 41-2272. The selective targeting of the sGCα1β1 isoform 
might offer a therapeutic approach to compensate for the depressed NO/cGMP pathway, 
which is the underlying cause of many vascular disease states.  
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VIII.1. NO-dependent corpus cavernosum smooth muscle 
relaxation in Wnt-1 conditional sGCα1-/- mice.  
VIII.1.1. Introduction 
Peripheral nitrergic nerves have a widespread distribution, and are particularly important in 
that they produce relaxation of smooth muscle in the gastrointestinal, respiratory, vascular and 
urogenital systems 1. Despite the importance of NO as neurotransmitter, little is known about 
the regulation of the release of NO from the peripheral nitrergic nerves. In rabbit colon 2 and 
corpus cavernosum 3, sGC/cGMP has been shown to exert a positive feedback on the release 
of NO from the autonomic neurons in the gastrointestinal tract and penis. How this proposed 
feedback is mediated is however unclear. The immunohistochemical detection of sGC in the 
nerve fibers of the corpus cavernosum (CC) 4 and neuromodulatory role of presynaptical sGC 
in the central nervous system 5, suggest a possible involvement of sGC in the neurons. 
Therefore, in the present study, using CC isolated from Wnt-1 conditional sGCα1-/- and 
sGCα1+/+ mice, we investigated if neuronal sGC modulates the nerve-induced NO release 
from autonomic neurons in the penis.  
 
VIII.1.2. Animals 
Through homologous recombination in mice embryonic stem (ES) cells, the sixth exon of the 
sGCα1 gene was flanked with loxP sites. These ES cells gave rise to chimeric mice, which 
were then used to produce mice homozygous for the floxed allel (see caption materials and 
methods: mice models: sGCα1 knockout mice). In the next step those sGCα1flox/flox mice were 
mated with transgenic mice expressing Cre recombinase under the control of the Wnt-1 
promoter and enhancer. The Wnt-1 protooncogene is found to be expressed in the dorsal 
neural tube of the vertebrate embryo, from which the pluripotent neural crest cells originate 6. 
Therefore, by utilizing the Wnt-1 promoter, Cre-expression and thus deletion of the sGCα1flox 
allele, was restricted to the derivatives of the neural crest cells 7, which include all peripheral 
autonomic neurons 8.  
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VIII.1.3. Tissue collection 
From male Wnt-1 conditional sGCα1-/- and sGCα1+/+ mice (genetic background: C57BL/6J), 
CC was isolated and transferred to cooled KRB solution (see caption III.4.1. Dissection).  
 
VIII.1.4. Tension measurements 
Of each mouse, one corpus cavernosum was mounted horizontally in a myograph (see caption 
III.4.3. Mounting of the penile tissue) and preloaded with 0.45 g of tension (see caption III.4.4. 
Preparation of the tissue before the experiment). In order to increase and stabilize the 
subsequent submaximal pre-contractile response to 5 µmol/L norepinephrine (NOR), the 
preparations were 3 times contracted with 5 µmol/L NOR, washed, and allowed to relax to 
resting tension before starting the protocol. When the pre-contraction response (5 µmol/L 
NOR) reached a stable level, electrical field stimulation (EFS), delivered by a Grass 
stimulator via two parallel platinum electrodes, was applied to the tissue or various 
vasodilating substances were added to the bath medium. The CC were washed and allowed to 
recover for 20 min between every response curve. 
 
VIII.1.5. Calculations and statistics 
Data are presented as mean values ± SEM; n represents the number of arteries (each obtained 
from a different mouse). Statistical significance was evaluated by using Student’s t-test for 
unpaired observations (SPSS, version 12). P<0.05 was considered as significant.  
 
VIII.1.6. Results 
The endothelium-dependent vasodilator acetylcholine (ACh) relaxed the CC preparations 
from both sGCα1+/+ and Wnt-1 conditional sGCα1-/- mice to a similar extend (response to 10 
µmol/L: 71.70%±6.07 vs. 72.77%±5.00 (n=6, P>0.05)).  
The CC from both sGCα1+/+ and Wnt-1 conditional sGCα1-/- mice responded to EFS-induced 
and thus neuronal derived NO in a similar way (response to 8Hz: 79.94%±13.50 vs. 
72.82%±4.69 (n=5, P>0.05)). 
Exogenous NO delivered by the NO-donor sodium nitroprusside (SNP) and NO-gas, had a 
concentration-dependent and similar relaxant effect in the CC preparations of sGCα1+/+ and 
Wnt-1 conditional sGCα1-/- mice (response to 10 µmol/L SNP: 99.72%±5.18 vs. 96.41%±5.84 
                                                                                                                                       Appendix 
 
215 
(n=5, P>0.05); response to 0.1 mmol/L NO-gas: 89.71%±7.89 (n=4) vs. 88.05%±7.69 (n=5, 
P>0.05)).  
 
VIII.1.7. Discussion 
It is widely accepted that the release of NO from autonomic neurons in the CC results in an 
increase of the cGMP-level in the penile tissue and will subsequently lead to corporal smooth 
muscle relaxation. Hallen et al. showed that the nerve-induced release of NO from the rabbit 
CC is subject to modulation by the sGC/cGMP pathway 3. It is however not clear whether this 
modulation occurs in the nitrergic neuron or in some other cell type. As there are no reports 
on the colocalisation of NOS and sGC in the neurons of the CC, Hallen et al. suggested that it 
is more likely that sGC upregulates the formation of NO within a cell located close to the 
nitrergic neuron 3. Our data however, give no indication towards a role for sGC as 
neuromodulator in the autonomic neurons of the penis. As the pelvic neurons arise from the 
sacral neural crest 9, the nerve fibers of the penis of the Wnt-1 sGCα1-/- mice lack the 
functional sGCα1 enzyme. The neural crest origin of the pelvic neurons is strengthened by the 
fact that they have been reported to express neurotrophic factors 10, 11 that promote the 
migration of the neural crest cells to their correct site. The CC preparations from both Wnt-1 
sGCα1-/- and sGCα1+/+ mice, responded to EFS in a similar way, suggesting that sGCα1β1, 
present in the cavernosal neurons, had no influence on the nerve-induced release of NO. As 
expected, the responses to ACh, SNP and NO-gas were not influenced by the targeted 
deletion of the sGCα1 subunit in the nervous system.   
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VIII.2. Influence of the genetic background on the 
phenotype of the sGCα1-/- mice. 
VIII.2.1. Introduction 
As the predominant intracellular target for NO, sGC regulates vascular smooth muscle 
relaxation, which is a very important process in the cardiovascular system 1. In order to get 
insight into the relevance of the two physiological active sGC isoforms in vasorelaxation, 
NO-induced relaxation was measured in vessel segments isolated from sGCα1-/- and sGCβ1ki/ki 
mice. The sGCα1-/- mice have a mixed Swiss-129/SvJ background, whereas the sGCβ1ki/ki 
mice have a mixed C57BL/6J-129/SvJ background. A mixed genetic background is known to 
produce a potential source of variability in the experiments and the phenotypes of mutant 
mice have been reported to be influenced by their genetic background 2. Moreover, a genetic 
background effect has been put forward as hypothesis for the gender-specific development of 
hypertension that was found in the sGCα1-/- mice on the mixed background but not in the 
sGCα1-/- mice backcrossed to a C57BL/6J background. In order to recognize the importance 
of the genetic background, we examined the relaxing influence of NO on the aortic rings from 
sGCα1-/- and sGCα1+/+ mice with a pure C57BL/6J background and compared this with the 
results obtained from sGCα1-/- and sGCα1+/+ mice with a mixed Swiss-129/SvJ background. 
 
VIII.2.2. Animals 
We used sGCα1-/- mice which were generated on a mixed Swiss-129/SvJ background and then 
backcrossed to a C57BL/6J background for more than 12 generations while selecting for the 
mutation of the sGCα1 gene.  
 
VIII.2.3. Tissue collection 
Aortic rings from female sGCα1-/- and sGCα1+/+ mice with a pure C57BL/6J background, were 
isolated and transferred to cooled KRB solution (see caption III.3.1. Dissection). 
 
VIII.2.4. Tension Measurements 
Aortic ring segments were mounted in a small vessel myograph (see caption III.3.2.2. 
Mounting of the ring segment) and gradually stretched until a stable preload of 0.5 g is 
obtained (see caption III.3.2.3. Preparation of the aortic segments before the experiment). 
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Subsequently, the preparations were contracted 3 times with a KRB solution containing 120 
mmol/L K+ and 5 µmol/L norepinephrine (NOR), washed, and allowed to relax to basal 
tension before starting the protocol. When a stable precontraction (30 µmol/L PGF2α) was 
obtained, cumulative concentration-response curves to ACh and SNP were obtained.  
 
VIII.2.5. Calculations and statistics 
Data are presented as mean values ± SEM; n represents the number of arteries (each obtained 
from a different mouse). Statistical significance was evaluated by using Student’s t-test for 
unpaired observations (SPSS, version 12). P<0.05 was considered as significant.  
 
VIII.2.6. Results 
The endothelium-dependent vasoactive substance ACh (Fig. 1A, B), induced a concentration-
dependent relaxation of the aortic rings from both sGCα1+/+ and sGCα1-/- mice. However, the 
ACh-induced response was significantly reduced in the aortic rings from sGCα1-/- mice with a 
pure background and almost completely blocked in the aortic rings from sGCα1-/- mice with a 
mixed background (response to 10 µmol/L ACh: mixed background: 67.8%±3.5 for sGCα1+/+ 
vs. 16.4%±5.2 for sGCα1-/- (n=6, P<0.05); pure background: 71.5%±4.9 for sGCα1+/+ vs. 
41.4%±10.2 for sGCα1-/- (n=4, P<0.05)) 
The aortic rings from both sGCα1+/+ and sGCα1-/- mice responded to the NO-donor SNP (Fig. 
1C, D) in a concentration-dependent way. However, the relaxing effect of SNP was 
significantly reduced in the aortic rings of the sGCα1-/- mice with a pure and a mixed 
background (response to 10 µmol/L SNP: mixed background: 77.9%±4.0 for sGCα1+/+ vs. 
48.6%±3.6 for sGCα1-/- (n=15, P<0.05); pure background: 58.0%±2.4 for sGCα1+/+ vs. 
35.2%±5.5 for sGCα1-/- (n=4, P<0.05)). 
 
VIII.2.7. Discussion 
Induced mutations are often generated and maintained on a mixed segregating background. 
Further backcrossing to another inbred strain may result in a phenotype different from the 
phenotype initially reported on the mixed genetic background 3. To look for possible 
phenotypic differences with the sGCα1-/- mice on a mixed background, the NO-induced 
response was obtained on aortic rings from sGCα1-/- and sGCα1+/+ mice with a pure C57BL/6J 
background. We found that the genetic background modulates the response to endogenous 
NO in the sGCα1-/- mice, as the ACh-induced relaxation was more reduced in the sGCα1-/- 
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mice on the mixed background compared to the sGCα1-/- mice on the pure background 
(reduction of the response to 10 µmol/L ACh: 75.83% vs. 42.17%). This also implies a 
background-related difference in the importance of the sGCα1β1 isoform and the participation 
of the sGCα2β1 isoform and/or (an) sGC-independent mechanism(s). In case of the response 
to exogenous NO, we found far less supporting evidence for a genetic background effect, as 
only the responses to the lowest concentrations of SNP were somewhat more reduced in the 
sGCα1-/- mice on a mixed background. The relaxing influence of 10 µmol/L SNP was 
however, similarly reduced in the sGCα1-/- mice on both a mixed background and a pure 
background (reduction of the response to 10 µmol/L SNP: 37.59% vs. 39.41%).  
In conclusion, we found that the physiological importance of the sGCα1β1 isoform in the 
response to endogenous NO is clearly dependent of the genetic background. This implies the 
presence of genetic modifiers 4, which have to be taken into consideration for the correct 
interpretation and comparison of the phenotypes of the genetically engineered mice.  
 
 
 
Figure VIII.1: Relaxation effect of ACh (A, B) and SNP (C, D) on precontracted (30 µmol/L PGF2α ) 
aortas from female sGCα1+/+ and sGCα1-/- mice on a mixed background (Swiss-129/SvJ) (A, C) and a 
pure background (C57BL/6J) (B, D). *(sGCα1+/+ vs. sGCα1-/- mice): P<0.05.  
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Summary 
Soluble guanylyl cyclase (sGC) plays a key role in the transduction of inter- and intracellular 
signals conveyed by NO; as such its physiological importance is invaluable. To fulfil this role, 
sGC has a unique heme coordination which makes its suitable as receptor for NO. Its product, 
cGMP, regulates a wide range of biological processes, including vascular and non-vascular 
smooth muscle relaxation, peripheral and central neurotransmission, platelet reactivity and 
phototransduction. Due to its widespread nature, signaling via the NO/cGMP pathway is 
depressed in many disease states (e.g. erectile dysfunction (ED)) providing a rationale for 
enhancing sGC activity by drugs.  
In 1998, the first oral treatment for ED, a phosphodiesterase (PDE) type 5 inhibitor 
(blocks the breakdown of cGMP) called sildenafil (Viagra®), became available. The 
assumption that Viagra® was a "cure" for erectile dysfunction raised high expectations for the 
treatment, sustained by the high interest of the media. However, treatment with PDE-5 
inhibitors turns out to be significantly less efficient in patients with a reduced bioavailability 
of endogenously generated NO such as in diabetics or patients with severe neurologic 
damage. Because sildenafil has a low selectivity for PDE-6, which is found in the retina, 
transient visual disturbances including blurring of vision, increased light sensitivity and 
impaired blue/green color discrimination, are common side effects. Furthermore, the 
concomitant use of Viagra and nitrovasodilators is absolutely contraindicated, since PDE-5 
inhibitors potentiate the systemic hypotensive effect of NO.  
Nitrovasodilators have been used for more than a century to induce vasodilatation via 
the NO/cGMP pathway, however the development of tolerance and potentially adverse 
cGMP-independent actions of nitrovasodilators such as promoting oxidative stress and protein 
modification are functionally important limitations for their use.  
This illustrates the interest for the design and development of more selective and NO-
independent therapeutic strategies, in which the understanding of the functional importance of 
the physiologically active sGC isoforms (the main sGCα1β1 and minor sGCα2β1) can be of 
great value. Therefore, the aim of this thesis was to gain more insight into the physiological 
relevance of the sGCα1β1 and sGCα2β1 isoform in vascular and corpus cavernosum (CC) 
smooth muscle relaxation. As there are no sGC isoform specific inhibitors available, we made 
use of a mouse transgenic approach to study the function of each isoform. From genetically 
engineered mice with a targeted deletion of the sGCα1 gene or a mutation of the sGCβ1 gene, 
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vascular and corporal tissues were isolated and mounted in a myograph to measure changes in 
isometric forces. These experiments were supplemented with measurements of cGMP 
concentrations in the aortic rings. Chapter III encloses a detailed description of those 
techniques.  
As sGCα1β1 is considered to be the "universal heterodimer" with the highest 
expression level, we first draw our attention to the sGCα1-/- mice in which the sGCα1β1 
isoform is not longer functionally active. In chapter IV, we demonstrated that the sGCα1β1 
isoform is of functional importance in vasorelaxation induced by endogenous NO (released 
from the endothelium in response to acetylcholine (ACh)), exogenous NO (delivered by NO-
donors (sodium nitroprusside (SNP) and SNAP) and NO-gas, which represents NO as such) 
as well as basal NO (examined by the accumulation of basally produced cGMP caused by the 
PDE-5 inhibitor T-1032). Also the vasorelaxing effect of NO-independent sGC stimulators 
(BAY 41-2272 and YC-1), which have been forwarded as potential new drugs for the 
treatment NO/cGMP related pathologies, was found to involve the sGCα1β1 activity.  
However, the observation that the responsiveness of the arteries from the sGCα1-/- mice is 
diminished but not completely abolished, suggests that besides sGCα1β1, also the less 
abundantly expressed isoform sGCα2β1 and/or (an) sGC-independent mechanism(s) play a 
substantial role.  
Subsequently, we performed a study on the CC isolated from sGCα1-/- mice (chapter 
V). CC are defined as two spongelike regions in the penis which run the length of the organ 
and which will become engorged with blood upon erection. The importance of CC smooth 
muscle relaxation in penile perfusion (and thus in erection) is illustrated by the fact that 
impaired responsiveness of CC smooth muscle cells is a common cause of ED or impotence. 
Our findings in the CC were overall comparable to the observations in the aorta and femoral 
artery. We demonstrated the involvement of the sGCα1β1 isoform in CC smooth muscle 
relaxation in response to NO (in addition to endothelium-derived NO, the release of 
endogenous NO from the nitrergic neurons was induced by electrical field stimulation) and 
NO-independent sGC-stimulators. Furthermore, also the participation of the sGCα2β1 isoform 
as well as (an) sGC-independent mechanism(s) could be argued.  
To get further insight into the mechanism responsible for the remaining relaxation in 
the sGCα1-/- mice, the relaxant properties of vessel and CC smooth muscle, was investigated in 
sGCβ1ki/ki mice (chapter VI). Those mice express a catalytically active but NO-insensitive 
sGC enzyme, as the axial ligand of the prosthetic heme group (histidine 105 of the sGCβ1 
subunit) is substituted. By comparing the impairment of the responses in the sGCβ1ki/ki mice 
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with those in the sGCα1-/- mice, we concluded that the cGMP producing capacity of the minor 
sGCα2β1 isoform is sufficient to largely compensate the absence of the sGCα1β1 isoform. 
Furthermore, we confirmed the unique role of sGC as target for NO in the aorta, whereas in 
the femoral artery and CC also sGC/cGMP-unrelated mechanisms are involved.  
Moreover, we also observed a higher contractile activity in the arteries from the sGCβ1ki/ki, 
which in the femoral artery appears to be specific for norepinephrine. The aortic rings from 
the sGCβ1ki/ki, on the other hand, contracted significantly stronger to a wide range of Ca2+ 
increasing substances. We suggest that this increased contractility to some extent may be 
explained by the unresponsiveness to basal endothelial NO.  
 Characterization of genetically engineered mice requires also a consideration of the 
genetic background on which the mutation is maintained, as numerous reports illustrate the 
influence of the genetic background on the phenotype. Also we found evidence for the 
presence of genetic modifiers (alleles present in the background strain genome that alter the 
expression of the gene of interest) since the contribution of the sGCα1β1 isoform in the 
response to endogenous NO was dependent on the genetic background (addendum VIII.2). 
This was taken into account by the interpretation and comparison of the phenotypes.  
 
In conclusion, the results obtained from the studies from this thesis demonstrate the 
physiological importance of sGCα1β1 in vascular and CC smooth muscle relaxation and in 
that way promote this isoform as a potential more selective therapeutic target for the treatment 
of cardiovascular diseases and ED. 
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Samenvatting 
Het feit dat oplosbaar guanylaatcyclase (sGC) een hoofdrol speelt in de signaaltransductie 
tussen de boodschappermoleculen stikstofmonoxide (NO) en cyclisch guanosine 3’, 5’-
monofosfaat (cGMP), illustreert het fysiologisch belang van dit enzym. sGC wordt 
gekenmerkt door een unieke heem-bindingsplaats die als receptor voor NO fungeert. Daarbij 
wordt cGMP gevormd, welke een brede waaier van biologische processen regelt, waaronder 
relaxatie van vasculaire en niet-vasculaire gladde spiercellen, neurotransmissie in perifere 
neuronen, aggregatie van bloedplaatjes en fototransductie. De NO/cGMP signaaltransductie is 
in heel wat ziektebeelden onderdrukt (bv. bij erectiele dysfunctie (ED)). Vandaar het 
veelvuldig gebruik van farmaca die de activiteit van sGC trachten te verhogen. 
 In 1998 werd de eerste orale medicatie voor ED op de markt gebracht, namelijk de 
fosfodiesterase (PDE) type 5 antagonist sildenafil (remt de afbraak van cGMP), beter gekend 
onder de naam Viagra®. De verwachtingen van deze behandeling waren zeer hoog aangezien 
sildenafil, mede door de enorme media-aandacht, naar voor werd gebracht als het middel 
tegen erectiestoornissen. PDE-5 remmers blijken echter significant minder doeltreffend te zijn 
voor de behandeling van ED bij patiënten met een verlaagde biologische beschikbaarheid van 
endogeen gegenereerd NO, zoals dit het geval is bij diabetici en bij patiënten met ernstige 
neurologische schade. Bovendien inibeert sildenafil ook de PDE-6 welke betrokken is bij de 
fototransductie in de retina. Hierdoor zijn tijdelijke effecten op het gezichtsvermogen zoals 
een wazig zicht, een verhoogde gevoeligheid voor licht en een verstoorde kleurdiscriminatie 
(blauw/groen) veel voorkomende bijwerkingen. Verder mag sildenafil ook niet gelijktijdig 
ingenomen worden met nitrovasodilatoren (nitraten) aangezien PDE-5 remmers het 
systemisch hypotensieve effect van NO versterken. 
 Van oudsher worden nitrovasodilatoren gebruikt als vaatverwijders via de NO/cGMP 
signaaltransductiecascade. Nochtans hebben deze geneesmiddelen ook belangrijke 
beperkingen: de ontwikkeling van tolerantie en de potentieel cGMP-onafhankelijke effecten 
van nitrovasodilatoren zoals het verhogen van oxidatieve stress en het modificeren van 
eiwitten.  
 Dit verklaart de interesse voor het ontwerpen en ontwikkelen van meer selectieve en 
NO-onafhankelijke therapieën. Hierbij kan informatie over het functioneel belang van de 
fysiologisch voorkomende sGC isovormen (sGCα1β1: de hoofd isovorm en sGCα2β1: de 
secundaire isovorm) heel nuttig zijn. Het hoofddoel van deze thesis was dan ook meer te 
weten te komen over het fysiologisch belang van sGCα1β1 en sGCα2β1 bij de relaxatie van 
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vasculaire en corpus cavernosum (CC) gladde spiercellen. Doordat er geen sGC isovorm-
specifieke inhibitoren beschikbaar zijn, hebben we gebruik gemaakt van transgene muizen om 
de functie van elke isovorm te achterhalen. Arteriën (de aorta en de femorale arterie) en CC 
werden geïsoleerd uit muizen, waarbij door genetisch manipulatie het gen coderend voor de 
sGCα1 subeenheid uitgeschakeld is of waarin het gen coderend voor de sGCβ1 subeenheid 
gemuteerd is. Deze weefsels werden vervolgens opgespannen op een myograaf om 
isometrische krachtveranderingen te meten. Daarnaast werd ook de cGMP concentratie in 
aortapreparaten bepaald. Deze technieken werden uitvoerig beschreven in hoofstuk II.  
Omdat sGCα1β1 beschouwd wordt als de universele heterodimeer met het hoogste 
expressie niveau, hebben we in ons onderzoek eerst de aandacht gevestigd op de sGCα1 
knockout (sGCα1-/-) muizen, waarbij de sGCα1β1 isovorm niet langer functioneel actief is. In 
hoofdstuk IV werd aangetoond dat de sGCα1β1 isovorm van functioneel belang is bij 
vasodilatatie geïnduceerd door zowel endogeen NO (vrijgesteld uit het endotheel als 
antwoord op acetylcholine (ACh)), als exogeen NO (geleverd door NO-donoren (natrium 
nitroprusside (SNP) en SNAP) en NO-gas als dusdanig), als basaal NO (onderzocht aan de 
hand van de opstapeling van basaal geproduceerd cGMP, veroorzaakt door de PDE-5 blokker 
T-1032). Verder werd ook vastgesteld dat de sGCα1β1 isovorm een rol speelt bij het 
relaxerend effect van NO-onafhankelijke sGC stimulatoren (BAY 41-2272 en YC-1). Door 
hun vermogen om sGC te activeren zonder NO, worden deze substanties naar voor gebracht 
als potentiële nieuwe medicamenteuze behandelingen voor NO/cGMP-gerelateerde 
pathologische aandoeningen. Het antwoord van de arteriën afkomstig van de sGCα1-/- muizen 
is nochtans slechts deels verminderd, wat er op wijst dat naast sGCα1β1 ook sGCα2β1 (de 
isovorm met een lagere expressie) en/of (een) sGC-onafhankelijke mechanisme(n) een 
substantiële rol spelen.  
 In hoofdstuk V hebben we de CC afkomstig van de sGCα1-/- muizen onderzocht. CC 
zijn opgebouwd uit twee cilindrische sponsachtige weefsels die zich uitstrekken in de lengte 
van de penis en die bij een erectie volstromen met bloed. Het belang van de relaxatie van de 
CC gladde spiercellen bij de bloeddoorstroming in de penis (en dus bij erectie) wordt 
geïllustreerd door het feit dat ED of impotentie veelal te wijten is aan een verminderd 
antwoord van de corporale gladde spiercellen. Algemeen gezien waren onze bevindingen in 
de CC vergelijkbaar met deze in de aorta en femorale arterie. We hebben aangetoond dat 
sGCα1β1 betrokken is bij de relaxatie van CC gladde spiercellen wanneer deze geïnduceerd 
wordt door NO (naast NO afkomstig van het endotheel werd ook NO vanuit de nitrerge 
zenuwen vrijgesteld door middel van electrische veldstimulatie) en NO-onafhankelijke sGC 
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stimulators. Verder werden argumenten gevonden voor het belang van zowel de sGCα2β1 
isovorm als (een) sGC-onafhankelijke mechanisme(n).  
 Om informatie te verkrijgen over het mechanisme dat verantwoordelijk is voor de 
resterende gladde spiercel relaxatie in de sGCα1-/- muizen, werd het relaxatievermogen 
onderzocht van de vasculaire en CC preparaten afkomstig van sGCβ1ki/ki muizen (hoofdstuk 
VI). Het sGC enzym in deze muizen is katalytisch actief maar ongevoelig voor NO door het 
vervangen van het axiale bindingsresidu voor de prosthetische heme groep (histidine 105 van 
de sGCβ1 subunit). De vermindering van de gladde spiercel relaxatie geobserveerd in de 
preparaten van de sGCβ1ki/ki muizen werd vergeleken met deze in de preparaten van de 
sGCα1-/- muizen. Hieruit konden we besluiten dat de afwezigheid van een functioneel 
sGCα1β1 isovorm grotendeels gecompenseerd wordt door cGMP geproduceerd door de 
minder tot expressie gebrachte sGCα2β1 isovorm. Verder werd in de aorta de rol van sGC als 
enige receptor voor NO bevestigd. Dit in tegenstelling tot de femorale arterie en de CC, 
waarin ook niet sGC-gerelateerde mechanismen actief zijn.  
Bovendien stelden we vast dat de arteriën geïsoleerd uit de sGCβ1ki/ki muizen een 
grotere contractie vertonen, welke in de femorale arterie specifiek bleek te zijn voor 
noradrenaline. De aortapreparaten uit de sGCβ1ki/ki muizen daarentegen, vertoonden een groter 
antwoord op een brede waaier van [Ca2+]i verhogende substanties. Deze verhoogde 
contractiliteit zou ten dele kunnen te wijten zijn aan de absentie van het vasodilaterend effect 
van basaal NO in de preparaten afkomstig van de sGCβ1ki/ki muizen.  
 Bij de karakterisering van genetisch gemanipuleerde muizen dient men steeds 
rekening te houden met de genetische achtergrond van de gemuteerde muizen. In de literatuur 
is namelijk veelvuldig beschreven welke invloed de genetische achtergrond kan hebben op het 
fenotype. In addendum VIII.2 rapporteren we dat de bijdrage van de sGCα1β1 isovorm in het 
antwoord op endogeen NO varieert naargelang de genetische achtergrond. Dit wijst op de 
aanwezigheid van ‘genetic modifiers’ (allelen die eigen zijn aan het genoom van de muisstam 
en die de expressie van het gen van interesse wijzigen), die in rekening dienen te worden 
gebracht bij de interpretatie en het vergelijken van fenotypes.  
 
Samenvattend tonen de resultaten van dit werk aan dat de sGCα1β1 isovorm van fysiologisch 
belang is bij de relaxatie van vasculaire en CC gladde spiercellen en dat deze isovorm kan 
aangegeven worden als een potentieel meer selectief therapeutisch doelwit voor de 
behandeling van cardiovasculaire aandoeningen en ED.  
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Dankwoord 
 
Een dankwoord neerpennen. Tja, niet bepaald een gemakkelijke opdracht. Hoe kan je nu in 
een paar regels iedereen bedanken die op welke manier dan ook geholpen heeft bij het tot 
stand komen van dit proefschrift. Een doctoraat behaal je immers niet alleen, zoveel is zeker.  
 
Allereerst en bovenal gaat mijn dank uit naar mijn promotor Prof. Johan Van de 
Voorde; zonder je fysiologische bijscholing, steun en positivisme was van dit onderzoek niets 
terecht gekomen. Hoe druk je het ook had, je was steeds bereid om me advies te geven en 
mijn vragen te beantwoorden. Ik heb dan ook enige tijd mogen doorbrengen in uw 
welbefaamde ‘zetelkes’. Niet alleen voor wetenschappelijke discussies maar ook voor een 
gezellige babbel. Je slaagde er steeds in om onverstoorbaar snel mijn schrijfsels te voorzien 
van de nodige verbeteringen, kritische aantekeningen en opbouwende suggesties. De 
typerende krabbeltjes in potlood, die enige decodering vergden, zullen me dan ook altijd 
bijblijven. Een welgemeende dank voor alle moeite die u gedaan hebt.  
 
De leden van de begeleidingscommissie, Prof. Dr. Romain Lefebvre en Prof. Dr. Peter 
Brouckaert, dank ik voor de wetenschappelijke bijdrage aan dit project.  
 
De vakgroepvoorzitters van de vakgroep Fysiologie en Fysiopathologie, Prof. Dr. 
Jaak Weyne en Prof. Dr. Jean-louis Pannier, zou ik willen bedanken voor het ter beschikking 
stellen van de apparatuur en het personeel van het labo. Prof. Dr. Jean-louis Pannier, wil ik 
ook bedanken om zitting te nemen in de examencommissie.  
 
I would like to thank the reading committee, Prof. Dr. Ulf Simonsen, Prof. Dr. Hidde 
Bult, Prof. Dr. Bart Lambrecht en Prof. Dr. Isabelle Colle, for reading and commenting this 
thesis.  
 
De afgelopen jaren heb ik genoten van de ongedwongen sfeer in blok B. Ik wil dan 
ook alle collega’s bedanken die mijn verblijf aangenaam gemaakt hebben.  
Julien Dupont, jij was ongetwijfeld de meest decibelproducerende en opgewekte persoon in 
het labo. Jouw optimisme en enthousiasme werkten dan ook aanstekelijk! Je was niet alleen 
de klusjesman maar tevens ook de paashaas en de Sinterklaas (spijtig genoeg zonder mijter, 
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mantel en staf). Julien, bedankt voor alles! Dirk, als mijn computer of proefopstelling weer 
eens rariteiten vertoonde, wist jij telkens snel raad. Bovendien trachtte je altijd de sfeer op te 
krikken met een boeiend verhaal. Tom Vanthuyne en Bart Blanckaert, als opvolgers van Dirk, 
wat hebben jullie prachtig werk geleverd! Cyriel Mabilde, bedankt voor het construeren van 
de fantastische ‘penisvoetjes’. André Van Baeveghem, bedankt voor de administratieve gang 
van zaken en je wijze raad. Eric Tack zou ik willen bedanken voor de assistentie bij het 
uitvoeren van tensiemetingen, het maken van perfusie en het opsporen van verdwenen 
producten. Marc Gillis, bedankt voor het overtekenen van curven en je esthetisch advies over 
posters en dia’s. Daniël Mestdagh, jij had slechts één telefoontje nodig om een praktisch 
probleem op te lossen, bedankt daarvoor. Mijn waardering gaat ook uit naar Francine Fuyat, 
voor het proper houden van de werkvloer. De ex-doctoraatstudenten: Koen Boussery, Joke 
Breyne, Siska Mortier en Ine De Clerck wil ik bedanken voor de sympathie waarmee ze mij 
(‘de snotneus’) hebben ontvangen in blok B. Dankzij jullie heb ik me altijd op mijn plek 
gevoeld. Gezelligheid tijdens de koffie of de lunch, wetenschappelijke discussies, hulp bij de 
experimenten, mijn hart uitstorten of zomaar wat kletsen,…. Ik kon altijd op jullie rekenen! 
Dat geldt trouwens ook voor mijn huidige mededoctorandi. Nele Maenhaut, toen de verhuis-
‘mania’ begon, werd je bureau plots in twee gedeeld en werd je tijdelijk met mij opgezadeld. 
En alsof dat nog niet erg genoeg was, werd die tijdelijke situatie echter een definitieve. 
Inderdaad, ik heb het daar zo naar mijn zin, dat ik daar niet meer weg wil. Nele, ik wil je dan 
ook bedanken voor het delen van lief, leed en bureauruimte. Zonder jou zouden mijn laatste 
maanden een stuk zwaarder geweest zijn. Mélissa Bol, de eerste verdieping zou niet hetzelfde 
zijn zonder jou. Ik bewonder je relativisme en zelfstandigheid. Bedankt, voor het fijne 
gezelschap. Kelly Decaluwé, je was vanaf het eerste uur gemotiveerd en hulpvaardig, ik had 
het echt getroffen met jou als thesisstudente. Jij bent dan ook zonder meer een geweldige 
aanwinst voor de ‘vascular research unit’. Het feit dat er op dit moment een tastbaar boekje is, 
is mede dankzij jouw hulp bij de kiki-experimenten. Een welgemeende dank daarvoor. Ook 
wil ik de mensen van op het derde bedanken en in het bijzonder Elke Devuyst om 
mishandeling van de spectrofotometer te voorkomen, maar vooral voor de steuntjes in de rug.  
 
Daarnaast waren ook de mensen van de vakgroep Farmacologie (alias die van naast de 
deur) onlosmakelijk verbonden met mijn onderzoek. Gwen Vanneste, Koen Van 
Crombruggen, Inge Van Colen, Ellen Elinck en Ole De Backer, bedankt voor de prettige sfeer 
en fijne samenwerking. Valère Geers, je ontferming (in de ruime zin van het woord) over de 
muizen maar vooral je persoonlijke bezorgdheid, apprecieer ik enorm. Inge(borg) Dhaese, jij 
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mag in mijn lijstje zeker niet ontbreken. Als projectgenootje wist je perfect hoe ik me voelde 
in moeilijke tijden. Ik kon dan ook altijd bij je binnenhollen om stoom af te blazen. 
Inge(borg), bedankt voor je steun en begrip.  
 
 Mijn verdere dank gaat uit naar de vakgroep Moleculaire Pathofysiologie voor de fok 
en levering van de transgene knagertjes. Bovenop die zware werklast, wil ik Patrick Sips, 
Robrecht Thoonen en Manu Buys ook nog bedanken voor alle adviezen en het kritisch nalezen 
van de teksten. Elke Rogge, bedankt voor de assistentie bij de eiwitbepalingen. Anje Cauwels, 
bedankt voor je inspirerende ideeën en interesse.  
 
Mijn appreciatie gaat ook uit naar de vroegere en huidige werknemers van de 
vakgroep Neurofysiologie, Experimentele heelkunde, Nefrologie en Gastrologie voor hun 
aangename collegialiteit. In het bijzonder Christophe Van Steenkiste wil ik bedanken voor de 
hulp bij de flow metingen en de leuke babbeltjes. 
 
Gelukkig bestaat er meer dan alleen maar onderzoek in het leven, al lijkt dat soms 
even niet zo. In het bijzonder wil ik Karolien Neyt, An Mathijsen en Evelien Wylocke noemen. 
Jullie waren onmisbaar als uitlaatklep, voor de broodnodige afleiding en om mijn conditie op 
peil te houden. Vriendinnen, bedankt! 
 
 Cartouche (Wolfke) bedank ik voor de ontspannende wandelingen, de plezante 
jachtdagen en de onvoorwaardelijke liefde. Ook al versta je geen mensentaal, toch voelde je 
aan wanneer ik een dipje had. Een schouderklopje of beter gezegd een pootje van jou, fleurde 
me direct op . 
 
Ten slotte wil ik mijn ouders bedanken. Zij hebben er in de eerste plaats voor gezorgd 
dat dit alles mogelijk was, niet alleen door mij 27 jaar geleden gezond en wel op de wereld te 
zetten, maar ook door mij al die jaren onafgebroken aan te moedigen en te steunen op kritieke 
momenten. Jullie hebben me altijd de mogelijkheden en vrijheid geschonken om te doen wat 
ik wou doen, zowel op studiegebied als daarbuiten. Bedankt voor alles! 
 
Sofie, juni 2008.

